A Phase 2 Study of Bortezomib in Relapsed, Refractory

New England Journal of Medicine
348, 2609-2617
DOI: 10.1056/nejmoa030288

Citation Report

#	Article	IF	Citations
1	TREATMENT OF RELAPSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA. , 0, , 46-63.		0
2	High-dose therapy in multiple myeloma. Annals of Oncology, 2002, 13, 49-54.	0.6	8
4	Proteasom-Inhibitoren. Onkologe, 2003, 9, 1102-1107.	0.7	2
5	The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma. British Journal of Haematology, 2003, 123, 886-895.	1.2	21
6	Targeted therapy for epithelial ovarian cancer: Current status and future prospects. International Journal of Gynecological Cancer, 2003, 13, 701-734.	1.2	43
8	Bortezomib. Nature Reviews Drug Discovery, 2003, 2, 611-612.	21.5	206
9	Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine, 2003, 349, 2495-2502.	13.9	938
10	Phase II Trials of Bortezomib (PS-341, Velcadeâ„¢), a Selective Proteasome Inhibitor, in Non-Hodgkin's Lymphoma. Clinical Lymphoma and Myeloma, 2003, 4, 79-82.	2.1	0
11	Velcade Â® : U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy. Oncologist, 2003, 8, 508-513.	1.9	562
13	Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Seminars in Hematology, 2003, 40, 3-7.	1.8	69
14	Overcoming Drug Resistance in Multiple Myeloma: The Emergence of Therapeutic Approaches to Induce Apoptosis. Journal of Clinical Oncology, 2003, 21, 4239-4247.	0.8	76
15	Bortezomib Treatment for Multiple Myeloma. Annals of Pharmacotherapy, 2003, 37, 1825-1830.	0.9	18
16	Treatment of multiple myeloma. BMJ: British Medical Journal, 2003, 327, 575-576.	2.4	6
17	The Proteasome â€" An Emerging Therapeutic Target in Cancer. New England Journal of Medicine, 2003, 348, 2597-2598.	13.9	116
18	Bortezomib in Multiple Myeloma. New England Journal of Medicine, 2003, 349, 1287-1288.	13.9	3
19	Multiple Myeloma, 2004 â€" One or Two Transplants?. New England Journal of Medicine, 2003, 349, 2551-2553.	13.9	16
20	Advances in Biology and Therapy of Multiple Myeloma. Hematology American Society of Hematology Education Program, 2003, 2003, 248-278.	0.9	61
21	Bortezomib (PS-341): A Novel, First-in-Class Proteasome Inhibitor for the Treatment of Multiple Myeloma and Other Cancers. Cancer Control, 2003, 10, 361-369.	0.7	269

#	Article	IF	Citations
22	Bortezomib Gefitinib. Hospital Pharmacy, 2003, 38, 733-736.	0.4	0
23	Ubiquitin-Protein Ligases - Novel Therapeutic Targets?. Current Protein and Peptide Science, 2004, 5, 163-176.	0.7	21
24	Angiogenesis in Multiple Myeloma: Implications in Myeloma Therapy. Cancer Reviews: Asia-Pacific, 2004, 02, 119-129.	0.1	2
25	Patient-Reported Outcomes in Multiple Myeloma. Journal of the National Comprehensive Cancer Network: JNCCN, 2004, 2, 379-383.	2.3	4
27	Molecular biological design of novel antineoplastic therapies. Expert Opinion on Investigational Drugs, 2004, 13, 577-607.	1.9	6
28	Targeted therapies in oncology: in the crosshairs or at the crossroads?. Expert Review of Anticancer Therapy, 2004, 4, 61-75.	1.1	6
30	Targeting Apoptosis Pathways in Cancer Therapy. Current Cancer Drug Targets, 2004, 4, 569-576.	0.8	158
31	Treatment of Relapsed/Refractory Multiple Myeloma with Thalidomide-based Regimens: Identification of Prognostic Factors. Leukemia and Lymphoma, 2004, 45, 2275-2279.	0.6	14
32	BAG-1 in carcinogenesis. Expert Reviews in Molecular Medicine, 2004, 6, 1-15.	1.6	31
33	Proteasomal Degradation of Topoisomerase I Is Preceded by c-Jun NH2-Terminal Kinase Activation, Fas Up-Regulation, and Poly(ADP-Ribose) Polymerase Cleavage in SN38-Mediated Cytotoxicity against Multiple Myeloma. Cancer Research, 2004, 64, 8746-8753.	0.4	30
34	Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors. Clinical Cancer Research, 2004, 10, 6111-6118.	3.2	143
35	Phase II Trial of Bortezomib for Patients With Advanced Renal Cell Carcinoma. Journal of Clinical Oncology, 2004, 22, 3720-3725.	0.8	176
36	Chemoresistance: Impact of Nuclear Factor (NF)-Î²B Inhibition by Small Interfering RNA: Fig. 1.. Clinical Cancer Research, 2004, 10, 3262-3264.	3.2	25
37	Transforming Growth Factor Î² Receptor I Kinase Inhibitor Down-Regulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment. Clinical Cancer Research, 2004, 10, 7540-7546.	3.2	111
38	Regulation of Constitutive p50/c-Rel Activity via Proteasome Inhibitor-Resistant IÎ²BÎ± Degradation in B Cells. Molecular and Cellular Biology, 2004, 24, 4895-4908.	1.1	34
39	Synergistic Induction of Oxidative Injury and Apoptosis in Human Multiple Myeloma Cells by the Proteasome Inhibitor Bortezomib and Histone Deacetylase Inhibitors. Clinical Cancer Research, 2004, 10, 3839-3852.	3.2	371
40	Evidence That Mitogen-Activated Protein Kinase Phosphatase-1 Induction by Proteasome Inhibitors Plays an Antiapoptotic Role. Molecular Pharmacology, 2004, 66, 1478-1490.	1.0	98
41	Expression of Pirh2, a Newly Identified Ubiquitin Protein Ligase, in Lung Cancer. Journal of the National Cancer Institute, 2004, 96, 1718-1721.	3.0	89

#	Article	IF	Citations
42	Bortezomib as a Potential Treatment for Prostate Cancer. Cancer Research, 2004, 64, 5036-5043.	0.4	120
43	NF-kappaB, IL-6 and myeloma cell growth: Making the connection. Cancer Biology and Therapy, 2004, 3, 1018-1020.	1.5	3
45	Multiple Myeloma. Hematology American Society of Hematology Education Program, 2004, 2004, 237-256.	0.9	76
46	Regulation of p53 by the Ubiquitin-conjugating Enzymes UbcH5B/C in Vivo. Journal of Biological Chemistry, 2004, 279, 42169-42181.	1.6	130
47	Phase I Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study (ADVL0015). Journal of Clinical Oncology, 2004, 22, 4804-4809.	0.8	110
48	Novel Agents in Epithelial Ovarian Cancer. Cancer Investigation, 2004, 22, 29-44.	0.6	16
49	Approval Summary for Bortezomib for Injection in the Treatment of Multiple Myeloma. Clinical Cancer Research, 2004, 10, 3954-3964.	3.2	316
50	Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma. Journal of Clinical Oncology, 2004, 22, 3269-3276.	0.8	301
51	Bortezomib, a Newly Approved Proteasome Inhibitor for the Treatment of Multiple Myeloma: Nursing Implications. Clinical Journal of Oncology Nursing, 2004, 8, 473-480.	0.3	35
52	Strategies to improve the outcome of stem cell transplantation in multiple myeloma. The Hematology Journal, 2004, 5, 9-23.	2.0	14
53	The ubiquitinâ€“proteasome system in cardiovascular diseasesâ€”a hypothesis extended. Cardiovascular Research, 2004, 61, 11-21.	1.8	153
54	In situ dynamically monitoring the proteolytic function of the ubiquitin-proteasome system in cultured cardiac myocytes. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 287, H1417-H1425.	1.5	62
55	Treatment advances in multiple myeloma. British Journal of Haematology, 2004, 125, 24-30.	1.2	17
56	The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cells. British Journal of Haematology, 2004, 125, 373-382.	1.2	25
57	Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. British Journal of Haematology, 2004, 125, 343-352.	1.2	74
58	Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. British Journal of Haematology, 2004, 125, 470-476.	1.2	104
59	Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. British Journal of Haematology, 2004, 127, 159-164.	1.2	71
60	A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. British Journal of Haematology, 2004, 127, 165-172.	1.2	632

#	Article	IF	Citations
61	Thalidomide for the treatment of multiple myeloma. Congenital Anomalies (discontinued), 2004, 44, 125-136.	0.3	28
62	The proteasome: a suitable antineoplastic target. Nature Reviews Cancer, 2004, 4, 349-360.	12.8	1,130
64	Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma. Bone Marrow Transplantation, 2004, 34, 229-234.	1.3	32
65	Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. Bone Marrow Transplantation, 2004, 34, 1057-1065.	1.3	69
66	Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia, 2004, 18, 1357-1363.	3.3	122
67	A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients. Leukemia, 2004, 18, 1518-1521.	3.3	75
68	Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia, 2004, 18, 1699-1704.	3.3	86
69	Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells. Oncogene, 2004, 23, 2554-2558.	2.6	110
70	p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene, 2004, 23, 8766-8776.	2.6	127
71	Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell, 2004, 5, 221-230.	7.7	579
72	The development of proteasome inhibitors as anticancer drugs. Cancer Cell, 2004, 5, 417-421.	7.7	723
73	Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy. Seminars in Oncology, 2004, 31, 40-46.	0.8	36
74	Lymphoma and myeloma in older patients. Seminars in Oncology, 2004, 31, 198-205.	0.8	30
75	Multiple myeloma: The role of transplant and novel treatment strategies. Seminars in Oncology, 2004, 31, 99-105.	0.8	11
76	Clinical update: Novel targets in multiple myeloma. Seminars in Oncology, 2004, 31, 27-32.	0.8	16
77	What Is New in Lymphoma?. Ca-A Cancer Journal for Clinicians, 2004, 54, 260-272.	157.7	37
78	Use of Proteasome Inhibition in the Treatment of Lung Cancer. Clinical Lung Cancer, 2004, 6, S89-S96.	1.1	20
79	The ubiquitin system: pathogenesis of human diseases and drug targeting. Biochimica Et Biophysica Acta - Molecular Cell Research, 2004, 1695, 3-17.	1.9	131

#	Article	IF	Citations
80	Focus on multiple myeloma. Cancer Cell, 2004, 6, 439-444.	7.7	147
81	Bayesian sample size calculations in phase II clinical trials using informative conjugate priors. Contemporary Clinical Trials, 2004, 25, 157-167.	2.0	41
82	Targeting cell cycle and apoptosis for the treatment of human malignancies. Current Opinion in Cell Biology, 2004, 16, 670-678.	2.6	96
83	Biology of Chronic Myeloid Leukemia and Possible Therapeutic Approaches to Imatinib-Resistant Disease. International Journal of Hematology, 2004, 79, 420-433.	0.7	41
84	Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration. Journal of Cancer Research and Clinical Oncology, 2004, 130, 623-5.	1.2	42
87	An update of novel therapeutic approaches for multiple myeloma. Current Treatment Options in Oncology, 2004, 5, 227-238.	1.3	10
88	New and emerging pharmacological targets for neuropathic pain. Current Pain and Headache Reports, 2004, 8, 192-198.	1.3	14
89	The role of Fas ligand and transforming growth factor ? in tumor progression. Cancer, 2004, 100, 2281-2291.	2.0	121
90	Prevalence of vitamin B12 deficiency in patients with plasma cell dyscrasias. Cancer, 2004, 101, 790-795.	2.0	37
91	CD147 and matrix metalloproteinase-2 protein expression as significant prognostic factors in esophageal squamous cell carcinoma. Cancer, 2004, 101, 1994-2000.	2.0	82
92	Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis. Leukemia Research, 2004, 28, 845-850.	0.4	26
93	Systemic therapies for hepatocellular carcinoma. Expert Opinion on Investigational Drugs, 2004, 13, 1555-1568.	1.9	48
94	Chromosome 13 Deletion/Hypodiploidy and Prognosis in Multiple Myeloma Patients. Leukemia and Lymphoma, 2004, 45, 1083-1091.	0.6	11
95	Bortezomib (Velcade). A New Therapy for Multiple Myeloma. Clinical Research and Regulatory Affairs, 2004, 21, 29-38.	2.1	0
96	Graft vs. Host Disease and Graft vs. Myeloma Effect after Non-myeloablative Allogeneic Transplantation. Leukemia and Lymphoma, 2004, 45, 1725-1729.	0.6	7
97	Proteasome inhibition in hematologic malignancies. Annals of Medicine, 2004, 36, 304-314.	1.5	59
98	Chemotherapy-induced peripheral neurotoxicity. Expert Opinion on Drug Safety, 2004, 3, 535-546.	1.0	43
100	Targeted Therapies for Cancer 2004. American Journal of Clinical Pathology, 2004, 122, 598-609.	0.4	261

#	Article	IF	Citations
101	The Impact of the Completed Human Genome Sequence on the Development of Novel Therapeutics for Human Disease. Annual Review of Medicine, 2004, 55, 1-13.	5.0	53
102	Case 38-2004. New England Journal of Medicine, 2004, 351, 2637-2645.	13.9	10
103	Clinical Course of Patients With Relapsed Multiple Myeloma. Mayo Clinic Proceedings, 2004, 79, 867-874.	1.4	319
104	New Developments with Bortezomib in Treating Multiple Myeloma. Clinical Lymphoma and Myeloma, 2004, 4, 215-216.	2.1	0
106	Proteasome inhibition as a major advance in oncology. European Journal of Cancer, Supplement, 2004, 2, 1-2.	2.2	0
107	The clinical potential of proteasome inhibition. European Journal of Cancer, Supplement, 2004, 2, 3-6.	2.2	0
108	Bortezomib in multiple myeloma: treatment approach and outcomes. European Journal of Cancer, Supplement, 2004, 2, 12-17.	2.2	3
109	Bortezomib: clinical profile in lymphoproliferative malignancies. European Journal of Cancer, Supplement, 2004, 2, 18-24.	2.2	0
110	Multiple Myeloma. New England Journal of Medicine, 2004, 351, 1860-1873.	13.9	1,291
111	Targeting the Ubiquitinâ€"Proteasome Pathway in Breast Cancer. Clinical Breast Cancer, 2004, 5, 148-157.	1.1	40
112	Update on the Proteasome Inhibitor Bortezomibin Hematologic Malignancies. Clinical Lymphoma and Myeloma, 2004, 4, 230-237.	2.1	32
113	Treatment Options in Waldenstrom's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2004, 5, 155-162.	2.1	5
114	Proteasome Inhibition. American Journal of Cancer, 2004, 3, 271-279.	0.4	0
115	NF-ÎºB in cancerâ€"a friend turned foe. Drug Resistance Updates, 2004, 7, 53-67.	6.5	131
116	The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. European Journal of Cancer, 2004, 40, 2217-2229.	1.3	203
117	The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib. Experimental Cell Research, 2004, 295, 555-566.	1.2	139
118	Degradation of survival motor neuron (SMN) protein is mediated via the ubiquitin/proteasome pathway. Neurochemistry International, 2004, 45, 1107-1112.	1.9	72
119	New drugs for treatment of multiple myeloma. Lancet Oncology, The, 2004, 5, 430-442.	5.1	59

#	Article	IF	Citations
121	Fitting bortezomib into clinical practice. Community Oncology, 2004, 1, 78-79.	0.2	0
122	Recent advances in the management of multiple myeloma. Seminars in Hematology, 2004, 41, 21-26.	1.8	9
123	Multiple myeloma. Lancet, The, 2004, 363, 875-887.	6.3	209
124	New therapeutic targets in multiple myeloma. Lancet, The, 2004, 364, 1648-1649.	6.3	8
125	Molecular Monitoring of Minimal Residual Disease in Patients with Multiple Myeloma. Hematology, 2004, 9, 17-33.	0.7	13
126	Advances in biology of multiple myeloma: clinical applications. Blood, 2004, 104, 607-618.	0.6	548
127	An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or antiâ€“IL-6 antibody-induced apoptosis. Blood, 2004, 103, 1829-1837.	0.6	65
128	The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic antiâ€“multiple myeloma (MM) activity and overcome bortezomib resistance. Blood, 2004, 103, 3158-3166.	0.6	122
129	Interruption of the NF-Î¹B pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells. Blood, 2004, 103, 2761-2770.	0.6	104
130	GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood, 2004, 103, 3474-3479.	0.6	87
131	Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood, 2004, 104, 509-518.	0.6	109
132	The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesionâ€“mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood, 2004, 104, 1825-1832.	0.6	115
133	Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood, 2004, 104, 2458-2466.	0.6	79
134	Management of the Older Patient with Multiple Myeloma. Journal of Pharmacy Practice and Research, 2004, 34, 142-146.	0.5	0
135	Advances in the Management of Myeloma. Scottish Medical Journal, 2005, 50, 47-50.	0.7	1
136	Toxic neuropathy. Current Opinion in Neurology, 2005, 18, 574-580.	1.8	55
137	Targeted Therapy in Multiple Myeloma. Cancer Control, 2005, 12, 91-104.	0.7	27
138	Proteasome: an emerging target for cancer therapy. Anti-Cancer Drugs, 2005, 16, 475-481.	0.7	65

#	Article	IF	Citations
139	Proteasome Inhibition in Cancer Therapy. Journal of Infusion Nursing, 2005, 28, 258-264.	1.2	3
140	Targeting the Proteasome in Cancer Therapy. , 2005, , 243-274.		1
141	Vav: a newcomer in innate receptor signaling. Blood, 2005, 106, 389-390.	0.6	1
142	Apoptosis-based therapies for hematologic malignancies. Blood, 2005, 106, 408-418.	0.6	368
143	Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood, 2005, 105, 3058-3065.	0.6	296
144	Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. Blood, 2005, 105, 3255-3262.	0.6	114
145	Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. Blood, 2005, 105, 4784-4791.	0.6	80
146	Oncogenes as molecular targets in lymphoma. Blood, 2005, 106, 1911-1923.	0.6	23
147	Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood, 2005, 106, 1042-1047.	0.6	172
148	Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. Blood, 2005, 106, 1794-1800.	0.6	167
149	Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood, 2005, 106, 2977-2981.	0.6	102
150	SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood, 2005, 106, 706-712.	0.6	54
151	High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood, 2005, 106, 3755-3759.	0.6	298
152	A clinically relevant mouse model of human multiple myeloma?. Blood, 2005, 106, 388-389.	0.6	1
153	The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. Blood, 2005, 106, 4322-4329.	0.6	56
154	Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood, 2005, 105, 4470-4476.	0.6	59
155	NF-ÂB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood, 2005, 107, 1156-1165.	0.6	127
156	Triptolide inhibits transcription factor NF-kappaB and induces apoptosis of multiple myeloma cells. Leukemia Research, 2005, 29, 99-105.	0.4	83

#	Article	IF	Citations
157	Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leukemia Research, 2005, 29, 587-590.	0.4	59
158	Phase II study of topotecan and cyclophosphamide in patients with relapsed and refractory multiple myeloma. Leukemia Research, 2005, 29, 1233-1234.	0.4	4
159	Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomib. Leukemia Research, 2005, 29, 1473-1477.	0.4	13
160	Structure-based design of derivatives of tyropeptin A as the potent and selective inhibitors of mammalian 20S proteasome. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1867-1871.	1.0	55
161	The Proteasome: A Central Regulator of Inflammation and Macrophage Function. Immunologic Research, 2005, 31, 243-260.	1.3	77
162	New Synthetic Route for the Enantioselective Total Synthesis of Salinosporamide A and Biologically Active Analogues. Organic Letters, 2005, 7, 2699-2701.	2.4	105
163	New agents for the treatment of ovarian cancer: the next generation. International Journal of Gynecological Cancer, 2005, 15, 252-257.	1.2	9
164	High plasma proteasome levels are detected in patients with metastatic malignant melanoma. British Journal of Dermatology, 2005, 152, 948-953.	1.4	68
165	Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments. British Journal of Haematology, 2005, 129, 607-614.	1.2	45
166	PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. British Journal of Haematology, 2005, 129, 755-762.	1.2	313
167	Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. British Journal of Haematology, 2005, 129, 776-783.	1.2	378
168	Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. British Journal of Haematology, 2005, 131, 71-73.	1.2	180
169	Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma. British Journal of Haematology, 2005, 131, 329-337.	1.2	7
170	Evolving treatment strategies for myeloma. British Journal of Cancer, 2005, 92, 217-221.	2.9	18
171	Nuclear factor-ÎºB inhibitors as sensitizers to anticancer drugs. Nature Reviews Cancer, 2005, 5, 297-309.	12.8	718
172	Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du MyÃ©lome (IFM) and the SociÃ©tÃ© FranÃ§aise de Greffe de Moelle et ThÃ©rapie Cellulaire (SFGM-TC). Bone Marrow Transplantation, 2005, 35, 165-169.	1.3	37
173	An elective single autograft with high-dose melphalan: single-center study of 451 patients. Bone Marrow Transplantation, 2005, 36, 19-24.	1.3	22
174	Severe irreversible bilateral hearing loss after bortezomib (VELCADEÂ®) therapy in a multiple myeloma (MM) patient. Leukemia, 2005, 19, 869-870.	3.3	16

#	Article	IF	Citations
175	Five decades of therapy for multiple myeloma: a paradigm for therapeutic models. Leukemia, 2005, 19, 910-912.	3.3	19
176	High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation. Leukemia, 2005, 19, 1102-1103.	3.3	50
177	Therapeutic renaissance of thalidomide in the treatment of haematological malignancies. Leukemia, 2005, 19, 1525-1531.	3.3	56
178	Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect. Leukemia, 2005, 19, 1702-1704.	3.3	28
179	Growth factors and antiapoptotic signaling pathways in multiple myeloma. Leukemia, 2005, 19, 2177-2185.	3.3	62
180	Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells. Oncogene, 2005, 24, 1-10.	2.6	119
181	Chemosensitization by erythropoietin through inhibition of the NF-Î¹B rescue pathway. Oncogene, 2005, 24, 737-745.	2.6	53
182	VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-Î¹B-dependent mechanism. Oncogene, 2005, 24, 1563-1570.	2.6	55
183	Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-Î² inhibitors. Oncogene, 2005, 24, 3121-3129.	2.6	43
184	Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene, 2005, 24, 5888-5896.	2.6	56
185	PS-341â€“mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis. Experimental Hematology, 2005, 33, 784-795.	0.2	56
186	In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells. European Journal of Haematology, 2005, 74, 407-417.	1.1	38
187	Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. European Journal of Haematology, 2005, 75, 376-383.	1.1	61
188	Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with multiple myeloma. European Journal of Haematology, 2005, 75, 505-510.	1.1	21
189	Accumulation of ubiquitin-conjugated cytokeratin fragments in tumor cells. Seminars in Cancer Biology, 2005, 15, 309-318.	4.3	9
190	Targeting Apoptosis Pathways in Cancer Therapy. Ca-A Cancer Journal for Clinicians, 2005, 55, 178-194.	157.7	1,111
191	Preclinical Data with Bortezomib in Lung Cancer. Clinical Lung Cancer, 2005, 7, S49-S55.	1.1	24
192	Bortezomib is an efficient agent in plasma cell leukemias. International Journal of Cancer, 2005, 114, 665-667.	2.3	59

#	Article	IF	Citations
193	Bortezomib in recurrent and/or refractory multiple myeloma. Cancer, 2005, 103, 1195-1200.	2.0	218
194	A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer, 2005, 103, 1431-1438.	2.0	78
195	A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer, 2005, 103, 2584-2589.	2.0	135
196	Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer, 2005, 104, 1794-1807.	2.0	159
197	Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer, 2005, 104, 2141-2148.	2.0	99
198	Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. American Journal of Hematology, 2005, 79, 194-197.	2.0	46
199	Adeno-associated virus serotypes 1 to 5 mediated tumor cell directed gene transfer and improvement of transduction efficiency. Journal of Gene Medicine, 2005, 7, 1429-1438.	1.4	51
200	Apoptosis: mechanisms and relevance in cancer. Annals of Hematology, 2005, 84, 627-639.	0.8	274
202	Synergistic apoptosis induction by proteasome and histone deacetylase inhibitors is dependent on protein synthesis. Apoptosis: an International Journal on Programmed Cell Death, 2005, 10, 743-758.	2.2	13
203	Treatment of myeloma in patients not eligible for transplantation. Current Treatment Options in Oncology, 2005, 6, 241-253.	1.3	9
204	New agents in the treatment of childhood leukemias and myelodysplastic syndromes. Current Oncology Reports, 2005, 7, 399-405.	1.8	5
205	Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell International, 2005, 5, 18.	1.8	196
206	Effects of PS-341 on the Activity and Composition of Proteasomes in Multiple Myeloma Cells. Cancer Research, 2005, 65, 7896-7901.	0.4	130
207	Targeted Therapy for Hematologic Malignancies. Cancer Control, 2005, 12, 82-90.	0.7	8
208	Proteasome inhibition as an anticancer target. Nature Reviews Drug Discovery, 2005, 4, 698-698.	21.5	0
209	Proteasome inhibition as an anticancer target. Nature Reviews Drug Discovery, 2005, 4, 698-698.	21.5	0
210	A Pilot Study of Bortezomib in Korean Patients with Relapsed or Refractory Myeloma. Journal of Korean Medical Science, 2005, 20, 598.	1.1	6
211	The Ubiquitin Proteasome Pathway from Bench to Bedside. Hematology American Society of Hematology Education Program, 2005, 2005, 220-225.	0.9	33

#	Article	IF	Citations
212	Classical and Alternative NF-.KAPPA.B Activation Pathways and Their Roles in Lymphoid Malignancies. Journal of Clinical and Experimental Hematopathology: JCEH, 2005, 45, 15-24.	0.3	90
215	Targeting Inducible Chemotherapy Resistance Mechanisms in Colon Cancer. , 2005, , 209-228.		1
216	Protease Inhibitors in the Clinic. Medicinal Chemistry, 2005, 1, 71-104.	0.7	244
218	Identification and Validation of Novel Therapeutic Targets for Multiple Myeloma. Journal of Clinical Oncology, 2005, 23, 6345-6350.	0.8	69
219	Advances in biology and treatment of multiple myeloma. Annals of Oncology, 2005, 16, ii106-ii112.	0.6	17
220	Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases. Prostate Cancer and Prostatic Diseases, 2005, 8, 327-334.	2.0	17
221	Targeting Protein Degradation in the Nervous System. Current Medicinal Chemistry - Central Nervous System Agents, 2005, 5, 285-306.	0.6	1
222	A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib,) Tj ETQq1 1 0.784314 rgBT /Ov	3.2	67
223	Proteasome Inhibition With Bortezomib (PS-341): A Phase I Study With Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day Cycle. Journal of Clinical Oncology, 2005, 23, 6107-6116.	0.8	86
224	Bortezomib Inhibits PKR-Like Endoplasmic Reticulum (ER) Kinase and Induces Apoptosis via ER Stress in Human Pancreatic Cancer Cells. Cancer Research, 2005, 65, 11510-11519.	0.4	292
225	Proteasome Inhibitor MG132 Induces Death Receptor 5 through CCAAT/Enhancer-Binding Protein Homologous Protein. Cancer Research, 2005, 65, 5662-5667.	0.4	158
226	Proteasome inhibitor therapy in multiple myeloma. Molecular Cancer Therapeutics, 2005, 4, 686-692.	1.9	148
227	Side Effects and Good Effects from New Chemotherapeutic Agents. Journal of Clinical Oncology, 2005, 23, 2426-2428.	0.8	21
228	PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study. Annals of Oncology, 2005, 16, 1654-1661.	0.6	93
229	Bortezomib: proteasome inhibition as an effective anticancer therapy. Future Oncology, 2005, 1, 161-167.	1.1	33
230	Dehydroxymethylepoxyquinomicin, a novel nuclear factor-Î¹B inhibitor, induces apoptosis in multiple myeloma cells in an Î¹BÎ±-independent manner. Molecular Cancer Therapeutics, 2005, 4, 1114-1120.	1.9	35
231	Development of Effective New Treatments for Multiple Myeloma. Journal of Clinical Oncology, 2005, 23, 7207-7211.	0.8	19
232	Medication and Toxin-Induced Peripheral Neuropathy. Seminars in Neurology, 2005, 25, 204-216.	0.5	27

#	Article	IF	Citations
233	A novel transgenic mouse model reveals deregulation of the ubiquitinâ€proteasome system in the heart by doxorubicin. FASEB Journal, 2005, 19, 2051-2053.	0.2	108
234	Bortezomib Sensitizes Pancreatic Cancer Cells to Endoplasmic Reticulum Stress-Mediated Apoptosis. Cancer Research, 2005, 65, 11658-11666.	0.4	278
235	High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 Years: Long-Term Results of a Randomized Control Trial From the Group Myelome-Autogreffe. Journal of Clinical Oncology, 2005, 23, 9227-9233.	0.8	356
236	Targeting Positive Regulatory Domain I-Binding Factor 1 and X Box-Binding Protein 1 Transcription Factors by Multiple Myeloma-Reactive CTL. Journal of Immunology, 2005, 175, 1301-1309.	0.4	11
237	FTY720 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Drug Resistance. Cancer Research, 2005, 65, 7478-7484.	0.4	97
238	Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 8567-8572.	3.3	571
239	The Farnesyltransferase Inhibitor L744832 Potentiates UCN-01â€“Induced Apoptosis in Human Multiple Myeloma Cells. Clinical Cancer Research, 2005, 11, 4589-4600.	3.2	30
240	Novel Biological Agents for the Treatment of Hormone-Refractory Prostate Cancer (HRPC). Current Medicinal Chemistry, 2005, 12, 277-296.	1.2	17
241	Extracellular matrix in bone marrow can mediate drug resistance in myeloma. Leukemia and Lymphoma, 2005, 46, 803-811.	0.6	47
242	Bortezomib for Myeloma â€" Much Ado about Something. New England Journal of Medicine, 2005, 352, 2546-2548.	13.9	23
243	Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma. Leukemia and Lymphoma, 2005, 46, 567-569.	0.6	12
245	Antitumorigenic Effect of Proteasome Inhibitors on Insulinoma Cells. Endocrinology, 2005, 146, 1718-1726.	1.4	12
246	Multiple myeloma: an update of developments in targeted therapy. Expert Review of Anticancer Therapy, 2005, 5, 379-389.	1.1	4
247	Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients. Expert Review of Proteomics, 2005, 2, 337-348.	1.3	43
248	Targeting signalling pathways for the treatment of multiple myeloma. Expert Opinion on Therapeutic Targets, 2005, 9, 359-381.	1.5	33
249	Proteasome Inhibitors in Cancer Therapy. , 2005, 301, 339-350.		13
250	The Ubiquitin-Proteasome Pathway and Its Role in Cancer. Journal of Clinical Oncology, 2005, 23, 4776-4789.	0.8	477
251	Advances in the management of myeloma bone disease. Expert Opinion on Pharmacotherapy, 2005, 6, 2781-2791.	0.9	5

#	Article	IF	Citations
252	Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood, 2005, 106, 3777-3784.	0.6	306
253	The ubiquitinâ€proteasome systemâ€"micro target for macro intervention?. International Journal of Cardiovascular Interventions, 2005, 7, 5-13.	0.5	7
254	Apoptosis-Inducing Anticancer Drugs in Clinical Trials. , 2005, , 341-364.		0
256	Intracellular Protein Degradation and Its Therapeutic Implications: Fig. 1.. Clinical Cancer Research, 2005, 11, 8530-8533.	3.2	50
257	The ubiquitinâ€"proteasome system in HIV replication: potential targets for antiretroviral therapy. Expert Review of Anti-Infective Therapy, 2005, 3, 61-79.	2.0	38
258	Control of ASPP2/53BP2L Protein Levels by Proteasomal Degradation Modulates p53 Apoptotic Function. Journal of Biological Chemistry, 2005, 280, 34473-34480.	1.6	27
259	Sulindac Enhances the Proteasome Inhibitor Bortezomib-Mediated Oxidative Stress and Anticancer Activity. Clinical Cancer Research, 2005, 11, 5248-5256.	3.2	56
260	ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of multiple myeloma. Annals of Oncology, 2005, 16, i45-i47.	0.6	22
261	Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2005, 23, 667-675.	0.8	517
262	Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma. Journal of Clinical Oncology, 2005, 23, 676-684.	0.8	562
263	Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma. Leukemia and Lymphoma, 2005, 46, 1103-1104.	0.6	22
264	Proteasome inhibition as a therapeutic strategy for hematologic malignancies. Expert Review of Anticancer Therapy, 2005, 5, 465-476.	1.1	14
265	The Changing Treatment Paradigm in Patients With Newly Diagnosed Multiple Myeloma: Implications for Nursing. Oncology Nursing Forum, 2005, 32, E127-E138.	0.5	12
266	Cooperative Cytotoxicity of Proteasome Inhibitors and Tumor Necrosis Factorâ€"Related Apoptosis-Inducing Ligand in Chemoresistant Bcl-2-Overexpressing Cells. Clinical Cancer Research, 2005, 11, 4259-4265.	3.2	57
267	Treatment of mantle cell lymphoma: targeting the microenvironment. Expert Review of Anticancer Therapy, 2005, 5, 477-485.	1.1	9
269	A Phase II Trial with Pharmacodynamic Endpoints of the Proteasome Inhibitor Bortezomib in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2005, 11, 5526-5533.	3.2	99
270	Three Emerging New Drugs for NSCLC: Pemetrexed, Bortezomib, and Cetuximab. Oncologist, 2005, 10, 282-291.	1.9	39
271	Anti-Angiogenic Effect of Bortezomib in Patients with Multiple Myeloma. Acta Haematologica, 2005, 114, 170-173.	0.7	28

#	Article	IF	Citations
272	The Mammalian Innate Immune System: Potential Targets for Drug Development. Current Drug Targets Immune, Endocrine and Metabolic Disorders, 2005, 5, 237-247.	1.8	4
273	A Randomized, Double-Blinded, Placebo-Controlled Phase II Trial of Recombinant Human Leukemia Inhibitory Factor (rhuLIF, emfilermin, AM424) to Prevent Chemotherapy-Induced Peripheral Neuropathy. Clinical Cancer Research, 2005, 11, 1685-1686.	3.2	6
274	Role for the Nuclear Factor ÎºB Pathway in Transforming Growth Factor-Î²1 Production in Idiopathic Myelofibrosis: Possible Relationship with FK506 Binding Protein 51 Overexpression. Cancer Research, 2005, 65, 3281-3289.	0.4	79
275	Bortezomib-Induced Severe Hepatitis in Multiple Myeloma. Archives of Internal Medicine, 2005, 165, 464.	4.3	42
276	Phase II Study of G3139, a Bcl-2 Antisense Oligonucleotide, in Combination With Dexamethasone and Thalidomide in Relapsed Multiple Myeloma Patients. Journal of Clinical Oncology, 2005, 23, 4089-4099.	0.8	96
277	Plasma Cell Problems. Journal of Clinical Oncology, 2005, 23, 3138-3140.	0.8	12
278	An Update of the Management of Multiple Myeloma: The Changing Landscape. Hematology American Society of Hematology Education Program, 2005, 2005, 353-359.	0.9	14
279	Multiple Myeloma: Challenges and Opportunities. , 2005, 113, 1-4.		4
280	Role of allogeneic stem cell transplantation in multiple myeloma. Expert Review of Anticancer Therapy, 2005, 5, 455-464.	1.1	3
281	Velcade displays promising activity in primary effusion lymphoma cells. Cancer Biology and Therapy, 2005, 4, 497-498.	1.5	2
282	Proteasome Inhibition in the Treatment of Cancer. Cell Cycle, 2005, 4, 289-295.	1.3	92
283	Severe Acute Enteritis in a Multiple Myeloma Patient Receiving Bortezomib and Spinal Radiotherapy: Case Report. Journal of Chemotherapy, 2005, 17, 343-346.	0.7	13
284	Evidence for a phosphorylation-independent role for Ser 32 and 36 in proteasome inhibitor-resistant (PIR) IÎºBÎ± degradation in B cells. Experimental Cell Research, 2005, 307, 15-25.	1.2	10
285	Cure of myeloma: hype or reality?. Bone Marrow Transplantation, 2005, 35, 215-224.	1.3	30
286	Lenalidomide and Thalidomide: Mechanisms of Actionâ€"Similarities and Differences. Seminars in Hematology, 2005, 42, S3-S8.	1.8	235
287	Current treatment options for myeloma. Expert Opinion on Pharmacotherapy, 2005, 6, 1127-1142.	0.9	11
288	Multiple Myeloma: Diagnosis and Treatment. Mayo Clinic Proceedings, 2005, 80, 1371-1382.	1.4	210
289	Weekly Cyclophosphamide and Alternate-Day Prednisone: An Effective, Convenient, and Well-Tolerated Oral Treatment for Relapsed Multiple Myeloma After Autologous Stem Cell Transplantation. Mayo Clinic Proceedings, 2005, 80, 1578-1582.	1.4	31

#	Article	IF	Citations
290	Insuffisance rÃ©nale aiguÃ« chez le malade d'oncohÃ©matologie. Reanimation: Journal De La Societe De Reanimation De Langue Francaise, 2005, 14, 508-518.	0.1	2
291	Extramedullary myeloma representing as a pericardial effusion with tamponade: Two case reports and a further review of 19 cases in the literature. Leukemia and Lymphoma, 2005, 46, 137-142.	0.6	14
292	The adverse prognostic impact of advanced age in multiple myeloma. Leukemia and Lymphoma, 2005, 46, 951-966.	0.6	31
293	Overview of drug therapy for multiple myeloma. Journal of Oncology Pharmacy Practice, 2005, 11, 83-100.	0.5	14
294	Early Mortality After Diagnosis of Multiple Myeloma: Analysis of Patients Entered Onto the United Kingdom Medical Research Council Trials Between 1980 and 2002â€"Medical Research Council Adult Leukaemia Working Party. Journal of Clinical Oncology, 2005, 23, 9219-9226.	0.8	402
296	New Cytotoxic Salinosporamides from the Marine ActinomyceteSalinisporatropica. Journal of Organic Chemistry, 2005, 70, 6196-6203.	1.7	174
297	New Approaches and Therapeutics Targeting Apoptosis in Disease. Pharmacological Reviews, 2005, 57, 187-215.	7.1	235
298	PROTEASOME INHIBITION IN MULTIPLE MYELOMA: Therapeutic Implication. Annual Review of Pharmacology and Toxicology, 2005, 45, 465-476.	4.2	132
300	Inflammation-associated cancer: NF-ÎºB is the lynchpin. Trends in Immunology, 2005, 26, 318-325.	2.9	259
301	Innovations in autologous transplantation for hematologic malignancy. Biology of Blood and Marrow Transplantation, 2005, 11, 28-33.	2.0	2
302	Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies. Cancer Treatment Reviews, 2005, 31, 591-602.	3.4	69
303	Perspectives for combination therapy to overcome drug-resistant multiple myeloma. Drug Resistance Updates, 2005, 8, 205-218.	6.5	41
304	Targeting senescence pathways to reverse drug resistance in cancer. Cancer Letters, 2005, 219, 1-13.	3.2	33
307	Tumor necrosis factor, cancer and anticancer therapy. Cytokine and Growth Factor Reviews, 2005, 16, 35-53.	3.2	263
308	Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma. New England Journal of Medicine, 2005, 352, 2487-2498.	13.9	2,356
309	Structureâ^'Activity Relationship Studies of Salinosporamide A (NPI-0052), a Novel Marine Derived Proteasome Inhibitor. Journal of Medicinal Chemistry, 2005, 48, 3684-3687.	2.9	223
310	Emerging Trends in the Clinical Use of Bortezomib in Multiple Myeloma. Clinical Lymphoma and Myeloma, 2005, 6, 84-88.	1.4	7
311	Evolving Role of Stem Cell Transplantation in Multiple Myeloma. Clinical Lymphoma and Myeloma, 2005, 6, 89-95.	1.4	8

#	Article	IF	Citations
312	Induction Therapy Before Transplantation in Multiple Myeloma: New Strategies to Achieve Complete Response. Clinical Lymphoma and Myeloma, 2005, 6, 96-101.	1.4	1
313	New Approaches to Treatment for Multiple Myeloma: Durable Remission and Quality of Life as Primary Goals. Clinical Lymphoma and Myeloma, 2005, 6, 181-190.	1.4	30
314	Risk Stratification of Patients with Newly Diagnosed Multiple Myeloma: Optimizing Treatment Based on Pretreatment Characteristics. Clinical Lymphoma and Myeloma, 2005, 6, 200-207.	1.4	6
315	Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer. Journal of Clinical Oncology, 2005, 23, 630-639.	0.8	526
316	Novel biological therapies for the treatment of multiple myeloma. Best Practice and Research in Clinical Haematology, 2005, 18, 619-634.	0.7	46
317	Conventional therapy and approach to management. Best Practice and Research in Clinical Haematology, 2005, 18, 585-601.	0.7	6
318	Renal, hematologic and infectious complications in multiple myeloma. Best Practice and Research in Clinical Haematology, 2005, 18, 635-652.	0.7	61
319	Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer. Lung Cancer, 2005, 49, 163-170.	0.9	58
320	Bortezomib: A valuable new antineoplastic strategy in multiple myeloma. Acta OncolÃ³gica, 2005, 44, 440-448.	0.8	35
321	HUMAN METABOLISM OF THE PROTEASOME INHIBITOR BORTEZOMIB: IDENTIFICATION OF CIRCULATING METABOLITES. Drug Metabolism and Disposition, 2005, 33, 771-777.	1.7	122
322	The Proteasome as a Target for Cancer Treatment. American Journal of Cancer, 2005, 4, 359-372.	0.4	5
324	Narrative Review: Protein Degradation and Human Diseases: The Ubiquitin Connection. Annals of Internal Medicine, 2006, 145, 676.	2.0	192
325	Management Strategies for Relapsed Multiple Myeloma. American Journal of Cancer, 2006, 5, 393-409.	0.4	2
326	Emerging Therapies for Multiple Myeloma. American Journal of Cancer, 2006, 5, 141-153.	0.4	2
327	Cachexia: Therapeutic Immunomodulation Beyond Cytokine Antagonism. , 2006, , 741-753.		1
328	Treatment of multiple myeloma: An emphasis on new developments. Annals of Medicine, 2006, 38, 111-115.	1.5	15
330	Chemotherapy-Induced Neuropathy. Clinics in Podiatric Medicine and Surgery, 2006, 23, 637-649.	0.2	6
331	Optimizing the Management of Treatment-Related Peripheral Neuropathy in Patients with Multiple Myeloma. Supportive Cancer Therapy, 2006, 4, 19-22.	0.3	6

#	Article	IF	Citations
332	Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Molecular Cancer Therapeutics, 2006, 5, 2378-2387.	1.9	102
333	Down-regulating constitutive activation of the NF-Î²B canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood, 2006, 107, 2354-2363.	0.6	165
334	Principles of Targeted and Biological Therapies. , 2006, , 73-90.		0
336	Mechanistic Rationale and Clinical Evidence for the Efficacy of Proteasome Inhibitors against Indolent and Mantle Cell Lymphomas. BioDrugs, 2006, 20, 13-23.	2.2	24
337	Investigational treatments for multiple myeloma. Expert Opinion on Investigational Drugs, 2006, 15, 1565-1582.	1.9	7
338	Targeting the proteasome in mantle cell lymphoma: A promising therapeutic approach. Leukemia and Lymphoma, 2006, 47, 195-205.	0.6	21
339	New horizons in multiple myeloma therapy. Expert Review of Anticancer Therapy, 2006, 6, 1483-1501.	1.1	1
340	Clinical implications of chromosomal abnormalities in multiple myeloma. Leukemia and Lymphoma, 2006, 47, 803-814.	0.6	39
341	Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma. Leukemia and Lymphoma, 2006, 47, 1360-1364.	0.6	7
342	Hsp90 Inhibitors in the Clinic. , 2006, , 331-358.		88
344	Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. European Journal of Immunology, 2006, 36, 681-689.	1.6	71
346	The emerging role of novel therapeutic agents in the management of patients with multiple myeloma. Community Oncology, 2006, 3, 575-582.	0.2	0
348	ModalitÃ©s thÃ©rapeutiques duÂmyÃ©lome multiple. Reanimation: Journal De La Societe De Reanimation De Langue Francaise, 2006, 15, 290-296.	0.1	0
349	Novel Treatment Approaches for Patients with Multiple Myeloma. Clinical Lymphoma and Myeloma, 2006, 6, 281-288.	1.4	5
350	Cyclophosphamide Mobilization Does Not Improve Outcome in Patients Receiving Stem Cell Transplantation for Multiple Myeloma. Clinical Lymphoma and Myeloma, 2006, 6, 384-388.	1.4	79
351	Superior 12-Year Survival After at Least 4-Year Continuous Remission with Tandem Transplantations for Multiple Myeloma. Clinical Lymphoma and Myeloma, 2006, 6, 469-474.	1.4	16
352	Emerging Role of Novel Combinations for Induction Therapy in Multiple Myeloma. Clinical Lymphoma and Myeloma, 2006, 7, 33-41.	1.4	7
354	Response to Bortezomib and Activation of Osteoblasts in Multiple Myeloma. Clinical Lymphoma and Myeloma, 2006, 7, 109-114.	1.4	46

#	Article	IF	Citations
355	Weekly Bortezomib/Methylprednisolone is Effective and Well Tolerated in Relapsed Multiple Myeloma. Clinical Lymphoma and Myeloma, 2006, 7, 131-134.	1.4	29
356	Phase I Trial of First-Line Bortezomib/Thalidomide plus Chemotherapy for Induction and Stem Cell Mobilization in Patients with Multiple Myeloma. Clinical Lymphoma and Myeloma, 2006, 7, 210-216.	1.4	42
357	Bortezomib-Induced Tumor Lysis Syndrome in Multiple Myeloma. Clinical Lymphoma and Myeloma, 2006, 7, 233-235.	1.4	46
358	THE PROTEASOME AND PROTEASOME INHIBITORS IN CANCER THERAPY. Annual Review of Pharmacology and Toxicology, 2006, 46, 189-213.	4.2	251
359	Management of Multiple Myeloma with Bortezomib: Experts Review the Data and Debate the Issues. Oncology, 2006, 70, 474-482.	0.9	43
360	Bortezomib: Proteasome Inhibition as an Effective Anticancer Therapy. Annual Review of Medicine, 2006, 57, 33-47.	5.0	317
361	Ubiquitin proteasome system as a pharmacological target in neurodegeneration. Expert Review of Neurotherapeutics, 2006, 6, 1337-1347.	1.4	26
362	Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. Nature Clinical Practice Oncology, 2006, 3, 374-387.	4.3	103
363	Phase I/II Trial Assessing Bortezomib and Melphalan Combination Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma. Journal of Clinical Oncology, 2006, 24, 937-944.	0.8	205
364	A CK2-Dependent Mechanism for Degradation of the PML Tumor Suppressor. Cell, 2006, 126, 269-283.	13.5	271
365	Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function. Clinical Therapeutics, 2006, 28, 953-959.	1.1	18
366	Biology and Treatment of Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2006, 12, 81-86.	2.0	10
367	The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Drug Resistance Updates, 2006, 9, 263-273.	6.5	151
368	State of the art therapy in multiple myeloma and future perspectives. European Journal of Cancer, 2006, 42, 1591-1600.	1.3	30
369	The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: Interplay of growth factors, their receptors and stromal interactions. European Journal of Cancer, 2006, 42, 1564-1573.	1.3	188
370	Cytogenetics and molecular cytogenetics in multiple myeloma. European Journal of Cancer, 2006, 42, 1520-1529.	1.3	56
371	Proteasome inhibition in multiple myeloma. European Journal of Cancer, 2006, 42, 1623-1639.	1.3	22
372	160 years of multiple myeloma: Progress and challenges. European Journal of Cancer, 2006, 42, 1507-1509.	1.3	11

#	Article	IF	Citations
373	Targeting ubiquitin in cancers. European Journal of Cancer, 2006, 42, 3095-3102.	1.3	15
374	The proteasome inhibitor VELCADEÂ® reduces infarction in rat models of focal cerebral ischemia. Neuroscience Letters, 2006, 398, 300-305.	1.0	39
375	Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma. Journal of the American Academy of Dermatology, 2006, 55, 897-900.	0.6	51
376	Plasma cell dyscrasias and leukemias. Update on Cancer Therapeutics, 2006, 1, 539-567.	0.9	0
377	Proteasome inhibitors and modulators of heat shock protein function. Update on Cancer Therapeutics, 2006, 1, 91-116.	0.9	7
378	Regulation of the Cell Cycle and Interventional Developmental Therapeutics. , 2006, , 123-140.		3
379	Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo. International Journal of Oncology, 2006, 28, 439.	1.4	16
380	Clinical trials. Frontiers in Bioscience - Landmark, 2006, 11, 2918.	3.0	3
381	LAGÎ»-1: A clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma. International Journal of Oncology, 2006, 28, 1409.	1.4	8
382	New Frontiers in the Treatment of Multiple Myeloma. Scientific World Journal, The, 2006, 6, 1475-1503.	0.8	10
383	Initial Therapy of Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation. Hematology American Society of Hematology Education Program, 2006, 2006, 338-347.	0.9	15
385	Bortezomib: the evidence of its clinical impact in multiple myeloma. Core Evidence, 2006, Volume 1-Issues 3 & 4, 0-0.	4.7	1
387	Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood, 2006, 108, 2165-2172.	0.6	373
388	Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood, 2006, 108, 3289-3294.	0.6	639
389	NF-ÎºB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. Blood, 2006, 107, 827-834.	0.6	109
390	The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood, 2006, 107, 257-264.	0.6	417
391	Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin. Blood, 2006, 107, 2895-2903.	0.6	77
392	The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism. Blood, 2006, 107, 232-240.	0.6	93

#	Article	IF	Citations
393	Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood, 2006, 107, 4053-4062.	0.6	398
394	Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood, 2006, 108, 551-558.	0.6	128
395	Marburg I polymorphism of factor VII-activating protease and risk of venous thromboembolism. Blood, 2006, 107, 1731-1731.	0.6	73
396	Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood, 2006, 107, 1731a-1732.	0.6	63
397	Long-term engraftment and clonal dominance of donor-derived del(20q) hematopoietic cells after allogeneic stem cell transplantation. Blood, 2006, 107, 1732-1733.	0.6	13
398	Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma. Blood, 2006, 107, 4063-4070.	0.6	37
399	Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood, 2006, 107, 3492-3494.	0.6	184
400	Severe pulmonary complication after bortezomib treatment for multiple myeloma. Blood, 2006, 108, 1113-1113.	0.6	37
401	A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, 108, 3458-3464.	0.6	494
402	Complete response in myeloma: a Trojan horse?. Blood, 2006, 108, 2134-2134.	0.6	12
403	Leukemia does not live by 1 lesion alone. Blood, 2006, 108, 2133-2134.	0.6	5
404	Novel Non-Cytotoxic Therapy in Ovarian Cancer: Current Status and Future Prospects. Journal of the National Comprehensive Cancer Network: JNCCN, 2006, 4, 955-966.	2.3	19
405	Bortezomib Plus Docetaxel in Advanced Non-small Cell Lung Cancer and Other Solid Tumors: A Phase I California Cancer Consortium Trial. Journal of Thoracic Oncology, 2006, 1, 126-134.	0.5	11
406	Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. Current Opinion in Oncology, 2006, 18, 598-608.	1.1	32
407	Novel Agents Aiming at Specific Molecular Targets Increase Chemosensitivity and Overcome Chemoresistance in Hematopoietic Malignancies. Current Pharmaceutical Design, 2006, 12, 111-128.	0.9	19
408	Proteasome Inhibition as a New Therapeutic Principle in Hematological Malignancies. Current Drug Targets, 2006, 7, 1341-1347.	1.0	40
409	Severe Pulmonary Complications in African-American Patient After Bortezomib Therapy. American Journal of Therapeutics, 2006, 13, 553-555.	0.5	26
412	Microarray-based understanding of normal and malignant plasma cells. Immunological Reviews, 2006, 210, 86-104.	2.8	56

#	Article	IF	Citations
413	Current status of new drugs for the treatment of patients with multiple myeloma. Internal Medicine Journal, 2006, 36, 781-789.	0.5	24
414	Guidelines on the diagnosis and management of multiple myeloma 2005. British Journal of Haematology, 2006, 132, 410-451.	1.2	234
415	Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib*. British Journal of Haematology, 2006, 134, 145-156.	1.2	94
416	Proteasome inhibition as novel treatment strategy in leukaemia. British Journal of Haematology, 2006, 134, 253-262.	1.2	40
417	Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?. British Journal of Haematology, 2006, 134, 391-398.	1.2	55
418	Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells. British Journal of Haematology, 2006, 135, 52-61.	1.2	20
419	Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. British Journal of Haematology, 2006, 135, 158-164.	1.2	155
420	Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nature Reviews Cancer, 2006, 6, 227-239.	12.8	1,104
421	Success in translational research: lessons from the development of bortezomib. Nature Reviews Drug Discovery, 2006, 5, 107-114.	21.5	78
422	Drug discovery in the ubiquitinâ€“proteasome system. Nature Reviews Drug Discovery, 2006, 5, 596-613.	21.5	548
423	Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma. Bone Marrow Transplantation, 2006, 37, 65-72.	1.3	11
424	Cure of multiple myeloma â€“ more hype, less reality. Bone Marrow Transplantation, 2006, 37, 1-18.	1.3	26
425	Targeting NF-Î²B in hematologic malignancies. Cell Death and Differentiation, 2006, 13, 748-758.	5.0	144
426	Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia, 2006, 20, 1341-1352.	3.3	115
427	International uniform response criteria for multiple myeloma. Leukemia, 2006, 20, 1467-1473.	3.3	2,332
428	Inhibition of bortezomib-induced apoptosis by red blood cell uptake. Leukemia, 2006, 20, 1646-1649.	3.3	6
429	Difference between hematological malignancy and Solid tumor research articles published in four major medical journals. Leukemia, 2006, 20, 1655-1657.	3.3	18
430	Proteasome inhibitors in lung cancer. Critical Reviews in Oncology/Hematology, 2006, 58, 177-189.	2.0	57

#	Article	IF	Citations
431	An Electrodiagnostic Evaluation of the Effect of Pre-existing Peripheral Nervous System Disorders in Patients Treated with the Novel Proteasome Inhibitor Bortezomib. Clinical Oncology, 2006, 18, 410-418.	0.6	22
432	No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib. Leukemia Research, 2006, 30, 240-241.	0.4	56
433	Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide. Leukemia Research, 2006, 30, 283-285.	0.4	17
434	Dexamethasone Reduces the Risk of Bortezomib-Induced Pulmonary Complications in Japanese Myeloma Patients. International Journal of Hematology, 2006, 84, 90-91.	0.7	6
435	Lung Injury Associated with Bortezomib Therapy in Relapsed/Refractory Multiple Myeloma in Japan: A Questionnaire-Based Report from the "Lung Injury by Bortezomib" Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology. International Journal of Hematology, 2006, 84, 406-412.	0.7	41
436	A Multicenter Retrospective Analysis of Adverse Events in Korean Patients Using Bortezomib for Multiple Myeloma. International Journal of Hematology, 2006, 83, 309-313.	0.7	32
437	Efficacy and Safety Results with the Combination Therapy of Arsenic Trioxide, Dexamethasone, and Ascorbic Acid in Multiple Myeloma Patients: A Phase 2 Trial. Medical Oncology, 2006, 23, 263-272.	1.2	33
438	TNFâ€Î± in Cancer Treatment: Molecular Insights, Antitumor Effects, and Clinical Utility. Oncologist, 2006, 11, 397-408.	1.9	624
439	Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: Comparative studies against doxorubicin and mitoxantrone. Investigational New Drugs, 2006, 24, 529-35.	1.2	68
440	Proteasome Inhibitors Induce a p38 Mitogen-activated Protein Kinase (MAPK)-dependent Anti-apoptotic Program Involving MAPK Phosphatase-1 and Akt in Models of Breast Cancer. Breast Cancer Research and Treatment, 2006, 100, 33-47.	1.1	64
441	Lactacystin Exhibits Potent Anti-tumor Activity in an Animal Model of Malignant Glioma when Administered via Controlled-release Polymers. Journal of Neuro-Oncology, 2006, 77, 225-232.	1.4	20
442	Parthenolide-induced apoptosis in multiple myeloma cells involves reactive oxygen species generation and cell sensitivity depends on catalase activity. Apoptosis: an International Journal on Programmed Cell Death, 2006, 11, 2225-2235.	2.2	58
443	The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells. Apoptosis: an International Journal on Programmed Cell Death, 2006, 11, 1175-1193.	2.2	84
444	Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisoneâ€"a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). Journal of Cancer Research and Clinical Oncology, 2006, 132, 205-212.	1.2	175
446	Is targeted chemotherapy an alternative to immunotherapy in chronic lymphocytic leukemia?. Cancer Immunology, Immunotherapy, 2006, 55, 221-228.	2.0	7
447	Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib. Annals of Hematology, 2006, 85, 132-133.	0.8	18
448	Successful treatment of lymph node extramedullary plasmacytoma with bortezomib. Annals of Hematology, 2006, 85, 188-190.	0.8	8
449	Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemotherapy and Pharmacology, 2006, 58, 13-23.	1.1	118

#	Article	IF	Citations
450	A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Cancer Chemotherapy and Pharmacology, 2006, 59, 207-215.	1.1	41
451	Novel treatment approaches for patients with relapsed and refractory multiple myeloma. Current Treatment Options in Oncology, 2006, 7, 246-257.	1.3	2
452	Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Experimental Hematology, 2006, 34, 770-775.	0.2	66
453	CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice. Experimental Hematology, 2006, 34, 721-727.	0.2	25
454	Can NF-Î¹B be a target for novel and efficient anti-cancer agents?. Biochemical Pharmacology, 2006, 72, 1054-1068.	2.0	108
455	Dermatologic Toxicity of Chemotherapeutic Agents. Seminars in Oncology, 2006, 33, 86-97.	0.8	70
456	Neurologic Complications of Cancer Chemotherapy. Seminars in Oncology, 2006, 33, 324-332.	0.8	62
457	Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines. European Journal of Haematology, 2006, 76, 265-268.	1.1	53
458	Bortezomib: an effective agent in extramedullary disease in multiple myeloma. European Journal of Haematology, 2006, 76, 405-408.	1.1	129
459	Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer, 2006, 106, 1084-1089.	2.0	69
460	Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:. Cancer, 2006, 106, 1316-1319.	2.0	133
461	Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer, 2006, 107, 916-924.	2.0	81
462	Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. Cancer, 2006, 107, 2482-2489.	2.0	47
463	A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer, 2006, 107, 2688-2697.	2.0	57
464	Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma. Hematological Oncology, 2006, 24, 205-211.	0.8	10
465	Proteasome inhibition with bortezomib: A new therapeutic strategy for non-Hodgkin's lymphoma. International Journal of Cancer, 2006, 119, 971-979.	2.3	51
466	Erythrocytosis associated with gestational hyperandrogenism. American Journal of Hematology, 2006, 81, 984-985.	2.0	2
467	Delayed profound thrombocytopenia associated with eptifibatide. American Journal of Hematology, 2006, 81, 984-984.	2.0	13

#	Article	IF	Citations
468	A long-lasting third complete remission after second autologous transplant followed by maintenance treatment with rituximab in a patient with diffuse large cell non-Hodgkin's lymphoma. American Journal of Hematology, 2006, 81, 986-987.	2.0	5
469	A family of severe congenital neutropenia with â^'199c to a substitution inELA2 promoter. American Journal of Hematology, 2006, 81, 985-986.	2.0	6
470	VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia. American Journal of Hematology, 2006, 81, 987-988.	2.0	8
471	Friend or Foe? The Proteasome in Combined Cancer Therapy. Cell Cycle, 2006, 5, 841-845.	1.3	7
472	Proteasome Inhibition: Novel Therapy for Multiple Myeloma. Oncology Research and Treatment, 2006, 29, 162-168.	0.8	5
473	Myeloma â€" new approaches to combined nephrologicalâ€"haematological management. Nephrology Dialysis Transplantation, 2006, 21, 582-590.	0.4	31
474	Bortezomib for multiple myeloma. Expert Opinion on Pharmacotherapy, 2006, 7, 1337-1346.	0.9	12
475	Advances in the treatment for haematological malignancies. Expert Opinion on Pharmacotherapy, 2006, 7, 721-732.	0.9	10
476	Pharmacotherapy of multiple myeloma. Expert Opinion on Pharmacotherapy, 2006, 7, 767-781.	0.9	4
477	Is bortezomib superior to high-dose dexamethasone for the treatment of relapsed multiple myeloma?. Nature Clinical Practice Oncology, 2006, 3, 16-17.	4.3	3
480	Antitumor Effects of the Proteasome Inhibitor Bortezomib in Medullary and Anaplastic Thyroid Carcinoma Cells in Vitro. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4013-4021.	1.8	120
481	Thalidomide in multiple myeloma: past, present and future. Future Oncology, 2006, 2, 577-589.	1.1	34
482	NF-κ B and Rheumatic Diseases. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2006, 6, 359-372.	0.6	70
483	Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib. Journal of Clinical Oncology, 2006, 24, 3113-3120.	0.8	587
484	Low dose velcade, thalidomide and dexamethasone (LD-VTD): An effective regimen for relapsed and refractory multiple myeloma patients. Leukemia and Lymphoma, 2006, 47, 171-173.	0.6	38
486	Bortezomib as an Antitumor Agent. Current Pharmaceutical Biotechnology, 2006, 7, 441-448.	0.9	75
487	Metabolism-Directed Optimisation of Antithrombotics: The Prodrug Principle. Current Pharmaceutical Design, 2006, 12, 73-91.	0.9	24
488	Haematology. Journal of the Royal Army Medical Corps, 2006, 152, 250-265.	0.8	0

#	Article	IF	Citations
489	Bortezomib (VELCADEÂ®) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Annals of Oncology, 2006, 17, 813-817.	0.6	121
490	Recent Advances in the Treatment of Multiple Myeloma. Current Pharmaceutical Biotechnology, 2006, 7, 381-393.	0.9	15
491	Multiple Myeloma. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 1322-1330.	2.2	35
492	Targeted Therapies in Non-Small Cell Lung Cancer: Proven Concepts and Unfulfilled Promises.. Current Cancer Drug Targets, 2006, 6, 271-294.	0.8	28
493	Targeting Signaling Pathways in Multiple Myeloma. Current Pharmaceutical Biotechnology, 2006, 7, 407-413.	0.9	4
494	New Treatment Strategies for Multiple Myeloma by Targeting BCL-2 and the Mevalonate Pathway. Current Pharmaceutical Design, 2006, 12, 327-340.	0.9	31
495	Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib. Molecular Cancer Therapeutics, 2006, 5, 3052-3061.	1.9	68
496	Immunotherapeutic and Immunoregulatory Drugs in Haematologic Malignancies. Current Topics in Medicinal Chemistry, 2006, 6, 1657-1686.	1.0	12
497	The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Molecular Cancer Therapeutics, 2006, 5, 1836-1843.	1.9	112
499	Inhibitors of NF-Î²B Activity. , 2006, , 162-178.		1
501	Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2006, 24, 5025-5033.	0.8	154
502	The Proteasome Is Required for Rapid Initiation of Death Receptor-Induced Apoptosis. Molecular and Cellular Biology, 2006, 26, 1967-1978.	1.1	37
503	Light-Chain (AL) Amyloidosis: Diagnosis and Treatment. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 1331-1341.	2.2	191
504	Ubiquitin-Proteasome System Stress Sensitizes Ovarian Cancer to Proteasome Inhibitorâ€“Induced Apoptosis. Cancer Research, 2006, 66, 3754-3763.	0.4	123
505	Farnesyl and Geranylgeranyl Transferase Inhibitors Induce G1 Arrest by Targeting the Proteasome. Cancer Research, 2006, 66, 1040-1051.	0.4	46
506	Descriptive and Prognostic Value of Patient-Reported Outcomes: The Bortezomib Experience in Relapsed and Refractory Multiple Myeloma. Journal of Clinical Oncology, 2006, 24, 976-982.	0.8	88
507	Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine, 2006, 354, 1021-1030.	13.9	684
508	Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Molecular Cancer Therapeutics, 2006, 5, 665-675.	1.9	98

#	Article	IF	Citations
509	Aggresome Disruption: A Novel Strategy to Enhance Bortezomib-Induced Apoptosis in Pancreatic Cancer Cells. Cancer Research, 2006, 66, 3773-3781.	0.4	226
510	Efficacy of Up-Front Treatment with a Double Stem Cell Transplantation in Multiple Myeloma. Japanese Journal of Clinical Oncology, 2006, 36, 432-438.	0.6	8
511	Targeting the ubiquitinâ€“proteasome pathway in breast cancer therapy. Future Oncology, 2006, 2, 121-135.	1.1	24
512	Histone Deacetylase Inhibitor Depsipeptide (FK228) Induces Apoptosis in Leukemic Cells by Facilitating Mitochondrial Translocation of Bax, Which Is Enhanced by the Proteasome Inhibitor Bortezomib. Acta Haematologica, 2006, 115, 78-90.	0.7	48
513	Bortezomib-Induced Skin Lesion. Acta Haematologica, 2006, 116, 226-227.	0.7	7
514	Treatment Strategies for Multiple Myeloma in the Age of Novel Therapies. Current Cancer Therapy Reviews, 2006, 2, 169-183.	0.2	0
515	Bortezomib-Induced Rhabdomyolysis in Multiple Myeloma. Acta Haematologica, 2006, 116, 203-206.	0.7	12
516	Bortezomib and Dexamethasone in Previously Untreated Multiple Myeloma Associated with Renal Failure and Reversal of Renal Failure. Acta Haematologica, 2006, 116, 255-258.	0.7	22
517	Immunosensitization of Tumor Cells to Dendritic Cell-Activated Immune Responses with the Proteasome Inhibitor Bortezomib (PS-341, Velcade). Journal of Immunology, 2006, 176, 4757-4765.	0.4	56
518	Targeted Therapies in Gynecologic Cancers. Current Cancer Drug Targets, 2006, 6, 333-363.	0.8	38
519	A Practical Update on the Use of Bortezomib in the Management of Multiple Myeloma. Oncologist, 2006, 11, 51-61.	1.9	102
520	Bortezomib in relapsed multiple myeloma complicated by extramedullary plasmacytomas. International Journal of Laboratory Hematology, 2006, 28, 267-269.	0.2	10
521	Targeting the proteasome as a therapeutic strategy against haematological malignancies. Expert Opinion on Investigational Drugs, 2006, 15, 117-130.	1.9	21
522	Lenalidomide in multiple myeloma. Expert Review of Anticancer Therapy, 2006, 6, 1165-1173.	1.1	50
523	Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma. Journal of Clinical Oncology, 2006, 24, 4867-4874.	0.8	675
524	Poorex vivoinduction of T-cell responses to idiotype or tumor cell lysate-pulsed autologous dendritic cells in advanced pre-treated multiple myeloma. Leukemia and Lymphoma, 2006, 47, 1340-1347.	0.6	4
525	Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 17408-17413.	3.3	228
526	PS-341 (Bortezomib) Induces Lysosomal Cathepsin B Release and a Caspase-2-dependent Mitochondrial Permeabilization and Apoptosis in Human Pancreatic Cancer Cells. Journal of Biological Chemistry, 2006, 281, 11923-11932.	1.6	70

#	Article	IF	Citations
527	Combined Effect of Proteasome and Calpain Inhibition on Cisplatin-Resistant Human Melanoma Cells. Cancer Research, 2006, 66, 7598-7605.	0.4	43
528	Proteasome blockade exerts an antifibrotic activity by coordinately downâ€regulating type I collagen and tissue inhibitor of metalloproteinaseâ€1 and upâ€regulating metalloproteinaseâ€1 production in human dermal fibroblasts. FASEB Journal, 2006, 20, 562-564.	0.2	55
529	A Novel Orally Active Small Molecule Potently Induces G1 Arrest in Primary Myeloma Cells and Prevents Tumor Growth by Specific Inhibition of Cyclin-Dependent Kinase 4/6. Cancer Research, 2006, 66, 7661-7667.	0.4	209
530	Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells. Molecular Cancer Therapeutics, 2006, 5, 2043-2050.	1.9	45
531	Development of Neuropathy in Patients With Myeloma Treated With Thalidomide: Patterns of Occurrence and the Role of Electrophysiologic Monitoring. Journal of Clinical Oncology, 2006, 24, 4507-4514.	0.8	195
532	Effect of Bortezomib on Human Neuroblastoma Cell Growth, Apoptosis, and Angiogenesis. Journal of the National Cancer Institute, 2006, 98, 1142-1157.	3.0	125
533	INVESTIGATION OF DRUG-DRUG INTERACTION POTENTIAL OF BORTEZOMIB IN VIVO IN FEMALE SPRAGUE-DAWLEY RATS AND IN VITRO IN HUMAN LIVER MICROSOMES. Drug Metabolism and Disposition, 2006, 34, 702-708.	1.7	29
534	Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Annals of Oncology, 2006, 17, 1766-1771.	0.6	132
535	Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMAâ€"Italian Multiple Myeloma Network. Journal of Clinical Oncology, 2007, 25, 4459-4465.	0.8	301
536	A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma. Clinical Cancer Research, 2007, 13, 1762-1768.	3.2	115
537	MG-132 Sensitizes TRAIL-Resistant Prostate Cancer Cells by Activating c-Fos/c-Jun Heterodimers and Repressing c-FLIP(L). Cancer Research, 2007, 67, 2247-2255.	0.4	83
538	5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Molecular Cancer Therapeutics, 2007, 6, 1718-1727.	1.9	154
539	Clinical Impact of Bortezomib in Frontline Regimens for Patients with Multiple Myeloma. Oncologist, 2007, 12, 978-990.	1.9	30
540	Management of paraproteinaemia. Postgraduate Medical Journal, 2007, 83, 217-223.	0.9	36
541	Combination Chemotherapy with Bortezomib, Cyclophosphamide and Dexamethasone may be Effective for Plasma Cell Leukemia. Japanese Journal of Clinical Oncology, 2007, 37, 382-384.	0.6	17
542	Phase I/II Study of Bortezomib Plus Docetaxel in Patients with Advanced Androgen-Independent Prostate Cancer. Clinical Cancer Research, 2007, 13, 1208-1215.	3.2	67
543	The evolving role of lenalidomide in the treatment of hematologic malignancies. Expert Opinion on Pharmacotherapy, 2007, 8, 497-509.	0.9	46
544	Emerging drugs in multiple myeloma. Expert Opinion on Emerging Drugs, 2007, 12, 155-163.	1.0	11

#	Article	IF	Citations
545	Neutrophilic dermatitis associated with bortezomib in a patient with multiple myeloma. Annals of Oncology, 2007, 18, 1744-1745.	0.6	7
546	Proteasome as an Emerging Therapeutic Target in Cancer. Current Pharmaceutical Design, 2007, 13, 471-485.	0.9	54
547	Towards the Development of Tumor Necrosis Factor (TNF) Sensitizers:Making TNF Work Against Cancer. Current Pharmaceutical Design, 2007, 13, 537-551.	0.9	17
548	Chemotherapy-Induced Peripheral Neuropathy: A Review and Implications for Oncology Nursing Practice. Clinical Journal of Oncology Nursing, 2007, 11, 361-376.	0.3	108
549	The Emerging Role of Targeted Therapy for Hematologic Malignancies: Update on Bortezomib and Tipifarnib. Oncologist, 2007, 12, 281-290.	1.9	32
550	NF-κB Signaling and Carcinogenesis. Current Pharmaceutical Design, 2007, 13, 447-462.	0.9	105
551	Bortezomib in Combination with Conventional Chemotherapeutic Agents for Multiple Myeloma Compared with Bortezomib Alone. Japanese Journal of Clinical Oncology, 2007, 37, 961-968.	0.6	17
552	Targeted Therapies for Non-Small Cell Lung Cancer. Current Pharmaceutical Design, 2007, 13, 2810-2831.	0.9	14
553	Strategies for Risk-Adapted Therapy in Myeloma. Hematology American Society of Hematology Education Program, 2007, 2007, 304-310.	0.9	11
554	Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica, 2007, 92, 546-549.	1.7	160
555	Satisfaction Guaranteed â€" â€œPayment by Resultsâ€•for Biologic Agents. New England Journal of Medicine, 2007, 357, 1575-1577.	13.9	58
556	Novel inhibitors in the treatment of metastatic melanoma. Expert Review of Anticancer Therapy, 2007, 7, 715-724.	1.1	26
557	Development ofNovel Compounds to Treat Autoimmune and Inflammatory Diseases and Graft Versus Host Reactions. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2007, 7, 93-97.	0.6	4
558	Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression. Journal of Clinical Oncology, 2007, 25, 3892-3901.	0.8	607
559	Image-Based Screening for the Identification of Novel Proteasome Inhibitors. Journal of Biomolecular Screening, 2007, 12, 203-210.	2.6	43
560	IFN-Î³ Enhances the Antimyeloma Activity of the Fully Human Antiâ€"Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3. Cancer Research, 2007, 67, 3269-3275.	0.4	18
561	Inhibitors of the Proteasome Suppress Homologous DNA Recombination in Mammalian Cells. Cancer Research, 2007, 67, 8536-8543.	0.4	105
562	Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003. Journal of Clinical Oncology, 2007, 25, 1993-1999.	0.8	275

#	Article	IF	Citations
563	Bortezomib Is Active in Patients With Untreated or Relapsed WaldenstrÃ¶m's Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 2007, 25, 1570-1575.	0.8	184
564	Inhibition of Interleukin-6 Signaling with CNTO 328 Enhances the Activity of Bortezomib in Preclinical Models of Multiple Myeloma. Clinical Cancer Research, 2007, 13, 6469-6478.	3.2	112
565	Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor. Molecular Cancer Therapeutics, 2007, 6, 987-994.	1.9	118
566	Different Induction of GRP78 and CHOP as a Predictor of Sensitivity to Proteasome Inhibitors in Thyroid Cancer Cells. Endocrinology, 2007, 148, 3258-3270.	1.4	42
567	New Drugs for Myeloma. Oncologist, 2007, 12, 664-689.	1.9	145
568	Cancer Stem Cells. , 2007, , .		2
569	A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Annals of Oncology, 2007, 18, 116-121.	0.6	151
570	Severe Epidermal Necrolysis after Bortezomib Treatment for Multiple Myeloma. Acta Haematologica, 2007, 118, 65-67.	0.7	21
571	Phase II Pethema Trial of Alternating Bortezomib and Dexamethasone As Induction Regimen Before Autologous Stem-Cell Transplantation in Younger Patients With Multiple Myeloma: Efficacy and Clinical Implications of Tumor Response Kinetics. Journal of Clinical Oncology, 2007, 25, 4452-4458.	0.8	106
572	Multiple myeloma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2007, 18, ii44-ii46.	0.6	4
573	Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248. Clinical Cancer Research, 2007, 13, 3320-3325.	3.2	186
574	Myeloma Cells and Their Interactions With the Bone Marrow Endothelial Cells. Current Immunology Reviews, 2007, 3, 41-55.	1.2	6
576	Rapid Response to High-Dose Steroids of Severe Bortezomib-Related Pulmonary Complication in Multiple Myeloma. Journal of Clinical Oncology, 2007, 25, 3380-3381.	0.8	36
577	Relationship Between Depth of Response and Outcome in Multiple Myeloma. Journal of Clinical Oncology, 2007, 25, 4933-4937.	0.8	40
578	Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma. Clinical Cancer Research, 2007, 13, 6162-6167.	3.2	68
579	Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. Molecular Cancer Therapeutics, 2007, 6, 61-69.	1.9	51
580	Targeted therapeutics for multiple myeloma: The arrival of a risk-stratified approach. Molecular Cancer Therapeutics, 2007, 6, 802-810.	1.9	24
581	Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism. Molecular Cancer Therapeutics, 2007, 6, 1774-1784.	1.9	82

#	Article	IF	Citations
582	Pseudomembranous Colitis following Bortezomib Therapy in a Myeloma Patient. Acta Haematologica, 2007, 117, 211-214.	0.7	13
583	The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD). Haematologica, 2007, 92, 1149-1150.	1.7	71
584	The Treatment of Relapsed and Refractory Multiple Myeloma. Hematology American Society of Hematology Education Program, 2007, 2007, 317-323.	0.9	53
585	Nuclear factor ÂB as a target for new drug development in myeloid malignancies. Haematologica, 2007, 92, 1224-1229.	1.7	84
586	Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica, 2007, 92, 1351-1358.	1.7	179
587	Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood, 2007, 110, 3557-3560.	0.6	485
588	Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood, 2007, 109, 3177-3188.	0.6	379
589	Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood, 2007, 109, 2604-2606.	0.6	242
590	Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood, 2007, 109, 2106-2111.	0.6	414
591	Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice. Blood, 2007, 110, 345-353.	0.6	47
592	The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood, 2007, 110, 334-338.	0.6	241
593	Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood, 2007, 110, 3281-3290.	0.6	669
594	Myelofibrosis with myeloid metaplasia: targeted therapy. Blood, 2007, 110, 2-3.	0.6	3
595	Severe Hyponatremia in a Patient with Mantle Cell Lymphoma Treated with Bortezomib: A Case Report and Review of the Literature. Oncology Research and Treatment, 2007, 30, 651-654.	0.8	9
596	The Emerging Role of Novel Therapies for the Treatment of Relapsed Myeloma. Journal of the National Comprehensive Cancer Network: JNCCN, 2007, 5, 149-162.	2.3	59
597	Neurologic complications of chemotherapy agents. Current Opinion in Neurology, 2007, 20, 719-725.	1.8	168
598	Novel therapies in myeloma. Current Opinion in Hematology, 2007, 14, 609-615.	1.2	18
599	Current Therapies for Multiple Myeloma. Journal of Infusion Nursing, 2007, 30, 113-118.	1.2	3

#	Article	IF	Citations
600	Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor. European Journal of Gastroenterology and Hepatology, 2007, 19, 599-601.	0.8	22
601	The Ubiquitin-Proteasome System and Proteasome Inhibitors in Central Nervous System Diseases. Cardiovascular & Hematological Disorders Drug Targets, 2007, 7, 250-273.	0.2	22
602	Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma. Haematologica, 2007, 92, 1505-1512.	1.7	33
603	Bortezomib sensitizes human head and neck carcinoma cells SQ20B to radiation. Cancer Biology and Therapy, 2007, 6, 156-159.	1.5	18
604	Proteasome inhibition specifically sensitizes leukemic cells to anthracyclin-induced apoptosis through the accumulation of Bim and Bax pro-apoptotic proteins. Cancer Biology and Therapy, 2007, 6, 603-611.	1.5	34
605	Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology, 2007, 12, 235-239.	0.7	101
606	Use of novel proteosome inhibitors as a therapeutic strategy in lymphomas current experience and emerging concepts. Transfusion and Apheresis Science, 2007, 37, 85-92.	0.5	4
608	Osteonecrosis of the Jaws and Bisphosphonates. The Alpha Omegan, 2007, 100, 194-202.	0.1	11
609	Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug Resistance Updates, 2007, 10, 144-151.	6.5	88
610	The proteasome: A worthwhile target for the treatment of solid tumours?. European Journal of Cancer, 2007, 43, 1125-1133.	1.3	86
611	Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation to Treat Patients with Poor-Risk, Relapsed, or Refractory Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2007, 13, 423-432.	2.0	40
612	Bortezomib after Allografting in Multiple Myeloma: Association between Neurotoxicity and Cyclosporine Treatment. Biology of Blood and Marrow Transplantation, 2007, 13, 497-499.	2.0	5
613	Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. Biochemical and Biophysical Research Communications, 2007, 361, 549-554.	1.0	59
614	Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat. Experimental Neurology, 2007, 204, 317-325.	2.0	228
615	Transcription factors in hematopoietic malignancies. Current Opinion in Genetics and Development, 2007, 17, 78-83.	1.5	9
616	Highlights in experimental therapeutics. Cancer Letters, 2007, 245, 11-21.	3.2	25
617	Patient-reported outcomes helped predict survival in multiple myeloma using partial least squares analysis. Journal of Clinical Epidemiology, 2007, 60, 670-679.e3.	2.4	31
618	Dendritic Cell Maturation Stage Determines Susceptibility to the Proteasome Inhibitor Bortezomib. Human Immunology, 2007, 68, 147-155.	1.2	46

#	Article	IF	Citations
619	Lenalidomide in Myeloma. Current Treatment Options in Oncology, 2007, 8, 154-163.	1.3	6
620	Cul4A is required for hematopoietic stem-cell engraftment and self-renewal. Blood, 2007, 110, 2704-2707.	0.6	16
621	JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Blood, 2007, 110, 709-718.	0.6	139
622	Managing and avoiding bortezomib toxicity. Community Oncology, 2007, 4, 480-484.	0.2	17
624	Management of Relapsed and Relapsed Refractory Myeloma. Hematology/Oncology Clinics of North America, 2007, 21, 1175-1215.	0.9	8
625	Recent Development in Novel Anticancer Therapies. , 2007, , 221-251.		1
626	Molecular and Clinical Aspects of Proteasome Inhibition in the Treatment of Cancer. , 2007, 176, 165-176.		21
627	Treatment Strategies in Elderly Patients with Multiple Myeloma. Drugs and Aging, 2007, 24, 829-850.	1.3	4
628	The Role of the Bone Marrow Microenvironment in the Pathophysiology of Myeloma and Its Significance in the Development of More Effective Therapies. Hematology/Oncology Clinics of North America, 2007, 21, 1007-1034.	0.9	110
629	The treatment of the elderly multiple myeloma patients. Leukemia and Lymphoma, 2007, 48, 469-480.	0.6	4
630	Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: Impact on stem cell harvesting and engraftment. Leukemia and Lymphoma, 2007, 48, 1910-1921.	0.6	37
631	Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and leukemia Group B protocol 50206. Leukemia and Lymphoma, 2007, 48, 1313-1319.	0.6	64
632	Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma. Leukemia and Lymphoma, 2007, 48, 2345-2351.	0.6	40
633	Proteasome Inhibitors in the Clinical Setting. Drugs in R and D, 2007, 8, 1-12.	1.1	26
634	A Phase II Study of Single Agent Bortezomib in Patients with Metastatic Breast Cancer: A Single Institution Experience. Cancer Investigation, 2007, 25, 733-737.	0.6	67
635	Management of Newly Diagnosed Myeloma. Hematology/Oncology Clinics of North America, 2007, 21, 1141-1156.	0.9	12
636	A high-dose bortezomib neuropathy with sensory ataxia and myelin involvement. Journal of the Neurological Sciences, 2007, 263, 40-43.	0.3	18
637	Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America. New England Journal of Medicine, 2007, 357, 2133-2142.	13.9	1,186

#	Article	IF	Citations
638	Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood, 2007, 109, 2100-2105.	0.6	117
639	Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood, 2007, 109, 2767-2772.	0.6	174
641	Current Management of Mantle Cell Lymphoma. Drugs, 2007, 67, 1689-1702.	4.9	25
642	Lenalidomide in Myelodysplastic Syndrome and Multiple Myeloma. Drugs, 2007, 67, 1869-1881.	4.9	37
643	Bortezomib in Combination with Pegylated Liposomal Doxorubicin for the Treatment of Multiple Myeloma. Clinical Lymphoma and Myeloma, 2007, 7, 266-271.	1.4	9
644	Repeated Complete Responses with Bortezomib in a Heavily Pretreated Primary Refractory Patient with Light Chain Multiple Myeloma. Clinical Lymphoma and Myeloma, 2007, 7, 373-375.	1.4	5
645	Preclinical Rationale, Mechanisms of Action, and Clinical Activity of Anthracyclines in Myeloma. Clinical Lymphoma and Myeloma, 2007, 7, S145-S149.	1.4	5
646	Emerging Data on the Use of Anthracyclines in Combination with Bortezomib in Multiple Myeloma. Clinical Lymphoma and Myeloma, 2007, 7, S156-S162.	1.4	8
647	Integration of Novel Agents into Treatment of Myeloma. Clinical Lymphoma and Myeloma, 2007, 7, S215-S221.	1.4	0
648	Multiple Myeloma: Novel Approaches for Relapsed Disease. Clinical Lymphoma and Myeloma, 2007, 8, S18-S23.	1.4	5
649	Molecular/Targeted Therapy of Cancer. , 2007, , 236-274.		0
650	Thalidomide in the treatment of multiple myeloma. Best Practice and Research in Clinical Haematology, 2007, 20, 681-699.	0.7	17
651	Lenalidomide in multiple myeloma. Best Practice and Research in Clinical Haematology, 2007, 20, 717-735.	0.7	13
652	Bortezomib in multiple myeloma. Best Practice and Research in Clinical Haematology, 2007, 20, 701-715.	0.7	40
653	Frontline treatment in multiple myeloma patients not eligible for stem-cell transplantation. Best Practice and Research in Clinical Haematology, 2007, 20, 737-746.	0.7	8
654	The Arkansas approach to therapy of patients with multiple myeloma. Best Practice and Research in Clinical Haematology, 2007, 20, 761-781.	0.7	31
655	From the bench to the bedside: emerging new treatments in multiple myeloma. Best Practice and Research in Clinical Haematology, 2007, 20, 797-816.	0.7	63
656	Multiple myeloma: New staging systems for diagnosis, prognosis and response evaluation. Best Practice and Research in Clinical Haematology, 2007, 20, 665-680.	0.7	42

#	Article	IF	Citations
657	Melphalan: old and new uses of a still master drug for multiple myeloma. Expert Opinion on Investigational Drugs, 2007, 16, 1467-1487.	1.9	17
658	The Proteasome Inhibitor Bortezomib Induces Apoptosis in Human Retinoblastoma Cell Lines In Vitro. , 2007, 48, 4706.		35
659	Bortezomib-induced peripheral neurotoxicity: still far from a painless gain. Haematologica, 2007, 92, 1308-1310.	1.7	44
660	Tratamento do Mieloma MÃºltiplo recidivado. Revista Brasileira De Hematologia E Hemoterapia, 2007, 29, .	0.7	0
661	The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells. International Journal of Oncology, 0, , .	1.4	8
662	Strategies to Eliminate Cancer Stem Cells. , 2007, , 219-230.		0
663	Current status and future directions in the treatment of multiple myeloma. Chinese Medical Journal, 2007, 120, 1651-1654.	0.9	1
665	Apoptosis-Based Drug Discovery for Cancer. , 0, , 408-438.		0
666	Community experience with bortezomib in patients with multiple myeloma. American Journal of Hematology, 2007, 82, 637-639.	2.0	6
667	Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: The combined effects of bortezomib and interferon-Î³ on the presentation of a cryptic epitope. International Journal of Cancer, 2007, 120, 594-604.	2.3	29
668	Marked regression of liver metastasis by combined therapy of ultrasoundâ€mediated NFκBâ€decoy transfer and transportal injection of paclitaxel, in mouse. International Journal of Cancer, 2008, 122, 1645-1656.	2.3	12
669	Multiple myeloma: A prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. Journal of Cellular Biochemistry, 2007, 101, 950-968.	1.2	83
670	Targeting cell signaling pathways for drug discovery: An old lock needs a new key. Journal of Cellular Biochemistry, 2007, 102, 580-592.	1.2	127
671	Restoration of wild-type p53 function in human cancer: Relevance for tumor therapy. Head and Neck, 2007, 29, 272-284.	0.9	79
672	Differential expression of caveolin-1 in renal neoplasms. Cancer, 2007, 110, 776-782.	2.0	22
673	Time to first disease progression, but not Î²2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. Cancer, 2007, 110, 824-829.	2.0	19
674	Neurotoxicity of bortezomib therapy in multiple myeloma: A singleâ€center experience and review of the literature. Cancer, 2007, 110, 1042-1049.	2.0	213
675	A Mechanistic and Kinetic Study of the Î²-Lactone Hydrolysis of Salinosporamide A (NPI-0052), A Novel Proteasome Inhibitor. Journal of Pharmaceutical Sciences, 2007, 96, 2037-2047.	1.6	28

#	Article	IF	Citations
676	Management of multiple myeloma: The changing landscape. Blood Reviews, 2007, 21, 301-314.	2.8	23
677	The Transcription Factor Nuclear Factor-kappa B and Cancer. Clinical Oncology, 2007, 19, 154-161.	0.6	198
678	Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leukemia Research, 2007, 31, 779-782.	0.4	81
679	Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway. Oncogene, 2007, 26, 1681-1692.	2.6	91
680	Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nature Reviews Cancer, 2007, 7, 585-598.	12.8	817
681	High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years. Bone Marrow Transplantation, 2007, 40, 1101-1114.	1.3	27
682	Targeted treatments to improve stem cell outcome: old and new drugs. Bone Marrow Transplantation, 2007, 40, 1129-1137.	1.3	4
683	Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia, 2007, 21, 151-157.	3.3	244
684	Proteasome inhibitors: antitumor effects and beyond. Leukemia, 2007, 21, 30-36.	3.3	208
685	Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia, 2007, 21, 164-168.	3.3	113
686	Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia, 2007, 21, 524-528.	3.3	61
687	The JAK2V617F mutation is detectable in granulocyte populations at greater than 2 copies per cell among individuals with myeloproliferative disorders. Leukemia, 2007, 21, 818-818.	3.3	0
688	Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide. Leukemia, 2007, 21, 818-820.	3.3	6
689	Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells. Leukemia, 2007, 21, 1464-1471.	3.3	50
690	Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia, 2007, 21, 2035-2042.	3.3	317
691	Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma. British Journal of Cancer, 2007, 97, 37-42.	2.9	73
692	Primary cutaneous peripheral T-cell lymphoma, unspecified, that completely regressed after skin biopsy. British Journal of Dermatology, 2007, 156, 785-786.	1.4	9
693	Bortezomib-associated rash: a new recognizable and avoidable side-effect. British Journal of Dermatology, 2007, 156, 784-785.	1.4	17

#	Article	IF	Citations
694	Bortezomib disrupts tumour?dendritic cell interactions in myeloma and lymphoma: therapeutic implications. British Journal of Haematology, 2007, 136, 106-110.	1.2	39
695	Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. British Journal of Haematology, 2007, 136, 393-399.	1.2	63
696	Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. British Journal of Haematology, 2007, 137, 429-435.	1.2	115
697	Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. British Journal of Haematology, 2007, 138, 176-185.	1.2	304
698	A strategic framework for novel drug development in multiple myeloma. British Journal of Haematology, 2007, 138, 153-159.	1.2	14
699	Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. British Journal of Haematology, 2007, 138, 330-337.	1.2	156
700	Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. British Journal of Haematology, 2007, 138, 783-791.	1.2	102
701	The histone deacetylase inhibitor, PXD101, potentiates bortezomibâ€induced antiâ€multiple myeloma effect by induction of oxidative stress and DNA damage. British Journal of Haematology, 2007, 139, 385-397.	1.2	118
702	Proteomic evaluation of pathways associated with dexamethasone-mediated apoptosis and resistance in multiple myeloma. British Journal of Haematology, 2007, 139, 559-567.	1.2	34
703	Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma. Cancer Science, 2007, 99, 071029014002001-???.	1.7	51
704	Multiple Myeloma: Charging Toward a Bright Future. Ca-A Cancer Journal for Clinicians, 2007, 57, 301-318.	157.7	82
705	Promiscuous Mutations Activate the Noncanonical NF-ÎºB Pathway in Multiple Myeloma. Cancer Cell, 2007, 12, 131-144.	7.7	941
706	Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Experimental Hematology, 2007, 35, 155-162.	0.2	135
707	Transcription Factors as Therapeutic Targets in Lymphoid Malignancies. International Reviews of Immunology, 2007, 26, 305-332.	1.5	3
708	The Role of Proteasome in Apoptosis. , 2006, , 273-293.		0
709	Therapy with Bortezomib plus Dexamethasone Induces Osteoblast Activation in Responsive Patients with Multiple Myeloma. International Journal of Hematology, 2007, 86, 180-185.	0.7	50
711	Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. Annals of Hematology, 2007, 86, 211-216.	0.8	43
712	Towards a new age in the treatment of multiple myeloma. Annals of Hematology, 2007, 86, 159-172.	0.8	31

#	Article	IF	Citations
713	Severe intestinal vasculitis in a patient under treatment with bortezomib. Annals of Hematology, 2007, 86, 923-924.	0.8	7
714	Proteasome inhibitor, bortezomib, for myeloma and lymphoma. International Journal of Clinical Oncology, 2007, 12, 318-326.	1.0	42
715	New therapies in multiple myeloma. Clinical and Experimental Medicine, 2007, 7, 83-97.	1.9	37
716	Primary clinical study on treatment with velcade for multiple myeloma. Chinese-German Journal of Clinical Oncology, 2007, 6, 579-581.	0.1	1
718	Current status of bortezomib in the treatment of multiple myeloma. Current Hematologic Malignancy Reports, 2007, 2, 128-137.	1.2	9
719	Pharmacodynamics: biological activity of targeted therapies in clinical trials. Clinical and Translational Oncology, 2007, 9, 634-644.	1.2	8
720	Molecular targeted therapy for advanced hepatocellular carcinoma. Targeted Oncology, 2007, 2, 199-210.	1.7	6
721	CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor. Molecular and Cellular Biochemistry, 2008, 316, 149-154.	1.4	48
722	Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up. Annals of Hematology, 2008, 87, 623-631.	0.8	38
723	Breast and pelvic masses in a myeloma patient. Annals of Hematology, 2008, 87, 1027-1029.	0.8	4
724	Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome. Cancer Chemotherapy and Pharmacology, 2008, 62, 181-182.	1.1	12
725	A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors. Cancer Chemotherapy and Pharmacology, 2008, 63, 99-107.	1.1	22
726	A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 2008, 63, 109-115.	1.1	17
727	From the bench to the bedside: emerging new treatments in multiple myeloma. Targeted Oncology, 2008, 3, 19-29.	1.7	0
729	Anti-tumor action and clinical application of proteasome inhibitor. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2008, 20, 77-84.	0.7	1
730	Hepatic veno-occlusive disease after tandem autologous stem cell transplantation conditioned by melphalan. International Journal of Hematology, 2008, 88, 291-293.	0.7	8
731	Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma. International Journal of Hematology, 2008, 88, 396-402.	0.7	11
732	Targeting the UPS as therapy in multiple myeloma. BMC Biochemistry, 2008, 9, S1.	4.4	35

#	Article	IF	Citations
733	The UPS: a promising target for breast cancer treatment. BMC Biochemistry, 2008, 9, S2.	4.4	20
734	Proteasome inhibition blocks caspaseâ€8 degradation and sensitizes prostate cancer cells to death receptorâ€mediated apoptosis. Prostate, 2008, 68, 200-209.	1.2	36
735	Multiâ€targeted therapy by curcumin: how spicy is it?. Molecular Nutrition and Food Research, 2008, 52, 1010-1030.	1.5	201
736	Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma. Cancer, 2008, 113, 765-771.	2.0	33
737	Newly developed effective antiâ€cancer drugs targeting multiple myeloma. Drug Development Research, 2008, 69, 451-459.	1.4	1
738	Review of peripheral neuropathy in plasma cell disorders. Hematological Oncology, 2008, 26, 55-65.	0.8	63
739	Synergistic antiâ€proliferative and proâ€apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with antiâ€epidermal growth factor receptor (EGFR) drugs in human cancer cells. Journal of Cellular Physiology, 2008, 216, 698-707.	2.0	33
740	Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: A gene expression profiling study with implications for potential combination therapies. Leukemia Research, 2008, 32, 275-285.	0.4	39
741	Efficacy of Bortezomib followed by local irradiation in two patients with extramedullary plasmacytomas. Leukemia Research, 2008, 32, 841-843.	0.4	8
742	Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions. Leukemia Research, 2008, 32, 1661-1668.	0.4	55
743	Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival. Journal of Clinical Oncology, 2008, 26, 5775-5782.	0.8	263
744	Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth. Gene Therapy, 2008, 15, 797-806.	2.3	58
745	Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin. Laboratory Investigation, 2008, 88, 306-317.	1.7	11
746	The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia, 2008, 22, 2247-2256.	3.3	117
747	VTD combination therapy with bortezomibâ€“thalidomideâ€“dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia, 2008, 22, 1419-1427.	3.3	129
748	Current status of autologous hematopoietic stem cell transplantation in myeloma. Bone Marrow Transplantation, 2008, 42, S28-S34.	1.3	10
749	Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. Bone Marrow Transplantation, 2008, 41, 953-960.	1.3	62
750	Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT. Bone Marrow Transplantation, 2008, 41, 1013-1019.	1.3	20

#	Article	IF	Citations
751	A pivotal role for Mcl-1 in Bortezomib-induced apoptosis. Oncogene, 2008, 27, 721-731.	2.6	114
752	Fold up or perish: unfolded protein response and chemotherapy. Cell Death and Differentiation, 2008, 15, 223-225.	5.0	16
753	Clinically relevant end points and new drug approvals for myeloma. Leukemia, 2008, 22, 231-239.	3.3	192
754	Atacicept (TACI-Ig) inhibits growth of TACIhigh primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia, 2008, 22, 406-413.	3.3	80
755	Position statement on the use of bortezomib in multiple myeloma. International Journal of Laboratory Hematology, 2008, 30, 1-10.	0.7	15
756	Chemotherapyâ€induced neuropathy. Journal of the Peripheral Nervous System, 2008, 13, 27-46.	1.4	602
757	Role of a preâ€existing neuropathy on the course of bortezomibâ€induced peripheral neurotoxicity. Journal of the Peripheral Nervous System, 2008, 13, 267-274.	1.4	55
758	Characteristics of bortezomibâ€and thalidomideâ€induced peripheral neuropathy. Journal of the Peripheral Nervous System, 2008, 13, 275-282.	1.4	143
759	Nuclear factorâ€ÎºB dependency of doxorubicin sensitivity in gastric cancer cells is determined by manganese superoxide dismutase expression. Cancer Science, 2008, 99, 1117-1124.	1.7	28
760	Overexpression of carboxylesteraseâ€2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPTâ€11), for multiple myeloma. Cancer Science, 2008, 99, 2309-2314.	1.7	33
761	Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1. British Journal of Haematology, 2008, 141, 433-444.	1.2	33
762	Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. British Journal of Haematology, 2008, 141, 41-51.	1.2	118
763	The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. British Journal of Haematology, 2008, 143, 46-53.	1.2	94
764	Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. British Journal of Haematology, 2008, 143, 222-229.	1.2	91
765	Updated survival analyses after prolonged followâ€up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. British Journal of Haematology, 2008, 143, 537-540.	1.2	84
766	Bortezomib is associated with better healthâ€related quality of life than highâ€dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. British Journal of Haematology, 2008, 143, 511-519.	1.2	55
767	Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line. Experimental Hematology, 2008, 36, 1278-1284.	0.2	80
768	AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies. Cancer Cell, 2008, 13, 167-180.	7.7	322

#	Article	IF	Citations
770	Multiple myeloma â€“ an update on diagnosis and treatment. European Journal of Haematology, 2008, 81, 329-343.	1.1	46
771	An Observational, Retrospective Analysis of Retreatment with Bortezomib for Multiple Myeloma. Clinical Lymphoma and Myeloma, 2008, 8, 140-145.	1.4	44
772	Features and Risk Factors of Peripheral Neuropathy During Treatment with Bortezomib for Advanced Multiple Myeloma. Clinical Lymphoma and Myeloma, 2008, 8, 146-152.	1.4	31
773	Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment. Clinical Lymphoma and Myeloma, 2008, 8, 352-355.	1.4	54
774	Treatment of Patients with Myeloma with Comorbid Conditions: Considerations for the Clinician. Clinical Lymphoma and Myeloma, 2008, 8, S149-S156.	1.4	9
775	Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade. Clinical Cancer Research, 2008, 14, 1649-1657.	3.2	532
778	Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Molecular Cancer, 2008, 7, 40.	7.9	56
779	Leaving Groups Prolong the Duration of 20S Proteasome Inhibition and Enhance the Potency of Salinosporamides. Journal of Medicinal Chemistry, 2008, 51, 6711-6724.	2.9	57
780	Bortezomib as an Alternative in the Treatment of Patients With Malignant Gammopathy. Farmacia Hospitalaria (English Edition), 2008, 32, 280-285.	0.0	1
781	Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clinical Neurophysiology, 2008, 119, 2507-2512.	0.7	88
782	Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. New England Journal of Medicine, 2008, 359, 906-917.	13.9	1,787
783	The potential of proteasome inhibitors in cancer therapy. Expert Opinion on Investigational Drugs, 2008, 17, 879-895.	1.9	112
784	Bortezomib-Induced Skin Eruption. Dermatology, 2008, 216, 156-158.	0.9	18
785	Homogeneous, Bioluminescent Proteasome Assays. , 2008, 414, 163-181.		14
786	Apoptosis and Cancer. , 2008, , .		1
788	Effects of the Proteasome Inhibitor Bortezomib on Gene Expression Profiles of Pancreatic Cancer Cells. Journal of Surgical Research, 2008, 145, 111-123.	0.8	30
789	Ro52 functionally interacts with IgG1 and regulates its quality control via the ERAD system. Molecular Immunology, 2008, 45, 2045-2054.	1.0	30
790	Proteasome Î² Subunit Pharmacogenomics: Gene Resequencing and Functional Genomics. Clinical Cancer Research, 2008, 14, 3503-3513.	3.2	35

#	Article	IF	Citations
791	The pathogenesis of the bone disease of multiple myeloma. Bone, 2008, 42, 1007-1013.	1.4	154
792	Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resistance Updates, 2008, 11, 164-179.	6.5	272
793	Biophosphonate-Related Osteonecrosis of the Jaws. Dental Clinics of North America, 2008, 52, 111-128.	0.8	62
794	Molecular-targeted therapies: Lessons from years of clinical development. Cancer Treatment Reviews, 2008, 34, 61-80.	3.4	45
795	Multiple myeloma: detecting the effects of new treatments. Lancet, The, 2008, 371, 1642-1644.	6.3	10
796	Cutaneous Reactions Related to Systemic Immunomodulators and Targeted Therapeutics. Dermatologic Clinics, 2008, 26, 121-159.	1.0	29
798	Treatment of Myeloma: Cure vs Control. Mayo Clinic Proceedings, 2008, 83, 1142-1145.	1.4	64
799	The role of high-dose chemotherapy followed by peripheral blood stem cell transplantation for the treatment of multiple myeloma. Leukemia and Lymphoma, 2008, 49, 1436-1451.	0.6	4
800	Inhibition of Yin Yang 1-Dependent Repressor Activity of DR5 Transcription and Expression by the Novel Proteasome Inhibitor NPI-0052 Contributes to its TRAIL-Enhanced Apoptosis in Cancer Cells. Journal of Immunology, 2008, 180, 6199-6210.	0.4	78
801	Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leukemia and Lymphoma, 2008, 49, 890-895.	0.6	74
803	Bortezomib-Resistant Nuclear Factor-Î¹B Activity in Multiple Myeloma Cells. Molecular Cancer Research, 2008, 6, 1356-1364.	1.5	135
804	Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs. Journal of Clinical Oncology, 2008, 26, 480-492.	0.8	55
805	Multiple Myeloma With Testicular Involvement. Journal of Clinical Oncology, 2008, 26, 1558-1559.	0.8	3
806	Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance. Cancer Research, 2008, 68, 190-197.	0.4	495
807	An update on drug combinations for treatment of myeloma. Expert Opinion on Investigational Drugs, 2008, 17, 1-12.	1.9	10
808	Updated follow-up of patients treated with bortezomib for relapsed multiple myeloma. Nature Clinical Practice Oncology, 2008, 5, 304-305.	4.3	0
809	The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. Haematologica, 2008, 93, 57-66.	1.7	56
810	Toxicity of targeted therapies in elderly patients. Expert Review of Anticancer Therapy, 2008, 8, 1965-1976.	1.1	5

#	Article	IF	Citations
811	Bortezomib in multiple myeloma. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 639-654.	1.5	22
812	Improved survival in multiple myeloma and the impact of novel therapies. Blood, 2008, 111, 2516-2520.	0.6	2,022
813	Treatment of relapsed and refractory myeloma. Leukemia and Lymphoma, 2008, 49, 1470-1485.	0.6	12
814	Bortezomib in the front-line treatment of multiple myeloma. Expert Review of Anticancer Therapy, 2008, 8, 1053-1072.	1.1	79
815	Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma. Journal of Clinical Oncology, 2008, 26, 4777-4783.	0.8	100
816	The role of novel drugs in multiple myeloma. Annals of Oncology, 2008, 19, vii121-vii127.	0.6	5
817	Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2008, 26, 2171-2177.	0.8	322
818	Cooperative Relationship Between Pharmaceutical Companies, Academia, and Media Explains Sharp Decrease in Frequency of Pulmonary Complications After Bortezomib in Japan. Journal of Clinical Oncology, 2008, 26, 5820-5823.	0.8	15
819	Commentary: Novel Therapies for Cancer: Why Dirty Might Be Better. Oncologist, 2008, 13, 277-283.	1.9	53
820	Proteasome inhibition improves diaphragm function in congestive heart failure rats. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2008, 294, L1260-L1268.	1.3	53
821	Deafness associated with the use of Bortezomib in multiple myeloma. Acta OncolÃ³gica, 2008, 47, 323-324.	0.8	5
822	Bortezomib: A novel chemotherapeutic agent for hematologic malignancies. American Journal of Health-System Pharmacy, 2008, 65, 1221-1231.	0.5	48
823	The Novel Polyamine Analogue CGC-11093 Enhances the Antimyeloma Activity of Bortezomib. Cancer Research, 2008, 68, 4783-4790.	0.4	26
824	Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in multiple myeloma. Journal of Leukocyte Biology, 2008, 84, 561-576.	1.5	12
825	Innovative Leukemia and Lymphoma Therapy. , 0, , .		0
826	A Profiling Platform for the Identification of Selective Metalloprotease Inhibitors. Journal of Biomolecular Screening, 2008, 13, 285-294.	2.6	19
827	Active roles for inhibitory ÎºB kinases Î± and Î² in nuclear factor-ÎºBâ€“mediated chemoresistance to doxorubicin. Molecular Cancer Therapeutics, 2008, 7, 1827-1835.	1.9	36
828	Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Annals of Oncology, 2008, 19, 1160-1165.	0.6	101

#	Article	IF	Citations
829	New treatments in multiple myeloma: beyond optimal treatment. Annals of Oncology, 2008, 19, v68-v70.	0.6	5
830	Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study. Journal of Clinical Oncology, 2008, 26, 4784-4790.	0.8	244
831	Proteasome Inhibition Activates Epidermal Growth Factor Receptor (EGFR) and EGFR-Independent Mitogenic Kinase Signaling Pathways in Pancreatic Cancer Cells. Clinical Cancer Research, 2008, 14, 5116-5123.	3.2	68
832	Role of bortezomib for the treatment of previously untreated multiple myeloma. Expert Review of Hematology, 2008, 1, 17-28.	1.0	3
833	Aggregopathy in Neurodegenerative Diseases: Mechanisms and Therapeutic Implication. Neurodegenerative Diseases, 2008, 5, 321-338.	0.8	55
834	In Vivo Investigations on Anti-Fibrotic Potential of Proteasome Inhibition in Lung and Skin Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2008, 39, 458-465.	1.4	40
835	New uses for old copper-binding drugs: converting the pro-angiogenic copper to a specific cancer cell death inducer. Expert Opinion on Therapeutic Targets, 2008, 12, 739-748.	1.5	60
836	Bortezomib-associated tumor lysis syndrome in multiple myeloma. Leukemia and Lymphoma, 2008, 49, 2380-2382.	0.6	15
837	Role of decorin in the antimyeloma effects of osteoblasts. Blood, 2008, 112, 159-168.	0.6	102
838	Novel agents in the frontline management of multiple myeloma. Hematology/ Oncology and Stem Cell Therapy, 2008, 1, 201-209.	0.6	0
839	Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cellâ€“mediated lysis of myeloma. Blood, 2008, 111, 1309-1317.	0.6	159
840	Cul4A is required for hematopoietic cell viability and its deficiency leads to apoptosis. Blood, 2008, 112, 320-329.	0.6	29
841	Phosphorylation of eIF2Î± in response to 26S proteasome inhibition is mediated by the haem-regulated inhibitor (HRI) kinase. Biochemical Journal, 2008, 412, 579-588.	1.7	77
842	The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood, 2008, 111, 1603-1609.	0.6	111
843	CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood, 2008, 111, 2765-2775.	0.6	239
844	Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood, 2008, 111, 2521-2526.	0.6	495
845	Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood, 2008, 111, 1654-1664.	0.6	193
846	Targeting the p27 E3 ligase SCFSkp2 results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood, 2008, 111, 4690-4699.	0.6	250

#	Article	IF	Citations
847	Multiple myeloma. Blood, 2008, 111, 2962-2972.	0.6	759
848	Increased proteasomal degradation of Bax is a common feature of poor prognosis chronic lymphocytic leukemia. Blood, 2008, 111, 2790-2796.	0.6	28
849	Is tandem autotransplantation necessary in myeloma?. Blood, 2008, 111, 1751-1752.	0.6	0
850	First thalidomide clinical trial in multiple myeloma: a decade. Blood, 2008, 112, 1035-1038.	0.6	47
851	Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood, 2008, 112, 3107-3114.	0.6	339
852	Molecular basis of bortezomib resistance: proteasome subunit Î²5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood, 2008, 112, 2489-2499.	0.6	406
853	Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood, 2008, 112, 2450-2462.	0.6	73
854	Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood, 2008, 112, 1593-1599.	0.6	362
855	Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood, 2008, 112, 4017-4023.	0.6	425
856	Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica, 2008, 93, 1908-1911.	1.7	111
857	Natural Compounds with Proteasome Inhibitory Activity for Cancer Prevention and Treatment. Current Protein and Peptide Science, 2008, 9, 227-239.	0.7	94
858	TREATMENT OF NEWLY DIAGNOSED MULTIPLE MYELOMA. , 0, , 26-36.		0
859	Advances in therapy of multiple myeloma. Current Opinion in Oncology, 2008, 20, 697-704.	1.1	29
860	Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection. Transplantation, 2008, 86, 1754-1761.	0.5	362
861	Expanding Role of Bortezomib in Multiple Myeloma. Cancer Nursing, 2008, 31, 239-249.	0.7	8
862	New drugs in multiple myeloma. Current Opinion in Supportive and Palliative Care, 2008, 2, 204-210.	0.5	9
863	Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. Anti-Cancer Drugs, 2008, 19, 115-124.	0.7	51
864	NF-??B in the pathogenesis and treatment of multiple myeloma. Current Opinion in Hematology, 2008, 15, 391-399.	1.2	91

#	Article	IF	Citations
865	The lymphomas and myeloma. , 0, , 347-369.		0
867	New drugs in the treatment of chronic myeloid leukaemia. Revista Brasileira De Hematologia E Hemoterapia, 0, 30, .	0.7	0
868	Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias. Biologics: Targets and Therapy, 2008, 2, 419.	3.0	3
869	Localized Osteolysis. , 2008, , 1391-1413.		0
870	Front line treatment of elderly multiple myeloma in the era of novel agents. Biologics: Targets and Therapy, 0, , 99.	3.0	3
871	Bortezomib in the management of multiple myeloma. Cancer Management and Research, 2009, Volume 1, 107-117.	0.9	8
872	Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma. Therapeutics and Clinical Risk Management, 2009, 5, 151.	0.9	14
873	Therapeutic Options in Multiple Myeloma: Focus on Bortezomib. Clinical Medicine Therapeutics, 2009, 1, CMT.S2119.	0.1	0
874	The ubiquitin–proteasome system as a molecular target in solid tumors: an update on bortezomib. OncoTargets and Therapy, 2009, 2, 171.	1.0	17
875	Enhancing Apoptosis and Overcoming Resistance of Gemcitabine in Pancreatic Cancer with Bortezomib: A Role of Death-Associated Protein Kinase-Related Apoptosis-Inducing Protein Kinase 1. Tumori, 2009, 95, 796-803.	0.6	14
876	Novel Therapies in the Treatment of Multiple Myeloma. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 947-960.	2.3	37
877	Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia. PLoS ONE, 2009, 4, e6257.	1.1	39
878	Proteasomeâ€“NFÎºB Signaling Pathway: Relevance in RCC. , 2009, , 305-320.		0
879	Clinical challenges associated with bortezomib therapy in multiple myeloma and WaldenstrÃ¶ms Macroglobulinemia. Leukemia and Lymphoma, 2009, 50, 694-702.	0.6	31
880	Implications of endoplasmic reticulum stress, the unfolded protein response and apoptosis for molecular cancer therapy. Part II: targeting cell cycle events, caspases, NF-ÎºB and the proteasome. Expert Opinion on Drug Discovery, 2009, 4, 907-921.	2.5	12
881	Enhanced Delivery of Cisplatin to Intraperitoneal Ovarian Carcinomas Mediated by the Effects of Bortezomib on the Human Copper Transporter 1. Clinical Cancer Research, 2009, 15, 553-560.	3.2	70
882	Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology, 2009, 27, 5713-5719.	0.8	155
883	Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-ÎºB Signaling Pathways in Waldenstrol̂m's Macroglobulinemia. Cancer Research, 2009, 69, 3579-3588.	0.4	154

#	Article	IF	Citations
884	The Development and Pharmacology of Proteasome Inhibitors for the Management and Treatment of Cancer. Advances in Pharmacology, 2009, 57, 91-135.	1.2	27
885	Reply to C.A. Dasanu et al. Journal of Clinical Oncology, 2009, 27, 2294-2296.	0.8	3
886	Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. British Journal of Cancer, 2009, 100, 1379-1384.	2.9	47
887	The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models. Molecular Cancer Therapeutics, 2009, 8, 3234-3243.	1.9	57
888	Multicenter Randomized Phase II Study of Weekly or Twice-Weekly Bortezomib Plus Rituximab in Patients With Relapsed or Refractory Follicular or Marginal-Zone B-Cell Lymphoma. Journal of Clinical Oncology, 2009, 27, 5023-5030.	0.8	96
889	Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan. Molecular Cancer Therapeutics, 2009, 8, 2329-2338.	1.9	59
891	Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib. Clinical Cancer Research, 2009, 15, 7153-7160.	3.2	65
892	Fatal Cytomegalovirus Pneumonia and Associated Herpes Virus Infection in a Relapsed/Refractory Multiple Myeloma Patient Treated with Bortezomib plus Dexamethasone. Case Reports in Oncology, 2009, 2, 140-143.	0.3	3
893	Dorsal Column Degeneration after Bortezomib Therapy in a Patient with Multiple Myeloma. Case Reports in Oncology, 2009, 2, 184-188.	0.3	2
894	c-Myc and telomerase activation. Cell Cycle, 2009, 8, 3073-3077.	1.3	2
895	Replication timing: Findings from fibers. Cell Cycle, 2009, 8, 3073-3077.	1.3	2
896	Selectively killing transformed cells through proteasome inhibition. Cell Cycle, 2009, 8, 3073-3077.	1.3	1
897	Aurora-C: The youngest of "The Three (Aurora kinase) Tenors" of mitotic symphony. Cell Cycle, 2009, 8, 3073-3077.	1.3	2
898	BCL-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress. Cancer Biology and Therapy, 2009, 8, 808-819.	1.5	34
899	Restoration of chemosensitivity by bortezomib: implications for refractory myeloma. Nature Reviews Clinical Oncology, 2009, 6, 237-240.	12.5	8
900	Mantle cell lymphoma: state-of-the-art management and future perspective. Leukemia and Lymphoma, 2009, 50, 1937-1970.	0.6	19
901	Bortezomib in Relapsed Multiple Myeloma â€“ Results of a Non-Interventional Study by Office-Based Haematologists. Oncology Research and Treatment, 2009, 32, 175-180.	0.8	3
902	Emerging therapies for multiple myeloma. Expert Opinion on Emerging Drugs, 2009, 14, 99-127.	1.0	48

#	Article	IF	Citations
903	The proteasome inhibitor Bortezomib aggravates renal ischemia-reperfusion injury. American Journal of Physiology - Renal Physiology, 2009, 297, F451-F460.	1.3	26
904	Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy. Journal of Clinical Oncology, 2009, 27, 3518-3525.	0.8	241
905	Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer. Clinical Cancer Research, 2009, 15, 3912-3916.	3.2	191
906	Beyond Monoclonal Antibodies: New Therapeutic Agents in Nonâ€Hodgkin's Lymphomas. Oncologist, 2009, 14, 511-525.	1.9	5
907	Effect of autophagy on multiple myeloma cell viability. Molecular Cancer Therapeutics, 2009, 8, 1974-1984.	1.9	135
908	Bortezomib induces canonical nuclear factor-ÎºB activation in multiple myeloma cells. Blood, 2009, 114, 1046-1052.	0.6	329
909	Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma. Journal of Clinical Oncology, 2009, 27, 5008-5014.	0.8	286
910	Clinical and Immunohistochemical Features Associated with a Response to Bortezomib in Patients with Multiple Myeloma. Clinical Cancer Research, 2009, 15, 714-722.	3.2	27
911	Phase II Trial of Combination Therapy With Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Myeloma. Journal of Clinical Oncology, 2009, 27, 5015-5022.	0.8	74
912	Primary Therapy of WaldenstrÃ¶m Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180. Journal of Clinical Oncology, 2009, 27, 3830-3835.	0.8	265
913	Retrospective Comparison of Bortezomib-containing Regimens with Vincristine-Doxorubicin-Dexamethasone (VAD) as Induction Treatment Prior to Autologous Stem Cell Transplantation for Multiple Myeloma. Japanese Journal of Clinical Oncology, 2009, 39, 449-455.	0.6	9
914	Potentiation of (−)-epigallocatechin-3-gallate-induced apoptosis by bortezomib in multiple myeloma cells. Acta Biochimica Et Biophysica Sinica, 2009, 41, 1018-1026.	0.9	20
915	Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma. Clinical Cancer Research, 2009, 15, 5250-5257.	3.2	228
916	Targeting the NF-ÎºB pathway in asthma and chronic obstructive pulmonary disease. , 2009, 121, 1-13.		323
917	Cardiac cachexia: A systematic overview. , 2009, 121, 227-252.		297
918	Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma. Experimental Cell Research, 2009, 315, 2471-2478.	1.2	12
919	Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are shortâ€lived. European Journal of Haematology, 2009, 83, 449-454.	1.1	15
920	Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib. European Journal of Haematology, 2009, 83, 528-534.	1.1	4

#	Article	IF	Citations
921	Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: A prospective, multicenter, open-label, randomized, two-way crossover drugâ€"drug interaction study. Clinical Therapeutics, 2009, 31, 2444-2458.	1.1	56
922	Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line. Experimental Hematology, 2009, 37, 831-837.	0.2	70
923	Activation of SHIP via a small molecule agonist kills multiple myeloma cells. Experimental Hematology, 2009, 37, 1274-1283.	0.2	32
924	The ubiquitin pathway: An emerging drug target in cancer therapy. European Journal of Pharmacology, 2009, 625, 199-205.	1.7	41
925	Proteasome Inhibitors in Multiple Myeloma. Seminars in Oncology, 2009, 36, S20-S26.	0.8	10
926	Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo. American Journal of Hematology, 2009, 84, 268-272.	2.0	40
927	Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after highâ€dose chemotherapy and autologous stem cell transplantation. American Journal of Hematology, 2009, 84, 283-286.	2.0	12
928	Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib. American Journal of Hematology, 2009, 84, 657-660.	2.0	43
929	Severe pulmonary complications after bortezomib treatment in multiple myeloma. Hematological Oncology, 2010, 28, 49-52.	0.8	11
930	Comparative expression analysis and characterization of 20S proteasomes in human intestinal tissues. Inflammatory Bowel Diseases, 2009, 15, 526-533.	0.9	39
931	p53â€induced RINGâ€H2 protein, a novel marker for poor survival in hepatocellular carcinoma after hepatic resection. Cancer, 2009, 115, 4554-4563.	2.0	34
932	Multiple Myeloma. Current Problems in Cancer, 2009, 33, 7-64.	1.0	64
933	Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience. International Journal of Hematology, 2009, 89, 34-38.	0.7	9
934	A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: Î²2-microglobulin associated with time to progression. International Journal of Hematology, 2009, 89, 342-347.	0.7	9
935	Effect of artesunate on inhibiting proliferation and inducing apoptosis of SP2/0 myeloma cells through affecting NFÎºB p65. International Journal of Hematology, 2009, 90, 513-521.	0.7	46
936	Cord blood transplantation with a reduced-intensity conditioning regimen for patients with relapsed aggressive multiple myeloma after cytoreduction with bortezomib. International Journal of Hematology, 2009, 90, 413-415.	0.7	4
937	Treatment of relapsed and refractory myeloma. Current Hematologic Malignancy Reports, 2009, 4, 99-107.	1.2	5
938	Perturbation of DNA repair pathways by proteasome inhibitors corresponds to enhanced chemosensitivity of cells to DNA damage-inducing agents. Cancer Chemotherapy and Pharmacology, 2009, 64, 1039-1046.	1.1	20

#	Article	IF	Citations
939	High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. British Journal of Haematology, 2009, 144, 169-175.	1.2	101
940	Bortezomib, lowâ€dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma. British Journal of Haematology, 2009, 144, 887-894.	1.2	46
941	Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a doseâ€modification guideline. British Journal of Haematology, 2009, 144, 895-903.	1.2	289
942	Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease. British Journal of Haematology, 2009, 145, 775-787.	1.2	25
943	Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. British Journal of Haematology, 2009, 146, 164-170.	1.2	79
944	Natural polyphenols antagonize the antimyeloma activity of proteasome inhibitor bortezomib by direct chemical interaction. British Journal of Haematology, 2009, 146, 270-281.	1.2	36
945	Extended followâ€up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. British Journal of Haematology, 2009, 146, 619-626.	1.2	58
946	Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma. British Journal of Haematology, 2009, 147, 531-534.	1.2	27
947	Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia, 2009, 23, 10-24.	3.3	317
948	Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia, 2009, 23, 961-970.	3.3	65
949	Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia, 2009, 23, 1152-1157.	3.3	176
950	Proteasome inhibitors in the treatment of multiple myeloma. Leukemia, 2009, 23, 1964-1979.	3.3	155
951	The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia, 2009, 23, 2222-2232.	3.3	75
952	Spotlight review series on multiple myeloma. Leukemia, 2009, 23, R1-R2.	3.3	2
953	Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia, 2009, 23, 1679-1686.	3.3	102
954	Transcription factors: their potential as targets for an individualized therapeutic approach to cancer. Cancer Gene Therapy, 2009, 16, 103-112.	2.2	43
955	Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nature Reviews Cancer, 2009, 9, 675-681.	12.8	93
956	Proteasome system of protein degradation and processing. Biochemistry (Moscow), 2009, 74, 1411-1442.	0.7	111

#	Article	IF	Citations
957	Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene, 2009, 28, 231-242.	2.6	171
958	Safety and efficacy results from an international Expanded Access Programme to bortezomib for patients with relapsed and/or refractory multiple myeloma: a subset analysis of the Australian and New Zealand data of 111 patients. Internal Medicine Journal, 2009, 39, 290-295.	0.5	3
959	Elucidation of potential bortezomib response markers in mutliple myeloma patients. Journal of Pharmaceutical and Biomedical Analysis, 2009, 49, 115-122.	1.4	17
960	Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leukemia Research, 2009, 33, 1475-1480.	0.4	75
961	Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: A Chinese experience. Leukemia Research, 2009, 33, 1615-1618.	0.4	14
962	The tumor proteasome as a novel target for gold(III) complexes: Implications for breast cancer therapy. Coordination Chemistry Reviews, 2009, 253, 1649-1660.	9.5	138
963	Selective Inhibitor of Proteasome's Caspase-like Sites Sensitizes Cells to Specific Inhibition of Chymotrypsin-like Sites. Chemistry and Biology, 2009, 16, 1278-1289.	6.2	147
964	Discovery and development of the anticancer agent salinosporamide A (NPI-0052). Bioorganic and Medicinal Chemistry, 2009, 17, 2175-2180.	1.4	259
965	MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood, 2009, 113, 6669-6680.	0.6	297
966	Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials. Journal of Clinical Oncology, 2009, 27, 5720-5726.	0.8	155
967	Clinical development of novel proteasome inhibitors for cancer treatment. Expert Opinion on Investigational Drugs, 2009, 18, 957-971.	1.9	85
968	Snapshots of the Fluorosalinosporamide/20S Complex Offer Mechanistic Insights for Fine Tuning Proteasome Inhibition. Journal of Medicinal Chemistry, 2009, 52, 5420-5428.	2.9	36
969	An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer. European Journal of Cancer, 2009, 45, 48-55.	1.3	31
970	Impairment of Filgrastim-Induced Stem Cell Mobilization after Prior Lenalidomide in Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2009, 15, 718-723.	2.0	150
971	Proteasome Inhibition and Allogeneic Hematopoietic Stem Cell Transplantation: A Review. Biology of Blood and Marrow Transplantation, 2009, 15, 1502-1512.	2.0	21
972	USP15 plays an essential role for caspase-3 activation during Paclitaxel-induced apoptosis. Biochemical and Biophysical Research Communications, 2009, 388, 366-371.	1.0	54
973	The proteasomal system. Molecular Aspects of Medicine, 2009, 30, 191-296.	2.7	353
974	Bortezomib and Dexamethasone Therapy for Newly Diagnosed Patients With Multiple Myeloma Complicated by Renal Impairment. Clinical Lymphoma and Myeloma, 2009, 9, 394-398.	1.4	26

#	Article	IF	Citations
975	Targeting Transglutaminase-2 to Overcome Chemoresistance in Cancer Cells. , 2009, , 95-114.		6
976	Role of Active Drug Transporters in Refractory Multiple Myeloma. Current Topics in Medicinal Chemistry, 2009, 9, 218-224.	1.0	18
977	Recent and new targets for small molecule anti-cancer agents. Drug Discovery Today: Technologies, 2009, 6, e3-e11.	4.0	7
978	A prospective phase II study: High-dose pemetrexed as second-line chemotherapy in small-cell lung cancer. Lung Cancer, 2009, 63, 88-93.	0.9	26
979	From Natural Product to Clinical Trials: NPI-0052 (Salinosporamide A), a Marine Actinomycete-Derived Anticancer Agent. RSC Biomolecular Sciences, 2009, , 355-373.	0.4	6
980	Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis. Gut, 2009, 58, 833-838.	6.1	37
981	Bortezomib. Drugs, 2009, 69, 859-888.	4.9	138
982	Multiple Significant Bortezomib-Related Toxicities in One Patient: Case Report and Literature Review. Clinical Lymphoma and Myeloma, 2009, 9, E1-E4.	1.4	4
983	Treatment of Multiple Myeloma: A Comprehensive Review. Clinical Lymphoma and Myeloma, 2009, 9, 278-288.	1.4	135
984	Reversibility of Renal Impairment in Patients With Multiple Myeloma Treated With Bortezomib-Based Regimens: Identification of Predictive Factors. Clinical Lymphoma and Myeloma, 2009, 9, 302-306.	1.4	101
985	Never Say Die: Survival Signaling in Large Granular Lymphocyte Leukemia. Clinical Lymphoma and Myeloma, 2009, 9, S244-S253.	1.4	18
986	Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report. Journal of Hematology and Oncology, 2009, 2, 19.	6.9	22
987	Bortezomib and Waldenstrom's macroglobulinemia. Expert Opinion on Pharmacotherapy, 2009, 10, 909-916.	0.9	9
988	Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047). Journal of Medicinal Chemistry, 2009, 52, 3028-3038.	2.9	244
989	Antiprotealide Is a Natural Product. Journal of Natural Products, 2009, 72, 295-297.	1.5	39
990	Chemotherapy Induced Peripheral Neuropathies (CIPNs): A Biobehavioral Approach. , 2009, , 259-284.		0
991	BU-32: a novel proteasome inhibitor for breast cancer. Breast Cancer Research, 2009, 11, R74.	2.2	21
992	Novel therapies for relapsed myeloma. Hematology American Society of Hematology Education Program, 2009, 2009, 578-586.	0.9	22

#	Article	IF	Citations
993	Predicting durable remissions following thalidomide therapy for relapsed myeloma. Leukemia and Lymphoma, 2009, 50, 223-229.	0.6	9
994	Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. Leukemia and Lymphoma, 2009, 50, 1096-1101.	0.6	22
995	Combination of hyperthermia and bortezomib results in additive killing in mantle cell lymphoma cells. International Journal of Hyperthermia, 2009, 25, 262-272.	1.1	21
996	Interleukin-6-independent expression of glucocorticoid receptor is upregulated by triptolide in multiple myeloma. Leukemia and Lymphoma, 2009, 50, 802-808.	0.6	7
997	New generation pharmacotherapy in elderly multiple myeloma patients. Expert Opinion on Pharmacotherapy, 2009, 10, 81-98.	0.9	3
998	New Proteasome Inhibitors. Clinical Lymphoma and Myeloma, 2009, 9, S43-S44.	1.4	0
999	Antiangiogenic Agents in Multiple Myeloma. Clinical Lymphoma and Myeloma, 2009, 9, S44-S45.	1.4	0
1000	The role of complete response in multiple myeloma. Blood, 2009, 114, 3139-3146.	0.6	206
1001	Treatment of Relapsed/Refractory Multiple Myeloma. Seminars in Hematology, 2009, 46, 143-157.	1.8	49
1002	Front-Line Treatment in Younger Patients With Multiple Myeloma. Seminars in Hematology, 2009, 46, 118-126.	1.8	18
1003	Multiple myeloma. Lancet, The, 2009, 374, 324-339.	6.3	685
1004	Aminopeptidase inhibition as a targeted treatment strategy in myeloma. Molecular Cancer Therapeutics, 2009, 8, 762-770.	1.9	44
1005	The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. American Journal of Hematology, 2009, 84, 6-14.	2.0	132
1007	Abrogation of Anti-HLA Antibodies via Proteasome Inhibition. Transplantation, 2009, 87, 1555-1561.	0.5	156
1008	Novel Agents for Relapsed and/or Refractory Multiple Myeloma. Cancer Journal (Sudbury, Mass), 2009, 15, 485-493.	1.0	2
1009	Multiple Myeloma, Painful Neuropathy, Acupuncture?. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 319-325.	0.6	23
1010	Future Novel Single Agent and Combination Therapies. Cancer Journal (Sudbury, Mass), 2009, 15, 511-518.	1.0	12
1011	NCCN Task Force Report: Management of Neuropathy in Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, S-1-S-26.	2.3	179

#	Article	IF	Citations
1013	The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood, 2009, 113, 517-525.	0.6	350
1014	Biologic sequelae of Iº¡B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. Blood, 2009, 113, 5228-5236.	0.6	70
1015	Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood, 2009, 113, 4667-4676.	0.6	194
1016	CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood, 2009, 113, 4341-4351.	0.6	398
1017	Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood, 2009, 114, 772-778.	0.6	145
1018	Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood, 2009, 114, 1489-1497.	0.6	153
1019	Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. Blood, 2009, 114, 3276-3284.	0.6	38
1020	Bortezomib paradigm shift in myeloma. Blood, 2009, 114, 931-932.	0.6	14
1021	Thalidomide in multiple myeloma in the elderly. Aging Health, 2009, 5, 7-18.	0.3	0
1022	Newly diagnosed multiple myeloma in Taiwan. Hematology/ Oncology and Stem Cell Therapy, 2009, 2, 385-393.	0.6	3
1023	The Role of Proteasome Inhibition With Bortezomib in the Treatment of Antibody-Mediated Rejection After Kidney-Only or Kidney-Combined Organ Transplantation. Transplantation, 2010, 90, 1486-1492.	0.5	97
1024	Medullary Thyroid Cancer: A Promising Model for Targeted Therapy. Current Molecular Medicine, 2010, 10, 608-625.	0.6	19
1025	The Ubiquitin-Proteasome System as a Prospective Molecular Target for Cancer Treatment and Prevention. Current Protein and Peptide Science, 2010, 11, 459-470.	0.7	106
1026	Cell Death Targeting Therapies in B Lymphoid Malignancies. Current Drug Targets, 2010, 11, 769-780.	1.0	1
1027	Effect of the Proteasome Inhibitor Bortezomib on Humoral Immunity in Two Presensitized Renal Transplant Candidates. Transplantation, 2010, 89, 1385-1390.	0.5	60
1029	Evidence-Based Mini-Review: Treatment Options for Patients with Relapsed/Refractory Myeloma Previously Treated with Novel Agents and High-Dose Chemotherapy and Autologous Stem-Cell Transplantation. Hematology American Society of Hematology Education Program, 2010, 2010, 310-313.	0.9	9
1031	Inhibition of catechol-ÎŸ-methyltransferase activity in human breast cancer cells enhances the biological effect of the green tea polyphenol (-)-EGCG. Oncology Reports, 2010, 24, 563-9.	1.2	45
1032	PI3K/p110Î´ is a novel therapeutic target in multiple myeloma. Blood, 2010, 116, 1460-1468.	0.6	177

#	Article	IF	Citations
1033	How I treat elderly patients with myeloma. Blood, 2010, 116, 2215-2223.	0.6	39
1034	Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood, 2010, 116, 3743-3750.	0.6	101
1035	A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood, 2010, 116, 4906-4915.	0.6	188
1036	Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood, 2010, 116, 5501-5506.	0.6	308
1037	Drug discovery and assay development in the ubiquitinâ€“proteasome system. Biochemical Society Transactions, 2010, 38, 14-20.	1.6	19
1038	Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood, 2010, 115, 834-845.	0.6	104
1039	Anti-tumor effect by inhibition of NF-ÎºB activation using nafamostat mesilate for pancreatic cancer in a mouse model. Oncology Reports, 2010, , .	1.2	1
1040	Complications of Multiple Myeloma Therapy, Part 1: Risk Reduction and Management of Peripheral Neuropathy and Asthenia. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, S-4-S-12.	2.3	33
1041	Early response assessment in patients with multiple myeloma during anti-angiogenic therapy using arterial spin labelling: first clinical results. European Radiology, 2010, 20, 2899-2906.	2.3	18
1042	Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study. Annals of Hematology, 2010, 89, 475-482.	0.8	47
1043	Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP). Annals of Hematology, 2010, 89, 489-497.	0.8	12
1044	Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety. Annals of Hematology, 2010, 89, 905-912.	0.8	17
1045	A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma. Annals of Hematology, 2010, 89, 1019-1027.	0.8	15
1046	A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2010, 66, 151-158.	1.1	12
1047	Amyloid myopathy: a therapeutic trial for the rare and underdiagnosed myopathy with bortezomib. Journal of Neurology, 2010, 257, 2091-2093.	1.8	3
1050	Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy. Targeted Oncology, 2010, 5, 281-289.	1.7	35
1051	Advances in treatment for relapses and refractory multiple myeloma. Medical Oncology, 2010, 27, 25-42.	1.2	10
1052	The evolution and impact of therapy in multiple myeloma. Medical Oncology, 2010, 27, 1-6.	1.2	34

#	Article	IF	Citations
1053	Treatment options for multiple myeloma patients with high-risk disease. Medical Oncology, 2010, 27, 53-61.	1.2	4
1054	Current treatment strategy and new agents in mantle cell lymphoma. International Journal of Hematology, 2010, 92, 25-32.	0.7	7
1055	A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma. International Journal of Hematology, 2010, 92, 503-509.	0.7	7
1056	Bortezomib and dexamethasone for Japanese patients with relapsed and refractory multiple myeloma: a single center experience. International Journal of Hematology, 2010, 92, 518-523.	0.7	6
1057	Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka. International Journal of Hematology, 2010, 92, 579-586.	0.7	16
1058	Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. Journal of Neuro-Oncology, 2010, 100, 95-103.	1.4	73
1059	The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells. Molecular Immunology, 2010, 47, 2388-2396.	1.0	42
1060	Phase II Study of Bortezomib and Pegylated Liposomal Doxorubicin in the Treatment of Metastatic Breast Cancer. Clinical Breast Cancer, 2010, 10, 465-470.	1.1	30
1061	Drug Interaction Between Itraconazole and Bortezomib: Exacerbation of Peripheral Neuropathy and Thrombocytopenia Induced by Bortezomib. Pharmacotherapy, 2010, 30, 661-665.	1.2	18
1062	Heteronemin, a spongean sesterterpene, inhibits TNFÎ±-induced NF-ÎºB activation through proteasome inhibition and induces apoptotic cell death. Biochemical Pharmacology, 2010, 79, 610-622.	2.0	85
1063	New treatments for myeloma. Joint Bone Spine, 2010, 77, 20-26.	0.8	5
1064	Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration. European Journal of Haematology, 2010, 84, 332-336.	1.1	19
1065	BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma. European Journal of Haematology, 2010, 85, 99-107.	1.1	8
1066	Pomalidomide: A new IMiD with remarkable activity in both multiple myeloma and myelofibrosis. American Journal of Hematology, 2010, 85, 95-96.	2.0	18
1067	Bortezomib plus intermediateâ€dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: A Chinese experience. American Journal of Hematology, 2010, 85, 499-501.	2.0	11
1068	The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvantâ€induced arthritis in rats. Arthritis and Rheumatism, 2010, 62, 3277-3288.	6.7	50
1070	Salinosporamide Natural Products: Potent 20â€‰S Proteasome Inhibitors as Promising Cancer Chemotherapeutics. Angewandte Chemie - International Edition, 2010, 49, 9346-9367.	7.2	214
1071	Bortezomib Plus Thalidomide for Newly Diagnosed Multiple Myeloma in China. Anatomical Record, 2010, 293, 1679-1684.	0.8	7

#	Article	IF	Citations
1073	Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. Leukemia Research, 2010, 34, 85-92.	0.4	49
1074	Bortezomib-induced peripheral neuropathy in multiple myeloma: A comparison between previously treated and untreated patients. Leukemia Research, 2010, 34, 471-474.	0.4	75
1075	Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma. Leukemia Research, 2010, 34, 1111-1118.	0.4	55
1076	Novel agents for B-cell non-Hodgkin lymphoma: Science and the promise. Blood Reviews, 2010, 24, 69-82.	2.8	13
1077	How best to use new therapies in multiple myeloma. Blood Reviews, 2010, 24, 91-100.	2.8	11
1078	Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasome. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6581-6586.	1.0	42
1079	Phase I Trial of Bortezomib and Concurrent External Beam Radiation in Patients With Advanced Solid Malignancies. International Journal of Radiation Oncology Biology Physics, 2010, 78, 521-526.	0.4	25
1080	The chemotherapeutic agent bortezomib induces the formation of stress granules. Cancer Cell International, 2010, 10, 12.	1.8	109
1081	NFÎºB: a promising target for natural products in cancer chemoprevention. Phytotherapy Research, 2010, 24, 949-963.	2.8	163
1082	Neurological monitoring reduces the incidence of bortezomibâ€induced peripheral neuropathy in multiple myeloma patients. Journal of the Peripheral Nervous System, 2010, 15, 17-25.	1.4	57
1083	Phase 2 study of two sequential threeâ€drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma. British Journal of Haematology, 2010, 148, 562-568.	1.2	35
1084	The proteasome inhibitor CEPâ€18770 enhances the antiâ€myeloma activity of bortezomib and melphalan. British Journal of Haematology, 2010, 148, 569-581.	1.2	70
1085	Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma. British Journal of Haematology, 2010, 148, 853-858.	1.2	10
1086	Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPIâ€0052 (marizomib) in a human plasmacytoma xenograft murine model. British Journal of Haematology, 2010, 149, 550-559.	1.2	58
1087	Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. British Journal of Haematology, 2010, 150, 428-437.	1.2	65
1088	Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 doseâ€escalation study. British Journal of Haematology, 2010, 150, 438-445.	1.2	62
1089	Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy. British Journal of Cancer, 2010, 103, 1580-1587.	2.9	38
1090	Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia, 2010, 24, 1350-1356.	3.3	77

#	Article	IF	Citations
1091	Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. Leukemia, 2010, 24, 1037-1042.	3.3	39
1092	Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nature Medicine, 2010, 16, 483-489.	15.2	281
1093	Antiproteases as Therapeutics to Target Inflammation in Cystic Fibrosis. Open Respiratory Medicine Journal, 2010, 4, 20-31.	1.3	13
1094	Bortezomib in Kidney Transplantation. Journal of Transplantation, 2010, 2010, 1-6.	0.3	22
1095	The risk factors for herpes zoster in bortezomib treatment in patients with multiple myeloma. The Korean Journal of Hematology, 2010, 45, 188.	0.7	12
1096	Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma. The Korean Journal of Hematology, 2010, 45, 183.	0.7	13
1097	THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT. Mediterranean Journal of Hematology and Infectious Diseases, 2010, 2, e2010009.	0.5	2
1098	Proteasome inhibition and its therapeutic potential in multiple myeloma. Biologics: Targets and Therapy, 2010, 4, 273.	3.0	20
1099	Targeting the Ubiquitin-proteasome System for the Treatment of Multiple Myeloma and Other Human Diseases. Clinical Medicine Insights Therapeutics, 2010, 2, CMT.S2889.	0.4	0
1100	Bortezomib Inhibits Hepatitis B Virus Replication in Transgenic Mice. Antimicrobial Agents and Chemotherapy, 2010, 54, 749-756.	1.4	23
1101	Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2010, 28, 1422-1428.	0.8	150
1102	A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study. Clinical Cancer Research, 2010, 16, 5079-5086.	3.2	94
1103	Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer. Cancer Research, 2010, 70, 1970-1980.	0.4	444
1104	A Phase I Trial of Bortezomib with Temozolomide in Patients with Advanced Melanoma: Toxicities, Antitumor Effects, and Modulation of Therapeutic Targets. Clinical Cancer Research, 2010, 16, 348-357.	3.2	36
1105	Patterns of Improved Survival in Patients With Multiple Myeloma in the Twenty-First Century: A Population-Based Study. Journal of Clinical Oncology, 2010, 28, 830-834.	0.8	165
1106	Multiple myeloma. Annals of Oncology, 2010, 21, vii313-vii319.	0.6	37
1107	Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis. Journal of Clinical Oncology, 2010, 28, 1031-1037.	0.8	273
1108	Reiterative Survival Analyses of Total Therapy 2 for Multiple Myeloma Elucidate Follow-Up Time Dependency of Prognostic Variables and Treatment Arms. Journal of Clinical Oncology, 2010, 28, 3023-3027.	0.8	39

#	Article	IF	Citations
1109	Clinical Value of Absolute Lymphocyte Counts before Bortezomib-Dexamethasone Therapy in Relapsed Multiple Myeloma Patients. Acta Haematologica, 2010, 124, 34-39.	0.7	9
1110	New Strategies in Peripheral T-Cell Lymphoma: Understanding Tumor Biology and Developing Novel Therapies. Clinical Cancer Research, 2010, 16, 5608-5617.	3.2	21
1111	Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents. Journal of Clinical Oncology, 2010, 28, 2612-2624.	0.8	186
1112	GÂ12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation. Carcinogenesis, 2010, 31, 1230-1237.	1.3	21
1113	Osteoblastogenesis and tumor growth in myeloma. Leukemia and Lymphoma, 2010, 51, 213-220.	0.6	48
1114	Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica, 2010, 95, 311-319.	1.7	142
1115	Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood, 2010, 116, 679-686.	0.6	790
1116	Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma. Clinical Cancer Research, 2010, 16, 3260-3269.	3.2	62
1117	Novel therapeutic targets for multiple myeloma. Future Oncology, 2010, 6, 407-418.	1.1	26
1118	Combination effects of bortezomib with gemcitabine and EMAP II in experimental pancreatic cancer. Cancer Biology and Therapy, 2010, 10, 99-107.	1.5	19
1119	Bortezomib Retreatment in Relapsed Multiple Myeloma â€“ Results from a Retrospective Multicentre Survey in Germany and Switzerland. Oncology, 2010, 79, 247-254.	0.9	37
1120	Relapsed Multiple Myeloma. Hematology American Society of Hematology Education Program, 2010, 2010, 303-309.	0.9	35
1121	Dealing with Neuropathy in Plasma-Cell Dyscrasias. Hematology American Society of Hematology Education Program, 2010, 2010, 423-430.	0.9	31
1122	MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity. Cancer Biology and Therapy, 2010, 9, 936-944.	1.5	79
1123	Rapid control of previously untreated multiple myeloma with bortezomibâ€“lenalidomideâ€“dexamethasone (BLD). Hematology, 2010, 15, 70-73.	0.7	17
1124	Cardiotoxicity. Annals of Oncology, 2010, 21, vii173-vii179.	0.6	61
1125	Proteasomal Regulation of Pulmonary Fibrosis. Proceedings of the American Thoracic Society, 2010, 7, 77-83.	3.5	36
1126	Bortezomib: A New Pro-Apoptotic Agent in Cancer Treatment. Current Cancer Drug Targets, 2010, 10, 55-67.	0.8	37

#	Article	IF	Citations
1127	The Clinically Approved Proteasome Inhibitor PS-341 Efficiently Blocks Influenza A Virus and Vesicular Stomatitis Virus Propagation by Establishing an Antiviral State. Journal of Virology, 2010, 84, 9439-9451.	1.5	45
1128	Apigenin, Chrysin, and Luteolin Selectively Inhibit Chymotrypsin-Like and Trypsin-Like Proteasome Catalytic Activities in Tumor Cells. Planta Medica, 2010, 76, 128-132.	0.7	30
1129	The Dual Role of Tumor Necrosis Factor (TNF) in Cancer Biology. Current Medicinal Chemistry, 2010, 17, 3337-3352.	1.2	98
1130	Controlling subcellular delivery to optimize therapeutic effect. Therapeutic Delivery, 2010, 1, 169-193.	1.2	45
1131	Advances in immunosuppression for renal transplantation. Nature Reviews Nephrology, 2010, 6, 160-167.	4.1	44
1132	Synthesis, in Vitro and in Vivo Biological Evaluation, and Comprehensive Understanding of Structureâ^'Activity Relationships of Dipeptidyl Boronic Acid Proteasome Inhibitors Constructed from Î²-Amino Acids. Journal of Medicinal Chemistry, 2010, 53, 8619-8626.	2.9	36
1133	Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S Î²5-subunit. Biochemical Journal, 2010, 430, 461-476.	1.7	148
1134	Characterization of bortezomib-adapted I-45 mesothelioma cells. Molecular Cancer, 2010, 9, 110.	7.9	24
1135	Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study. Molecular Cancer, 2010, 9, 56.	7.9	28
1136	Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients. Journal of Translational Medicine, 2010, 8, 124.	1.8	7
1137	Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma. Journal of Hematology and Oncology, 2010, 3, 13.	6.9	19
1138	Weekly Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone Is a Safe and Effective Therapy for Elderly Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 68-72.	0.2	16
1139	Bortezomib as a Treatment Option in Patients With WaldenstrÃ¶m Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 110-117.	0.2	20
1140	Rapid Fatal Pulmonary Complications in a Chinese Patient After Bortezomib Treatment for ALK-Negative Anaplastic Large-Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 152-154.	0.2	6
1141	Outcome and Toxicity in the Modern Era of New Drugs for Multiple Myeloma: A Reappraisal for Comparison With Future Investigational Trials. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 353-360.	0.2	4
1142	Ten Years of Improvement in the Management of Multiple Myeloma: 2000-2010. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 424-442.	0.2	26
1143	Generating a Generation of Proteasome Inhibitors: From Microbial Fermentation to Total Synthesis of Salinosporamide A (Marizomib) and Other Salinosporamides. Marine Drugs, 2010, 8, 835-880.	2.2	55
1144	Sodium butyrate down-regulation of indoleamine 2, 3-dioxygenase at the transcriptional and post-transcriptional levels. International Journal of Biochemistry and Cell Biology, 2010, 42, 1840-1846.	1.2	29

#	Article	IF	Citations
1145	Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. European Journal of Cancer, 2010, 46, 420-429.	1.3	65
1146	Combined Submyeloablative and Myeloablative Dose Intense Melphalan Results in Satisfactory Responses with Acceptable Toxicity in Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2010, 16, 1402-1410.	2.0	5
1147	Non-antigen processing immunoproteasomes in diabetic hearts?. Journal of Molecular and Cellular Cardiology, 2010, 49, 1-4.	0.9	1
1148	NF-Î²B as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia. Expert Opinion on Therapeutic Targets, 2010, 14, 1157-1176.	1.5	46
1149	Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice. Experimental Neurology, 2010, 223, 599-608.	2.0	85
1150	Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet, The, 2010, 376, 2075-2085.	6.3	770
1151	Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncology, The, 2010, 11, 1086-1095.	5.1	187
1152	Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncology, The, 2010, 11, 1057-1065.	5.1	204
1153	Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial. Journal of Clinical Oncology, 2010, 28, 4621-4629.	0.8	512
1154	Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leukemia and Lymphoma, 2010, 51, 1178-1187.	0.6	136
1155	Targeted Therapies for Cancer. , 2010, , 532-547.		1
1156	Small Molecules in Oncology. Recent Results in Cancer Research, 2010, , .	1.8	5
1157	Bortezomib for previously untreated multiple myeloma. Expert Opinion on Pharmacotherapy, 2011, 12, 2553-2564.	0.9	7
1158	Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. Leukemia, 2011, 25, 1627-1631.	3.3	51
1159	Anaplastic thyroid cancer: a comprehensive review of novel therapy. Expert Review of Anticancer Therapy, 2011, 11, 387-402.	1.1	33
1160	Clinicopathologic significances of nuclear expression of nuclear factor-ÂB transcription factors in retinoblastoma. Journal of Clinical Pathology, 2011, 64, 695-700.	1.0	11
1161	In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells. Clinical Cancer Research, 2011, 17, 5311-5321.	3.2	290
1162	Imaging Mass Spectrometry Provides Fingerprints for Distinguishing Hepatocellular Carcinoma from Cirrhosis. Journal of Proteome Research, 2011, 10, 3755-3765.	1.8	51

#	Article	IF	Citations
1163	Harnessing Tumor Necrosis Factor Receptors to Enhance Antitumor Activities of Drugs. Chemical Research in Toxicology, 2011, 24, 1610-1616.	1.7	15
1164	Management of Myeloma: An Italian Perspective. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S82-S86.	0.2	0
1165	Oxathiazole-2-one derivative of bortezomib: Synthesis, stability and proteasome inhibition activity. MedChemComm, 2011, 2, 1083.	3.5	4
1166	Bortezomib for previously untreated multiple myeloma. Expert Review of Hematology, 2011, 4, 381-398.	1.0	3
1167	Effect of Cytochrome P450 3A4 Inducers on the Pharmacokinetic, Pharmacodynamic and Safety Profiles of Bortezomib in Patients with Multiple Myeloma or Non-HodgkinÊ¼s Lymphoma. Clinical Pharmacokinetics, 2011, 50, 781-791.	1.6	31
1168	Equipoise and the Dilemma of Randomized Clinical Trials. New England Journal of Medicine, 2011, 364, 476-480.	13.9	165
1169	Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in Myeloma. Journal of Clinical Oncology, 2011, 29, 1916-1923.	0.8	78
1170	Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leukemia and Lymphoma, 2011, 52, 1787-1794.	0.6	111
1171	Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treatment Reviews, 2011, 37, 266-283.	3.4	66
1172	Immune modulatory agents in hematopoietic malignancies. Cancer Treatment Reviews, 2011, 37, S2-S7.	3.4	1
1173	Antibody-mediated rejection in kidney transplantation: an update. Expert Opinion on Pharmacotherapy, 2011, 12, 579-592.	0.9	58
1174	Therapeutic Utility of Proteasome Inhibitors for Acute Leukemia. , 2011, , 273-298.		0
1175	Pomalidomide therapy for multiple myeloma and myelofibrosis: an update. Leukemia and Lymphoma, 2011, 52, 560-566.	0.6	10
1176	Pomalidomide therapy for myeloma. Expert Opinion on Investigational Drugs, 2011, 20, 691-700.	1.9	29
1177	Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncology, The, 2011, 12, 431-440.	5.1	835
1178	N-(2-{3-[3,5-Bis(trifluoromethyl)phenyl]ureido}ethyl)-glycyrrhetinamide (6b): A Novel Anticancer Glycyrrhetinic Acid Derivative that Targets the Proteasome and Displays Anti-Kinase Activity. Journal of Medicinal Chemistry, 2011, 54, 6501-6513.	2.9	38
1179	From the observation DAC: romidepsin revisited. Blood, 2011, 118, 6231-6232.	0.6	3
1180	Pilot Study of Bortezomib for Patients With Imatinib-Refractory Chronic Myeloid Leukemia in Chronic or Accelerated Phase. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 355-360.	0.2	16

#	Article	IF	Citations
1181	Preclinical Assessment of Strategies for Enhancement of Metaiodobenzylguanidine Therapy of Neuroendocrine Tumors. Seminars in Nuclear Medicine, 2011, 41, 334-344.	2.5	14
1182	Management of Relapsed and Relapsed/Refractory Multiple Myeloma. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 1209-1216.	2.3	22
1183	Advances in the Autologous and Allogeneic Transplantation Strategies for Multiple Myeloma. Cancer Control, 2011, 18, 258-267.	0.7	17
1184	Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma. Core Evidence, 2011, 6, 43.	4.7	41
1185	Signal Transduction Pathways in Breast Cancer â€“ Drug Targets and Challenges. , 0, , .		0
1186	Targeting the Ubiquitin-Proteasome Pathway: An Emerging Concept in Cancer Therapy. Current Topics in Medicinal Chemistry, 2011, 11, 2888-2905.	1.0	75
1187	Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives. Current Cancer Drug Targets, 2011, 11, 239-253.	0.8	671
1188	Current treatment options for elderly patients with multiple myeloma: clinical impact of novel agents. Therapy: Open Access in Clinical Medicine, 2011, 8, 415-429.	0.2	4
1189	Proteasome Inhibitors and Modulators of Angiogenesis in Multiple Myeloma. Current Medicinal Chemistry, 2011, 18, 5185-5195.	1.2	15
1190	Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials. Current Cancer Drug Targets, 2011, 11, 254-284.	0.8	200
1191	The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib. Current Pharmaceutical Design, 2011, 17, 1483-1499.	0.9	42
1192	Delivery of Intracellular-Acting Biologics in Pro-Apoptotic Therapies. Current Pharmaceutical Design, 2011, 17, 293-319.	0.9	31
1193	A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood, 2011, 118, 6274-6283.	0.6	83
1194	Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood, 2011, 117, 3041-3044.	0.6	109
1195	RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. Blood, 2011, 117, 3847-3857.	0.6	97
1196	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood, 2011, 117, 4691-4695.	0.6	849
1197	Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. Blood, 2011, 118, 535-543.	0.6	82
1198	Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood, 2011, 118, 4086-4092.	0.6	173

#	Article	IF	Citations
1199	Genetics and molecular epidemiology of multiple myeloma: The rationale for the IMMEnSE consortium (Review). International Journal of Oncology, 2011, 40, 625-38.	1.4	14
1200	A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancerA phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer. Oncology Reports, 2012, 27, 657-63.	1.2	45
1201	Polymorphisms of nuclear factor-ÂB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens. Haematologica, 2011, 96, 729-737.	1.7	46
1202	Effects of proteasome inhibitors on rat renal fibrosis in vitro and in vivo. Nephrology, 2011, 16, 76-86.	0.7	25
1203	Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. British Journal of Haematology, 2011, 152, 367-379.	1.2	118
1204	Molecular and cellular effects of multiâ€targeted cyclinâ€dependent kinase inhibition in myeloma: biological and clinical implications. British Journal of Haematology, 2011, 152, 420-432.	1.2	23
1205	Guidelines for the diagnosis and management of multiple myeloma 2011. British Journal of Haematology, 2011, 154, 32-75.	1.2	252
1206	Guidelines for supportive care in multiple myeloma 2011. British Journal of Haematology, 2011, 154, 76-103.	1.2	176
1207	Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. British Journal of Haematology, 2011, 153, 729-740.	1.2	102
1208	Evaluation of preâ€existing neuropathy and bortezomib retreatment as risk factors to develop severe neuropathy in a mouse model. Journal of the Peripheral Nervous System, 2011, 16, 199-212.	1.4	21
1209	The unfolded protein response transducer IRE1Î± prevents ER stress-induced hepatic steatosis. EMBO Journal, 2011, 30, 1357-1375.	3.5	302
1210	Emerging therapies for the treatment of relapsed or refractory multiple myeloma. European Journal of Haematology, 2011, 86, 1-15.	1.1	70
1211	Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses. Antiviral Research, 2011, 91, 304-313.	1.9	22
1212	An Integrated InÂVitro and InÂVivo High-Throughput Screen Identifies Treatment Leads for Ependymoma. Cancer Cell, 2011, 20, 384-399.	7.7	105
1213	Novel Proteasome Inhibitors to Overcome Bortezomib Resistance. Journal of the National Cancer Institute, 2011, 103, 1007-1017.	3.0	226
1214	Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach. Journal of Clinical Oncology, 2011, 29, 3805-3812.	0.8	302
1215	Chemical â€˜Jekyll and Hydeâ€™s: small-molecule inhibitors of developmental signaling pathways. Chemical Society Reviews, 2011, 40, 4318.	18.7	30
1216	Analysis of Two Commercially Available Bortezomib Products: Differences in Assay of Active Agent and Impurity Profile. AAPS PharmSciTech, 2011, 12, 461-467.	1.5	16

#	Article	IF	Citations
1217	Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cells. Cell Biology and Toxicology, 2011, 27, 123-131.	2.4	4
1218	Analysis of physiciansâ€™ perspectives versus patientsâ€™ preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma. European Journal of Health Economics, 2011, 12, 193-203.	1.4	67
1219	Concurrent p16 methylation pattern as an adverse prognostic factor in multiple myeloma: a methylation-specific polymerase chain reaction study using two different primer sets. Annals of Hematology, 2011, 90, 73-79.	0.8	13
1220	Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Annals of Hematology, 2011, 90, 429-439.	0.8	60
1221	Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemotherapy and Pharmacology, 2011, 67, 57-67.	1.1	97
1222	Proteasome inhibitors in cancer therapy. Journal of Cell Communication and Signaling, 2011, 5, 101-110.	1.8	257
1223	Reversion of multidrug-resistance by proteasome inhibitor bortezomib in K562/DNR cell line. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2011, 23, 69-73.	0.7	2
1224	New Immunomodulatory Drugs in Myeloma. Current Hematologic Malignancy Reports, 2011, 6, 120-125.	1.2	9
1225	Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells. Journal of Hematology and Oncology, 2011, 4, 37.	6.9	67
1226	Proteasomal nonâ€catalytic subunit PSMD2 as a potential therapeutic target in association with various clinicopathologic features in lung adenocarcinomas. Molecular Carcinogenesis, 2011, 50, 301-309.	1.3	48
1227	Multiple myeloma: 2011 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2011, 86, 57-65.	2.0	137
1228	Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial. American Journal of Hematology, 2011, 86, 640-645.	2.0	57
1229	Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents. American Journal of Hematology, 2011, 86, 699-701.	2.0	8
1230	Oxaliplatinâ€induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. EMBO Molecular Medicine, 2011, 3, 266-278.	3.3	304
1231	Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer, 2011, 117, 2442-2451.	2.0	52
1232	Practical management of adverse events in multiple myeloma: Can therapy be attenuated in older patients?. Blood Reviews, 2011, 25, 181-191.	2.8	49
1233	Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains. Leukemia Research, 2011, 35, 95-98.	0.4	40
1234	The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-Î²B activity. Leukemia Research, 2011, 35, 243-249.	0.4	82

#	Article	IF	Citations
1235	In vitro growth of hematopoietic progenitors and stromal bone marrow cells from patients with multiple myeloma. Leukemia Research, 2011, 35, 250-255.	0.4	7
1236	Successful treatment with a modified bortezomib schedule of weekly and longer intervals for patients with refractory/resistance multiple myeloma. Leukemia Research, 2011, 35, 591-597.	0.4	13
1237	An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation. Immunotherapy, 2011, 3, 1033-1040.	1.0	11
1238	Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma. Molecular Cancer Therapeutics, 2011, 10, 2034-2042.	1.9	246
1239	Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution, and Excretion of Carfilzomib in Rats. Drug Metabolism and Disposition, 2011, 39, 1873-1882.	1.7	114
1240	Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients. Haematologica, 2011, 96, 1728-1732.	1.7	48
1241	Luteinizing Hormone-Releasing Hormone (LHRH)-I Antagonist Cetrorelix Inhibits Myeloma Cell Growth In vitro and In vivo. Molecular Cancer Therapeutics, 2011, 10, 148-158.	1.9	13
1243	Efficacy of Continuous, Daily, Oral, Ultra-low-dose 200 mg Acyclovir to Prevent Herpes Zoster Events Among Bortezomib-treated Patients: A Report From Retrospective Study. Japanese Journal of Clinical Oncology, 2011, 41, 876-881.	0.6	19
1244	Small Compound 6-O-Angeloylplenolin Induces Mitotic Arrest and Exhibits Therapeutic Potentials in Multiple Myeloma. PLoS ONE, 2011, 6, e21930.	1.1	44
1245	Multiple myeloma with lung plasmacytoma. Lung India, 2011, 28, 136.	0.3	7
1246	Experimental approaches in the treatment of multiple myeloma. Therapeutic Advances in Hematology, 2011, 2, 213-230.	1.1	3
1247	Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms. Clinical Cancer Research, 2011, 17, 3388-3397.	3.2	49
1248	Quality assessment, standardization. Clinical Chemistry and Laboratory Medicine, 2011, 49, .	1.4	1
1249	The Promise of Comparative Effectiveness Research. JAMA - Journal of the American Medical Association, 2011, 305, 400.	3.8	82
1250	A Case of Disseminated and Fulminant Plasmacytomas That Developed during Bortezomib Treatment. Case Reports in Oncology, 2011, 4, 101-105.	0.3	4
1251	Proteasome Structure, Function, and Lessons Learned from Beta-Lactone Inhibitors. Current Topics in Medicinal Chemistry, 2011, 11, 2850-2878.	1.0	46
1252	Out Foxing Bcr-Abl. Cancer Biology and Therapy, 2011, 11, 769-770.	1.5	0
1253	Peptides Targeting Estrogen Receptor Alpha-Potential Applications for Breast Cancer Treatment. Current Pharmaceutical Design, 2011, 17, 2632-2653.	0.9	19

#	Article	IF	Citations
1254	Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 957-970.	0.2	40
1255	Activated Invariant NKT Cells Regulate Osteoclast Development and Function. Journal of Immunology, 2011, 186, 2910-2917.	0.4	33
1256	Estrogen-Dependent Gene Transcription in Human Breast Cancer Cells Relies upon Proteasome-Dependent Monoubiquitination of Histone H2B. Cancer Research, 2011, 71, 5739-5753.	0.4	138
1257	Treatment Options for Relapsed and Refractory Multiple Myeloma. Clinical Cancer Research, 2011, 17, 1264-1277.	3.2	118
1258	A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. Leukemia and Lymphoma, 2011, 52, 2308-2315.	0.6	25
1259	Oncogenomics to Target Myeloma in the Bone Marrow Microenvironment. Clinical Cancer Research, 2011, 17, 1225-1233.	3.2	54
1260	Proteasome inhibition improves diaphragm function in an animal model for COPD. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2011, 301, L110-L116.	1.3	21
1261	Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma. Bone Marrow Transplantation, 2011, 46, 764-765.	1.3	18
1262	Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial. Journal of Clinical Oncology, 2011, 29, 4243-4249.	0.8	118
1263	Modification by Ubiquitin-Like Proteins: Significance in Apoptosis and Autophagy Pathways. International Journal of Molecular Sciences, 2012, 13, 11804-11831.	1.8	45
1264	Implications of Therapy-Induced Selective Autophagy on Tumor Metabolism and Survival. International Journal of Cell Biology, 2012, 2012, 1-11.	1.0	15
1265	Bortezomib-associated fatal liver failure in a haemodialysis patient with multiple myeloma. Clinical Toxicology, 2012, 50, 444-445.	0.8	12
1266	Bortezomib a safety treatment for patients with Multiple Myeloma and Cystic Fibrosis. Mediterranean Journal of Hematology and Infectious Diseases, 2012, 4, e2012035.	0.5	4
1267	Neurological complications of chemotherapy to the peripheral nervous system. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 105, 917-936.	1.0	3
1268	Hypertension impairs myocardin function: a novel mechanism facilitating arterial remodelling. Cardiovascular Research, 2012, 96, 120-129.	1.8	38
1269	Recommendations for standardized reporting of protein electrophoresis in Australia and New Zealand. Annals of Clinical Biochemistry, 2012, 49, 242-256.	0.8	71
1270	Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma. Leukemia and Lymphoma, 2012, 53, 1174-1182.	0.6	19
1271	Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica, 2012, 97, 1925-1928.	1.7	119

#	Article	IF	Citations
1272	Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma. Therapeutic Advances in Hematology, 2012, 3, 117-124.	1.1	31
1273	Targeting the ubiquitinâ€“proteasome pathway with inorganic compounds to fight cancer: a challenge for the future. Future Medicinal Chemistry, 2012, 4, 525-543.	1.1	52
1274	Multiple myeloma. Current Opinion in Supportive and Palliative Care, 2012, 6, 330-336.	0.5	17
1275	Opposing effects of bortezomib-induced nuclear factor-ÂB inhibition on chemical lung carcinogenesis. Carcinogenesis, 2012, 33, 859-867.	1.3	17
1276	Protein Degradation by the Ubiquitin-Proteasome Pathway and Organ Fibrosis. Current Medicinal Chemistry, 2012, 19, 893-900.	1.2	11
1277	Targeting the Tumor Proteasome as a Mechanism to Control the Synthesis and Bioactivity of Matrix Macromolecules. Current Molecular Medicine, 2012, 12, 1068-1082.	0.6	16
1278	An Epigenetic Approach to Pancreatic Cancer Treatment: The Prospective Role of Histone Deacetylase Inhibitors. Current Cancer Drug Targets, 2012, 12, 439-452.	0.8	29
1279	Dual Inhibition of Canonical and Noncanonical NF-Î°B Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma. Clinical Cancer Research, 2012, 18, 4669-4681.	3.2	75
1280	Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets. Future Oncology, 2012, 8, 787-801.	1.1	38
1281	Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica, 2012, 97, 64-72.	1.7	109
1282	Genomic stratification of multiple myeloma treated with novel agents. Leukemia and Lymphoma, 2012, 53, 202-207.	0.6	13
1283	Targeting neddylation in cancer therapy. Future Oncology, 2012, 8, 1461-1470.	1.1	30
1284	Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient program. Expert Opinion on Biological Therapy, 2012, 12, 1449-1462.	1.4	18
1285	Twenty Years of G-CSF. , 2012, , .		8
1286	The novel proteasome inhibitor BSc2118 protects against cerebral ischaemia through HIF1A accumulation and enhanced angioneurogenesis. Brain, 2012, 135, 3282-3297.	3.7	65
1287	Severe Heart Failure after Bortezomib Treatment in a Patient with Multiple Myeloma: A Case Report and Review of the Literature. Acta Haematologica, 2012, 128, 244-247.	0.7	69
1288	Immune Mechanism of the Antitumor Effects Generated by Bortezomib. Journal of Immunology, 2012, 189, 3209-3220.	0.4	71
1289	Carfilzomib and ONX 0912 Inhibit Cell Survival and Tumor Growth of Head and Neck Cancer and Their Activities Are Enhanced by Suppression of Mcl-1 or Autophagy. Clinical Cancer Research, 2012, 18, 5639-5649.	3.2	72

#	Article	IF	Citations
1290	Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 2012, 30, 2475-2482.	0.8	185
1291	Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease. Leukemia and Lymphoma, 2012, 53, 275-281.	0.6	13
1292	HDAC Inhibitor Modulation of Proteotoxicity as a Therapeutic Approach in Cancer. Advances in Cancer Research, 2012, 116, 131-163.	1.9	31
1293	DangER: protein ovERload. Targeting protein degradation to treat myeloma. Haematologica, 2012, 97, 1119-1130.	1.7	61
1294	Efficacy and safety of reduced-intensity induction therapy with a bortezomib-based regimen in elderly patients with multiple myeloma. Therapeutic Advances in Hematology, 2012, 3, 147-154.	1.1	5
1295	Molecular Pathways: Targeting Proteasomal Protein Degradation in Cancer. Clinical Cancer Research, 2012, 18, 15-20.	3.2	54
1296	Sorafenib Has Potent Antitumor Activity against Multiple Myeloma In Vitro, Ex Vivo, and In Vivo in the 5T33MM Mouse Model. Cancer Research, 2012, 72, 5348-5362.	0.4	44
1297	Tolerogenic therapies in transplantation. Frontiers in Immunology, 2012, 3, 198.	2.2	58
1298	Bortezomib-induced Pneumonitis During Bortezomib Retreatment in Multiple Myeloma. Japanese Journal of Clinical Oncology, 2012, 42, 637-639.	0.6	11
1299	Bortezomib-Cyclophosphamide-Dexamethasone for Relapsing Multiple Myeloma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 562-565.	0.6	14
1300	Targeting the Proteasome With Bortezomib in Multiple Myeloma. American Journal of Therapeutics, 2012, 19, 133-144.	0.5	13
1301	Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo. Molecular Cancer Therapeutics, 2012, 11, 1122-1132.	1.9	29
1302	MicroRNAs in the Pathobiology of Multiple Myeloma. Current Cancer Drug Targets, 2012, 12, 823-837.	0.8	44
1303	Proteasome Inhibitors: A New Perspective for Treating Autoimmune Diseases. Current Drug Targets, 2012, 13, 1665-1675.	1.0	24
1304	Bortezomib partially protects the rat diaphragm from ventilator-induced diaphragm dysfunction*. Critical Care Medicine, 2012, 40, 2449-2455.	0.4	38
1305	Advantageous use of lenalidomide in multiple myeloma. Current Opinion in Oncology, 2012, 24, S13-S20.	1.1	2
1306	Role of Cancer Stem Cells in Spine Tumors. Neurosurgery, 2012, 71, 117-125.	0.6	11
1307	Clinical utility and implementation of gene-expression profiling in myeloma: current status and challenges. International Journal of Hematologic Oncology, 2012, 1, 133-146.	0.7	0

#	Article	IF	Citations
1308	Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood, 2012, 119, 2579-2589.	0.6	544
1309	Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood, 2012, 120, 9-19.	0.6	305
1310	Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood, 2012, 120, 376-385.	0.6	174
1311	A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood, 2012, 120, 1801-1809.	0.6	393
1312	A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood, 2012, 120, 2817-2825.	0.6	608
1313	Novel Therapies for Relapsed/Refractory Multiple Myeloma: How Can We Improve on â€œSalvageâ€• Therapy?â€”Introduction. Seminars in Hematology, 2012, 49, S1-S2.	1.8	5
1314	Management Strategies for Relapsed/Refractory Multiple Myeloma: Current Clinical Perspectives. Seminars in Hematology, 2012, 49, S16-S32.	1.8	31
1315	Relapsed/Refractory Multiple Myeloma: Defining Refractory Disease and Identifying Strategies to Overcome Resistance. Seminars in Hematology, 2012, 49, S3-S15.	1.8	10
1316	Discovery and Development of Second-Generation Proteasome Inhibitors. Seminars in Hematology, 2012, 49, 207-214.	1.8	17
1317	The Use of Bortezomib as a Rescue Treatment for Acute Antibody-Mediated Rejection: Report of Three Cases and Review of Literature. Transplantation Proceedings, 2012, 44, 2971-2975.	0.3	27
1318	Model of translational cancer research in multiple myeloma. Cancer Science, 2012, 103, 1907-1912.	1.7	5
1319	Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs. Expert Opinion on Investigational Drugs, 2012, 21, 1075-1087.	1.9	19
1320	Targeting Galectin-3 Unveils the Complexity of Multiple Myeloma: A Sweet Context. ACS Symposium Series, 2012, , 289-307.	0.5	0
1321	Roles of Estrogen Receptor and p21Waf1 in Bortezomib-Induced Growth Inhibition in Human Breast Cancer Cells. Molecular Cancer Research, 2012, 10, 1473-1481.	1.5	5
1322	Sequential or combination therapy for multiple myeloma. Expert Review of Hematology, 2012, 5, 533-545.	1.0	5
1323	Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial. Journal of Clinical Oncology, 2012, 30, 2946-2955.	0.8	735
1324	A case of peripheral nerve microvasculitis associated with multiple myeloma and bortezomib treatment. Muscle and Nerve, 2012, 46, 964-970.	1.0	21
1325	A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance. Cancer Cell, 2012, 22, 345-358.	7.7	491

#	Article	IF	Citations
1326	Myeloma Kidney: Improving Clinical Outcomes?. Advances in Chronic Kidney Disease, 2012, 19, 342-351.	0.6	11
1328	An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 310-318.	0.2	104
1329	Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology, 2012, 30, 1960-1965.	0.8	184
1330	A gene expression signature for high-risk multiple myeloma. Leukemia, 2012, 26, 2406-2413.	3.3	233
1331	Proteasome inhibition by bortezomib: Effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation. Transplant Immunology, 2012, 26, 171-175.	0.6	42
1332	Ritonavir Interacts With Bortezomib to Enhance Protein Ubiquitination and Histone Acetylation Synergistically in Renal Cancer Cells. Urology, 2012, 79, 966.e13-966.e21.	0.5	19
1333	Probing the Specificity and Activity Profiles of the Proteasome Inhibitors Bortezomib and Delanzomib. Molecular Pharmaceutics, 2012, 9, 1126-1135.	2.3	40
1334	The role of natural killer cells in immunity against multiple myeloma. Leukemia and Lymphoma, 2012, 53, 1666-1676.	0.6	63
1335	Ask the Experts: Deriving new treatment strategies in multiple myeloma. International Journal of Hematologic Oncology, 2012, 1, 21-26.	0.7	0
1336	Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib. Human Pathology, 2012, 43, 858-864.	1.1	16
1337	Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE. International Immunopharmacology, 2012, 12, 257-270.	1.7	55
1338	Proteasome inhibition-induced p38 MAPK/ERK signaling regulates autophagy and apoptosis through the dual phosphorylation of glycogen synthase kinase 3Î². Biochemical and Biophysical Research Communications, 2012, 418, 759-764.	1.0	51
1339	Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD. Journal of Hematology and Oncology, 2012, 5, 28.	6.9	13
1340	Itraconazole may increase the risk of early-onset bortezomib-induced peripheral neuropathy. International Journal of Hematology, 2012, 96, 758-763.	0.7	11
1341	Latest advances and current challenges in the treatment of multiple myeloma. Nature Reviews Clinical Oncology, 2012, 9, 135-143.	12.5	193
1342	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia, 2012, 26, 149-157.	3.3	664
1343	Molecular Mechanisms of Acquired Proteasome Inhibitor Resistance. Journal of Medicinal Chemistry, 2012, 55, 10317-10327.	2.9	80
1344	Proteasome and Cancer. Progress in Molecular Biology and Translational Science, 2012, 109, 277-293.	0.9	16

#	Article	IF	Citations
1345	General Aspects and Mechanisms of Peripheral Neuropathy Associated With Bortezomib in Patients With Newly Diagnosed Multiple Myeloma. Seminars in Hematology, 2012, 49, 249-257.	1.8	22
1346	The Immunoproteasome as a Target in Hematologic Malignancies. Seminars in Hematology, 2012, 49, 258-262.	1.8	71
1347	An Historic Perspective of Proteasome Inhibition. Seminars in Hematology, 2012, 49, 196-206.	1.8	13
1348	Bortezomib Combination Therapy in Multiple Myeloma. Seminars in Hematology, 2012, 49, 228-242.	1.8	66
1349	Treatment decisions for elderly patients with haematological malignancies: a dilemma. Lancet Oncology, The, 2012, 13, e344-e352.	5.1	39
1350	Detection of ubiquitinâ€“proteasome enzymatic activities in cells: Application of activity-based probes to inhibitor development. Biochimica Et Biophysica Acta - Molecular Cell Research, 2012, 1823, 2029-2037.	1.9	41
1351	Proteasome inhibitors in mantle cell lymphoma. Best Practice and Research in Clinical Haematology, 2012, 25, 133-141.	0.7	25
1352	Proteasome deubiquitinases as novel targets for cancer therapy. International Journal of Biochemistry and Cell Biology, 2012, 44, 1729-1738.	1.2	103
1353	Proteasome inhibitor bortezomi-induced the apoptosis of laryngeal squamous cell carcinoma Hep-2 cell line via disrupting redox equilibrium. Biomedicine and Pharmacotherapy, 2012, 66, 607-611.	2.5	5
1354	Risk factors for multiple myeloma: A hospital-based caseâ€“control study in Northwest China. Cancer Epidemiology, 2012, 36, 439-444.	0.8	32
1355	Chemotherapeutic Agents Increase the Risk for Pulmonary Function Test Abnormalities in Patients With Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 325-329.	0.2	8
1356	Phase I Trial of Vorinostat Combined With Bortezomib for the Treatment of Relapsing and/or Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 319-324.	0.2	45
1357	Bortezomib for myeloma: optimizing treatment strategies. Community Oncology, 2012, 9, 272-273.	0.2	2
1358	Rad knockdown induces mitochondrial apoptosis in bortezomib resistant leukemia and lymphoma cells. Leukemia Research, 2012, 36, 1172-1178.	0.4	14
1359	CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma. Leukemia Research, 2012, 36, 1422-1427.	0.4	24
1360	Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy. Leukemia, 2012, 26, 839-841.	3.3	10
1361	Inhibition of the purified 20S proteasome by non-heme iron complexes. Metallomics, 2012, 4, 174-178.	1.0	3
1362	Proteasome Inhibitors. Progress in Molecular Biology and Translational Science, 2012, 109, 161-226.	0.9	28

#	Article	IF	Citations
1363	Failure of Amino Acid Homeostasis Causes Cell Death following Proteasome Inhibition. Molecular Cell, 2012, 48, 242-253.	4.5	264
1364	Bortezomib regulates the chemotactic characteristics of T cells through downregulation of CXCR3/CXCL9 expression and induction of apoptosis. International Journal of Hematology, 2012, 96, 764-772.	0.7	21
1365	Analysing Properties of Proteasome Inhibitors Using Kinetic and X-Ray Crystallographic Studies. Methods in Molecular Biology, 2012, 832, 373-390.	0.4	18
1366	Myeloma and Leukemia. , 2012, , 509-529.		1
1368	Proteasome inhibitors in multiple myeloma: 10 years later. Blood, 2012, 120, 947-959.	0.6	438
1369	Gallium-containing anticancer compounds. Future Medicinal Chemistry, 2012, 4, 1257-1272.	1.1	146
1370	Role of carfilzomib in the treatment of multiple myeloma. Expert Review of Hematology, 2012, 5, 361-372.	1.0	16
1371	MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy. Expert Opinion on Investigational Drugs, 2012, 21, 1563-1573.	1.9	154
1372	Achieving an Early Myeloma Response in Patients With Kidney Impairment. Advances in Chronic Kidney Disease, 2012, 19, 303-311.	0.6	4
1373	Long-Term Bortezomib Treatment Reduces Allergen-Specific IgE but Fails to Ameliorate Chronic Asthma in Mice. International Archives of Allergy and Immunology, 2012, 158, 43-53.	0.9	17
1375	Rescue of Murine F508del CFTR Activity in Native Intestine by Low Temperature and Proteasome Inhibitors. PLoS ONE, 2012, 7, e52070.	1.1	22
1376	Pathogenic Role of the CRL4 Ubiquitin Ligase in Human Disease. Frontiers in Oncology, 2012, 2, 21.	1.3	57
1377	Proteasome Targeted Therapies in Rheumatoid Arthritis. , 0, , .		0
1378	Proteasome Inhibitors in the Treatment of Multiple Myeloma. , 0, , .		1
1379	Hepatitis B Reactivation in a Multiple Myeloma Patient with Resolved Hepatitis B Infection during Bortezomib Therapy : Case Report. Journal of Clinical and Experimental Hematopathology: JCEH, 2012, 52, 67-69.	0.3	26
1380	Successful treatment of multicentric Castleman's disease accompanying myeloma with bortezomib. BMJ Case Reports, 2012, 2012, bcr2012007646-bcr2012007646.	0.2	11
1381	8.5 Pharmacological targeting of proteoglycans and metalloproteinases: an emerging aspect in cancer treatment. , 2012, , 785-801.		1
1382	Epidemiology, Biology, and Outcome in Multiple Myeloma Patients in different Geographical Areas of the World. Orthodontic Journal of Nepal, 2012, 1, 20-32.	0.0	4

#	Article	IF	Citations
1383	A Case of Drug-Induced Hepatitis due to Bortezomib in Multiple Myeloma. Immune Network, 2012, 12, 126.	1.6	9
1384	New applications of old metal-binding drugs in the treatment of human cancer. Frontiers in Bioscience - Scholar, 2012, S4, 375.	0.8	16
1385	A randomized phase 2 trial of a preparative regimen of bortezomib, highâ€dose melphalan, arsenic trioxide, and ascorbic acid. Cancer, 2012, 118, 2507-2515.	2.0	39
1386	Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer, 2012, 118, 3549-3555.	2.0	69
1387	In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donors. Investigational New Drugs, 2012, 30, 1396-1403.	1.2	3
1388	Therapeutic Potential of the Proteasome Inhibitor Bortezomib on Titanium Particle-Induced Inflammation in a Murine Model. Inflammation, 2012, 35, 905-912.	1.7	14
1389	Protection Against Titanium Particle-Induced Inflammatory Osteolysis by the Proteasome Inhibitor Bortezomib In Vivo. Inflammation, 2012, 35, 1378-1391.	1.7	9
1390	Inhibition of Titanium Particle-Induced Inflammation by the Proteasome Inhibitor Bortezomib in Murine Macrophage-Like RAW 264.7 Cells. Inflammation, 2012, 35, 1411-1418.	1.7	22
1391	Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma. International Journal of Hematology, 2012, 95, 516-526.	0.7	15
1392	The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma. Annals of Hematology, 2012, 91, 847-856.	0.8	29
1394	Critically ill cancer patients in the intensive care unit: shortâ€term outcome and 1â€year mortality. Acta Anaesthesiologica Scandinavica, 2012, 56, 178-189.	0.7	27
1395	Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells. International Journal of Urology, 2012, 19, 565-574.	0.5	11
1396	CD48 as a novel molecular target for antibody therapy in multiple myeloma. British Journal of Haematology, 2012, 156, 213-224.	1.2	35
1397	Proteasome Inhibitors: An Expanding Army Attacking a Unique Target. Chemistry and Biology, 2012, 19, 99-115.	6.2	464
1398	The 26S proteasome complex: An attractive target for cancer therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1825, 64-76.	3.3	127
1399	Vincristine and bortezomib cause axon outgrowth and behavioral defects in larval zebrafish. Journal of the Peripheral Nervous System, 2012, 17, 76-89.	1.4	13
1400	The potential benefits of participating in earlyâ€phase clinical trials in multiple myeloma: longâ€term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. European Journal of Haematology, 2012, 88, 446-449.	1.1	10
1401	Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. European Journal of Haematology, 2012, 88, 485-496.	1.1	42

#	Article	IF	Citations
1402	CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells. Oral Oncology, 2012, 48, 585-593.	0.8	54
1403	In vivo imaging of proteasome inhibition using a proteasomeâ€sensitive fluorescent reporter. Cancer Science, 2012, 103, 1730-1736.	1.7	15
1404	Bortezomib salvage followed by a <scp>P</scp>hase <scp>I</scp>/<scp>II</scp> study of bortezomib plus highâ€dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. British Journal of Haematology, 2012, 157, 553-563.	1.2	21
1405	Outcome disparities in multiple myeloma: a <scp>SEER</scp>â€based comparative analysis of ethnic subgroups. British Journal of Haematology, 2012, 158, 91-98.	1.2	97
1406	Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells. British Journal of Haematology, 2012, 158, 336-346.	1.2	100
1407	Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically. BJU International, 2012, 109, 1258-1268.	1.3	23
1408	Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients. International Journal of Hematology, 2012, 95, 64-70.	0.7	44
1409	Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial. Annals of Hematology, 2012, 91, 249-256.	0.8	15
1410	An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Investigational New Drugs, 2012, 30, 387-394.	1.2	59
1411	A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response. Investigational New Drugs, 2012, 30, 714-722.	1.2	6
1412	Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma. Cancer, 2013, 119, 339-347.	2.0	59
1414	The Fifth Element in Drug Design: Boron in Medicinal Chemistry. Australian Journal of Chemistry, 2013, 66, 1118.	0.5	48
1415	Impact of Genetic Targets on Cancer Therapy. Advances in Experimental Medicine and Biology, 2013, 779, v-vi.	0.8	1
1416	The resistance mechanisms of proteasome inhibitor bortezomib. Biomarker Research, 2013, 1, 13.	2.8	117
1417	Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. Journal of Cancer Research and Clinical Oncology, 2013, 139, 499-508.	1.2	33
1418	Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens. International Journal of Hematology, 2013, 97, 382-387.	0.7	19
1419	Bortezomib, Dexamethasone, and High-Dose Melphalan as Conditioning for Stem Cell Transplantation in Young Japanese Multiple Myeloma Patients: A Pilot Study. Indian Journal of Hematology and Blood Transfusion, 2013, 29, 147-151.	0.3	3
1420	Bortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy for relapsed or refractory multiple myeloma: a multicenter phase 2 study. International Journal of Hematology, 2013, 98, 179-185.	0.7	8

#	Article	IF	Citations
1421	Drug-induced neuropathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 115, 729-742.	1.0	23
1422	Subcutaneous Bortezomib. Drugs, 2013, 73, 45-54.	4.9	15
1423	Erectile Dysfunction Associated With Bortezomib Treatment in a Patient With Multiple Myeloma and Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 331-332.	0.2	2
1424	Evolving Strategies in the Initial Treatment of Multiple Myeloma. Seminars in Oncology, 2013, 40, 592-601.	0.8	5
1425	Clinical Translation in Multiple Myeloma: From Bench to Bedside. Seminars in Oncology, 2013, 40, 549-553.	0.8	9
1426	Treatment tradeâ€offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies. Cancer, 2013, 119, 4308-4315.	2.0	12
1427	Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma. Journal of Clinical Oncology, 2013, 31, 247-255.	0.8	69
1428	Increasing Intracellular Bioavailable Copper Selectively Targets Prostate Cancer Cells. ACS Chemical Biology, 2013, 8, 1621-1631.	1.6	115
1429	New insights into the molecular mechanisms underlying sensitivity/resistance to the atypical retinoid ST1926 in acute myeloid leukaemia cells: The role of histone H2A.Z, cAMP-dependent protein kinase A and the proteasome. European Journal of Cancer, 2013, 49, 1491-1500.	1.3	14
1430	A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia. Leukemia Research, 2013, 37, 1502-1508.	0.4	18
1431	Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials. Journal of Clinical Oncology, 2013, 31, 3279-3287.	0.8	238
1432	Proteasome inhibitors act as bifunctional antagonists of human immunodeficiency virus type 1 latency and replication. Retrovirology, 2013, 10, 120.	0.9	26
1434	Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2013, 14, 1055-1066.	5.1	710
1435	Molecular mechanisms of effectiveness of novel therapies in multiple myeloma. Leukemia and Lymphoma, 2013, 54, 229-241.	0.6	17
1436	Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma. Leukemia and Lymphoma, 2013, 54, 1465-1472.	0.6	13
1437	Carfilzomib. Blood, 2013, 121, 893-897.	0.6	179
1438	Complications and Special Presentations of Plasma Cell Myeloma. , 2013, , 665-680.		1
1439	Diagnosis and Treatment of Multiple Myeloma. , 2013, , 637-663.		2

#	Article	IF	Citations
1440	Quantitative proteomic analysis to decipher the differential apoptotic response of bortezomibâ€treated APL cells before and after retinoic acid differentiation reveals involvement of protein toxicity mechanisms. Proteomics, 2013, 13, 37-47.	1.3	7
1441	Novel Agents for Multiple Myeloma to Overcome Resistance in Phase III Clinical Trials. Seminars in Oncology, 2013, 40, 634-651.	0.8	38
1442	Targeting the ubiquitin proteasome system in haematological malignancies. Blood Reviews, 2013, 27, 297-304.	2.8	61
1443	The Future of Drug Development and Therapy in Myeloma. Seminars in Oncology, 2013, 40, 652-658.	0.8	6
1444	Novel Generation of Agents With Proven Clinical Activity in Multiple Myeloma. Seminars in Oncology, 2013, 40, 618-633.	0.8	24
1445	New Developments in Post-transplant Maintenance Treatment of Multiple Myeloma. Seminars in Oncology, 2013, 40, 602-609.	0.8	8
1446	Bortezomib Subcutaneous Injection in Combination Regimens for Myeloma or Systemic Light-Chain Amyloidosis: A Retrospective Chart Review of Response Rates and Toxicity in Newly Diagnosed Patients. Clinical Therapeutics, 2013, 35, 1614-1620.	1.1	18
1447	Bortezomib influences the expression of malignant plasma cells membrane antigens. European Journal of Pharmacology, 2013, 706, 11-16.	1.7	12
1448	Acute pancreatitis caused by bortezomib. Pancreatology, 2013, 13, 189-190.	0.5	12
1449	Gain(1)(q21) is an Unfavorable Genetic Prognostic Factor for Patients With Relapsed Multiple Myeloma Treated With Thalidomide but Not for Those Treated With Bortezomib. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 123-130.	0.2	20
1450	Phase <scp>I</scp>/<scp>II</scp> trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. British Journal of Haematology, 2013, 160, 321-330.	1.2	48
1451	Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Journal of Hematology and Oncology, 2013, 6, 2.	6.9	42
1452	Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest. Cell Cycle, 2013, 12, 923-934.	1.3	48
1453	Molecular/Targeted Therapy of Cancer. , 2013, , 215-244.		0
1454	Computationally Designed Peptide Inhibitors of the Ubiquitin E3 Ligase SCF^{Fbx4}. ChemBioChem, 2013, 14, 445-451.	1.3	7
1455	History of Multiple Myeloma. , 2013, , 521-533.		0
1456	Bortezomib Plus Dexamethasone Followed by Escalating Donor Lymphocyte Infusions for Patients with Multiple Myeloma Relapsing or Progressing after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 424-428.	2.0	24
1457	Targeted Therapy of Multiple Myeloma. Advances in Experimental Medicine and Biology, 2013, 779, 197-221.	0.8	20

#	Article	IF	Citations
1458	Development of cellular signaling pathway inhibitors as new antivirals against influenza. Antiviral Research, 2013, 98, 457-468.	1.9	94
1459	Diagnostic-Therapeutic Combinations. , 2013, , 798-819.		0
1460	Proteasome Inhibition as a Novel Strategy for Cancer Treatment. , 2013, , 303-329.		2
1461	The role of the ubiquitin proteasome system in lymphoma. Critical Reviews in Oncology/Hematology, 2013, 87, 306-322.	2.0	16
1462	Proteasome inhibitors in the treatment of multiple myeloma. Expert Review of Anticancer Therapy, 2013, 13, 339-358.	1.1	42
1463	Evolving therapeutic paradigms for multiple myeloma: back to the future. Leukemia and Lymphoma, 2013, 54, 451-463.	0.6	15
1464	Novel Proteasome Inhibitors. , 2013, , 157-180.		0
1466	Boronic Acid-Containing Proteasome Inhibitors: Alert to Potential Pharmaceutical Bioactivation. Chemical Research in Toxicology, 2013, 26, 608-615.	1.7	13
1467	Mechanisms of G1 cell cycle arrest and apoptosis in myeloma cells induced by hybrid-compound histone deacetylase inhibitor. Biochemical and Biophysical Research Communications, 2013, 434, 413-420.	1.0	15
1468	Combination chemotherapy of serine protease inhibitor nafamostat mesilate with oxaliplatin targeting NF-Î°B activation for pancreatic cancer. Cancer Letters, 2013, 333, 89-95.	3.2	26
1470	A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. British Journal of Haematology, 2013, 160, 649-659.	1.2	111
1471	Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1937-1946.	1.2	35
1473	Gene Expression of Catalytic Proteasome Subunits and Resistance Toward Proteasome Inhibition of B Lymphocytes from Patients with Primary SjÃ¶gren Syndrome. Journal of Rheumatology, 2013, 40, 663-673.	1.0	10
1474	Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. Genetics in Medicine, 2013, 15, 123-131.	1.1	75
1475	Therapeutic Enhancement of ER Stress by Insulin-Like Growth Factor I Sensitizes Myeloma Cells to Proteasomal Inhibitors. Clinical Cancer Research, 2013, 19, 3556-3566.	3.2	14
1476	Combination treatment with 2-methoxyestradiol overcomes bortezomib resistance of multiple myeloma cells. Experimental and Molecular Medicine, 2013, 45, e50-e50.	3.2	16
1477	Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica, 2013, 98, 1753-1761.	1.7	300
1478	Incidence of skeletal morbidity rates over time in patients with multiple myeloma-related bone disease as reported in randomized trials employing bone-modifying agents. Journal of Comparative Effectiveness Research, 2013, 2, 69-76.	0.6	1

#	Article	IF	Citations
1479	Pegylated Liposomal Doxorubicin in Salvage Chemotherapy for Multiple Myeloma Patients. Current Cancer Therapy Reviews, 2013, 9, 1-7.	0.2	0
1480	From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma. Therapeutic Advances in Hematology, 2013, 4, 354-365.	1.1	24
1481	Decursin and Doxorubicin Are in Synergy for the Induction of Apoptosis via STAT3 and/or mTOR Pathways in Human Multiple Myeloma Cells. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-13.	0.5	25
1482	Cowden Syndrome-Related Mutations in PTEN Associate with Enhanced Proteasome Activity. Cancer Research, 2013, 73, 3029-3040.	0.4	21
1484	Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. Haematologica, 2013, 98, 1264-1272.	1.7	35
1485	Phase II Study of Gemcitabine in Combination With Regional Arterial Infusion of Nafamostat Mesilate for Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 44-48.	0.6	30
1486	Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model. Molecular Cancer Therapeutics, 2013, 12, 1140-1150.	1.9	68
1487	Bortezomib for the treatment of previously untreated multiple myeloma. Immunotherapy, 2013, 5, 327-352.	1.0	22
1488	Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma. Annals of Oncology, 2013, 24, 1038-1044.	0.6	10
1489	Phase <scp>II</scp> clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (<scp>RIC</scp>) and postâ€allogeneic transplantation for highâ€risk myeloma patients. British Journal of Haematology, 2013, 162, 474-482.	1.2	36
1490	Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells. International Journal of Cancer, 2013, 133, 1357-1367.	2.3	67
1491	Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma. European Journal of Haematology, 2013, 90, 420-425.	1.1	11
1492	Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer. Pharmacological Reviews, 2013, 65, 1351-1395.	7.1	33
1493	Second autologous transplant as salvage therapy in multiple myeloma. British Journal of Haematology, 2013, 163, 565-572.	1.2	37
1494	Baicalin and Scutellarin Are Proteasome Inhibitors that Specifically Target Chymotrypsinâ€like Catalytic Activity. Phytotherapy Research, 2013, 27, 1362-1367.	2.8	18
1495	Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood, 2013, 121, 1961-1967.	0.6	152
1496	Fas apoptosis inhibitory molecule is upregulated by IGF-1 signaling and modulates Akt activation and IRF4 expression in multiple myeloma. Leukemia, 2013, 27, 1165-1171.	3.3	27
1497	Phytohemagglutinin-induced IL2 mRNA in whole blood can predict bortezomib-induced peripheral neuropathy for multiple myeloma patients. Blood Cancer Journal, 2013, 3, e150-e150.	2.8	5

#	Article	IF	Citations
1498	A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo. Blood Cancer Journal, 2013, 3, e141-e141.	2.8	25
1499	Phosphorylation of signal transducer and activator of transcription 1 reduces bortezomib-mediated apoptosis in cancer cells. Cell Death and Disease, 2013, 4, e512-e512.	2.7	19
1500	Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. Blood Cancer Journal, 2013, 3, e162-e162.	2.8	56
1501	Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia, 2013, 27, 1959-1969.	3.3	90
1502	Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. Leukemia, 2013, 27, 2075-2077.	3.3	45
1503	Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics. Blood Cancer Journal, 2013, 3, e121-e121.	2.8	57
1504	High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood, 2013, 121, 624-627.	0.6	114
1505	Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood, 2013, 121, 4647-4654.	0.6	128
1506	PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood, 2013, 122, 2331-2337.	0.6	281
1507	Intracellular NAD+ depletion enhances bortezomib-induced anti-myeloma activity. Blood, 2013, 122, 1243-1255.	0.6	74
1508	Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells. International Journal of Oncology, 2013, 42, 1541-1550.	1.4	87
1509	Treatment of relapsed/refractory myeloma. , 0, , 144-166.		0
1510	Treatment of emergent peripheral neuropathy in plasma cell disorders. , 0, , 245-254.		0
1511	Multiple Myeloma, Version 1.2013. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 11-17.	2.3	63
1513	Induction of apoptosis and antitumor effects of a small molecule inhibitor of Bcl-2 and Bcl-xl, gossypol acetate, in multiple myeloma in vitro and in vivo. Oncology Reports, 2013, 30, 731-738.	1.2	24
1514	Proteasome Inhibition Profoundly Affects Activated Human B Cells. Transplantation, 2013, 95, 1331-1337.	0.5	38
1516	Autologous hematopoietic stem cell transplantation and maintenance therapy for multiple myeloma. International Journal of Hematologic Oncology, 2013, 2, 71-83.	0.7	3
1517	Iron increases the susceptibility of multiple myeloma cells to bortezomib. Haematologica, 2013, 98, 971-979.	1.7	40

#	Article	IF	Citations
1518	NS-398 enhances the efficacy of bortezomib against RPMI8226 human multiple myeloma cells. Molecular Medicine Reports, 2013, 7, 1641-1645.	1.1	7
1519	Part I: The Role of Maintenance Therapy in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 35-42.	2.3	14
1520	Novel Targeted Therapies and Combinations for the Treatment of Multiple Myeloma. Cardiovascular & Hematological Disorders Drug Targets, 2013, 13, 2-15.	0.2	9
1521	The protective effects of lafutidine for bortezomib induced peripheral neuropathy. Journal of Blood Medicine, 2013, 4, 81.	0.7	14
1522	Review Bortezomib-induced painful neuropathy in patients with multiple myeloma. Wspolczesna Onkologia, 2013, 5, 421-426.	0.7	12
1523	Cytogenetics and Chromosomal Abnormalities in Multiple Myeloma-A Review. Cloning & Transgenesis, 2013, 02, .	0.1	1
1524	Down-Regulation of 11Î²-Hydroxysteroid Dehydrogenase Type 2 by Bortezomib Sensitizes Jurkat Leukemia T Cells against Glucocorticoid-Induced Apoptosis. PLoS ONE, 2013, 8, e67067.	1.1	6
1525	cMyc/miR-125b-5p Signalling Determines Sensitivity to Bortezomib in Preclinical Model of Cutaneous T-Cell Lymphomas. PLoS ONE, 2013, 8, e59390.	1.1	46
1526	From Bortezomib to other Inhibitors of the Proteasome and Beyond. Current Pharmaceutical Design, 2013, 19, 4025-4038.	0.9	128
1527	Multiple Myeloma: An Update. Oman Medical Journal, 2013, 28, 3-11.	0.3	33
1528	Endoplasmic Reticulum Stress and Cancer. Journal of Cancer Prevention, 2014, 19, 75-88.	0.8	291
1529	Inhibition of Human and Yeast 20S Proteasome by Analogues of Trypsin Inhibitor SFTI-1. PLoS ONE, 2014, 9, e89465.	1.1	14
1530	Reversal of Bortezomib Resistance in Myelodysplastic Syndrome Cells by MAPK Inhibitors. PLoS ONE, 2014, 9, e90992.	1.1	4
1531	An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma. OncoTargets and Therapy, 2014, 7, 1793.	1.0	43
1532	Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Management and Research, 2014, 6, 135.	0.9	222
1533	Efficacy of Subcutaneous Bortezomib in the Management of Patients with Multiple Myeloma or Relapsed Mantle Cell Lymphoma. Clinical Medicine Insights Therapeutics, 2014, 6, CMT.S9308.	0.4	1
1534	Establishment and characterization of bortezomib-resistant U266 cell line: Constitutive activation of NF-Î²B-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis. BMB Reports, 2014, 47, 274-279.	1.1	20
1536	Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials. Future Oncology, 2014, 10, 1795-1807.	1.1	101

#	Article	IF	Citations
1537	Bortezomib for the treatment of multiple myeloma. Expert Review of Hematology, 2014, 7, 173-185.	1.0	17
1538	The role of ubiquitin-binding domains in human pathophysiology. Critical Reviews in Clinical Laboratory Sciences, 2014, 51, 280-290.	2.7	6
1539	Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors. Cancer Biology and Therapy, 2014, 15, 1142-1152.	1.5	20
1540	Elotuzumab for the treatment of multiple myeloma. Future Oncology, 2014, 10, 949-956.	1.1	9
1542	Bortezomib for the treatment of non-Hodgkinâ€™s lymphoma. Expert Opinion on Pharmacotherapy, 2014, 15, 2443-2459.	0.9	32
1543	Improved Response Rates with Bortezomib in Relapsed or Refractory Multiple Myeloma: An Observational Study in Chinese Patients. Advances in Therapy, 2014, 31, 1082-1094.	1.3	10
1544	Acetyl-l-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. Cancer Chemotherapy and Pharmacology, 2014, 74, 875-882.	1.1	31
1545	Association of response endpoints with survival outcomes in multiple myeloma. Leukemia, 2014, 28, 258-268.	3.3	128
1546	Proteasome inhibitors in progressive renal diseases. Nephrology Dialysis Transplantation, 2014, 29, i25-i30.	0.4	24
1547	Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood, 2014, 124, 1038-1046.	0.6	192
1548	p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma. BioMed Research International, 2014, 2014, 1-9.	0.9	32
1549	Authorising bortezomib treatment prior to reviewing haematology results: a step toward home administration. Journal of Oncology Pharmacy Practice, 2014, 20, 351-355.	0.5	2
1550	A practical approach to relapsed multiple myeloma. Hematology American Society of Hematology Education Program, 2014, 2014, 262-267.	0.9	7
1551	The Positive Effects of One-Hour Intravenous Administration of Bortezomib on Peripheral Neuropathy in Multiple Myeloma Patients. BioMed Research International, 2014, 2014, 1-6.	0.9	3
1552	Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options. Turkish Journal of Haematology, 2014, 31, 374-380.	0.2	3
1553	Immunosuppression in Transplantation. , 2014, , 741-751.		0
1554	Recent improvement in survival of patients with multiple myeloma: variation by ethnicity. Leukemia and Lymphoma, 2014, 55, 1083-1089.	0.6	82
1555	Proteasome Inhibitor Bortezomib Enhances the Activity of Multiple Mutant Forms of Lysosomal Î±-Glucosidase in Pompe Disease. JIMD Reports, 2014, 18, 33-39.	0.7	24

#	Article	IF	Citations
1556	Future agents and treatment directions in multiple myeloma. Expert Review of Hematology, 2014, 7, 127-141.	1.0	30
1557	European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica, 2014, 99, 232-242.	1.7	185
1558	Bortezomibâ€Induced Sweet's Syndrome Confirmed by Rechallenge. Pharmacotherapy, 2014, 34, e18-21.	1.2	17
1559	In Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells. Molecular Cancer Therapeutics, 2014, 13, 2886-2897.	1.9	37
1560	Bortezomib-induced acute pancreatitis in a patient with multiple myeloma. Leukemia and Lymphoma, 2014, 55, 1404-1405.	0.6	9
1561	Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients. European Journal of Haematology, 2014, 93, 207-213.	1.1	12
1562	Profiling human protein degradome delineates cellular responses to proteasomal inhibition and reveals a feedback mechanism in regulating proteasome homeostasis. Cell Research, 2014, 24, 1214-1230.	5.7	13
1563	Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. British Journal of Haematology, 2014, 166, 401-409.	1.2	35
1564	A multicenter, openâ€label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma. American Journal of Hematology, 2014, 89, 1037-1042.	2.0	36
1566	Real-life patterns of use and effectiveness of bortezomib: the VESUVE cohort study. Leukemia and Lymphoma, 2014, 55, 848-854.	0.6	9
1567	Choosing treatment options for patients with relapsed/refractory multiple myeloma. Expert Review of Anticancer Therapy, 2014, 14, 199-215.	1.1	5
1568	Overcoming Bortezomib Resistance: A Review of the Second-Generation Proteasome Inhibitor Carfilzomib in the Treatment of Multiple Myeloma. Resistance To Targeted Anti-cancer Therapeutics, 2014, , 81-98.	0.1	0
1569	The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma. Leukemia and Lymphoma, 2014, 55, 1707-1714.	0.6	26
1570	Proteotoxic Stress and Proteasome Inhibitor Efficacy and Resistance. Resistance To Targeted Anti-cancer Therapeutics, 2014, , 275-289.	0.1	0
1571	Phase I Trial of Bortezomib (PS-341; NSC 681239) and â€œNonhybridâ€•(Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms. Clinical Cancer Research, 2014, 20, 5652-5662.	3.2	26
1572	Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model. Experimental Neurology, 2014, 253, 165-173.	2.0	39
1573	Dispelling the myths around cancer care delivery: It's not all about costs. Journal of Cancer Policy, 2014, 2, 22-29.	0.6	25
1574	Activity of 129 Single-Agent Drugs in 228 Phase I and II Clinical Trials in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 284-290.e5.	0.2	15

#	Article	IF	Citations
1575	Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes. Annals of Hematology, 2014, 93, 123-128.	0.8	15
1576	Bortezomib-induced apoptosis in cultured pancreatic cancer cells is associated with ceramide production. Cancer Chemotherapy and Pharmacology, 2014, 73, 69-77.	1.1	45
1577	The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy. Biomaterials, 2014, 35, 316-326.	5.7	96
1578	Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach. Investigational New Drugs, 2014, 32, 542-548.	1.2	12
1579	A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood, 2014, 123, 1461-1469.	0.6	174
1580	PML tumour suppression and beyond: Therapeutic implications. FEBS Letters, 2014, 588, 2653-2662.	1.3	18
1582	Stability of the proteasome inhibitor bortezomib in cell based assays determined by ultra-high performance liquid chromatography coupled to tandem mass spectrometry. Journal of Chromatography A, 2014, 1345, 128-138.	1.8	9
1583	Small Molecules in Oncology. Recent Results in Cancer Research, 2014, , .	1.8	4
1584	Systematic Comparison of Peptidic Proteasome Inhibitors Highlights the Î±â€Ketoamide Electrophile as an Auspicious Reversible Lead Motif. Angewandte Chemie - International Edition, 2014, 53, 1679-1683.	7.2	74
1585	The combination of proteasome inhibitors bortezomib and gambogic acid triggers synergistic cytotoxicity in vitro but not in vivo. Toxicology Letters, 2014, 224, 333-340.	0.4	22
1586	Bortezomib-Cyclophosphamide-Dexamethasone (VCD)versusBortezomib-Thalidomide-Dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis. British Journal of Haematology, 2014, 166, 702-710.	1.2	45
1587	Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia, 2014, 28, 1122-1128.	3.3	1,128
1588	Endoplasmic reticulum stress associated responses in cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 2143-2149.	1.9	163
1590	New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia, 2014, 28, 525-542.	3.3	214
1591	Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma. Expert Opinion on Investigational Drugs, 2014, 23, 1193-1209.	1.9	6
1592	Ubiquitination in disease pathogenesis and treatment. Nature Medicine, 2014, 20, 1242-1253.	15.2	845
1593	Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients. Cancer Chemotherapy and Pharmacology, 2014, 74, 653-657.	1.1	12
1594	High throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells. British Journal of Haematology, 2014, 166, 711-719.	1.2	10

#	Article	IF	Citations
1595	Identification of an inhibitor of the ubiquitinâ€“proteasome system that induces accumulation of polyubiquitinated proteins in the absence of blocking of proteasome function. MedChemComm, 2014, 5, 376-385.	3.5	4
1596	Proteasome inhibitors â€“ molecular basis and current perspectives in multiple myeloma. Journal of Cellular and Molecular Medicine, 2014, 18, 947-961.	1.6	144
1597	Advances in multiple myeloma therapy during two past decades. Computational and Structural Biotechnology Journal, 2014, 10, 38-40.	1.9	17
1598	1â€Acetylâ€3,5â€diarylâ€4,5â€dihydro(1H)pyrazoles: Exhibiting Anticancer Activity through Intracellular ROS Scavenging and the Mitochondriaâ€Dependent Death Pathway. Archiv Der Pharmazie, 2014, 347, 717-727.	2.1	19
1599	Bortezomib induces thrombocytopenia by the inhibition of proplatelet formation of megakaryocytes. European Journal of Haematology, 2014, 93, 290-296.	1.1	22
1600	Panobinostat for the treatment of multiple myeloma. Lancet Oncology, The, 2014, 15, 1178-1179.	5.1	18
1602	Î±â€Keto Phenylamides as P1â€²â€Extended Proteasome Inhibitors. ChemMedChem, 2014, 9, 2557-2564.	1.6	12
1603	Regulation of PSMB5 Protein and Î² Subunits of Mammalian Proteasome by Constitutively Activated Signal Transducer and Activator of Transcription 3 (STAT3). Journal of Biological Chemistry, 2014, 289, 12612-12622.	1.6	59
1604	High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 15, 874-885.	5.1	139
1605	Bortezomibâ€and thalidomideâ€induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. American Journal of Hematology, 2014, 89, 1085-1091.	2.0	45
1606	Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival. BMC Cancer, 2014, 14, 462.	1.1	30
1607	Bortezomib treatment causes long-term testicular dysfunction in young male mice. Molecular Cancer, 2014, 13, 155.	7.9	19
1608	Boronic Acids as Probes for Investigation of Allosteric Modulation of the Chemokine Receptor CXCR3. ACS Chemical Biology, 2014, 9, 2664-2677.	1.6	23
1609	Bortezomib-induced peripheral neurotoxicity: an update. Archives of Toxicology, 2014, 88, 1669-1679.	1.9	73
1610	Maintenance Therapy for Multiple Myeloma. Hematology/Oncology Clinics of North America, 2014, 28, 839-859.	0.9	14
1611	Bortezomib-induced acute congestive heart failure: a case report and review of literature. Annals of Hematology, 2014, 93, 1797-1799.	0.8	16
1612	Impact of dose modification on intravenous Bortezomib-induced peripheral neuropathy in multiple myeloma patients. Supportive Care in Cancer, 2014, 22, 2669-2675.	1.0	9
1613	Ultra high performance liquid chromatography coupled with high resolution quantitation mass spectrometry method development and validation for determining genotoxic 2,5-dichlorobenzoyl chloride in MLN9708 drug substance. Journal of Pharmaceutical and Biomedical Analysis, 2014, 89, 233-239.	1.4	12

#	Article	IF	Citations
1614	Proapoptotic effects of the novel proteasome inhibitor b-AP15 on multiple myeloma cells and natural killer cells. Experimental Hematology, 2014, 42, 172-182.	0.2	21
1615	A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2014, 61, 1754-1760.	0.8	44
1617	An analysis of the safety profile of proteasome inhibitors for treating various cancers. Expert Opinion on Drug Safety, 2014, 13, 1043-1054.	1.0	17
1618	Modified Bortezomib, Adriamycin and Dexamethasone (PAD) Regimen in Advanced Multiple Myeloma. Pathology and Oncology Research, 2014, 20, 987-995.	0.9	4
1619	Chalazia Associated with Bortezomib Therapy for Multiple Myeloma. Ophthalmology, 2014, 121, 1845-1847.e3.	2.5	19
1620	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncology, The, 2014, 15, 1195-1206.	5.1	695
1621	Bortezomib protects from varicoseâ€like venous remodeling. FASEB Journal, 2014, 28, 3518-3527.	0.2	16
1622	An overview of the progress in the treatment of multiple myeloma. Expert Review of Hematology, 2014, 7, 5-7.	1.0	29
1623	Bortezomib inhibits C2C12 growth by inducing cell cycle arrest and apoptosis. Biochemical and Biophysical Research Communications, 2014, 445, 375-380.	1.0	9
1624	Linking the activity of bortezomib in multiple myeloma and autoimmune diseases. Critical Reviews in Oncology/Hematology, 2014, 92, 61-70.	2.0	20
1625	New orally active proteasome inhibitors in multiple myeloma. Leukemia Research, 2014, 38, 1-9.	0.4	66
1626	Development of inhibitors in the ubiquitination cascade. FEBS Letters, 2014, 588, 356-367.	1.3	67
1627	Dwu-, trzy- i czterolekowe schematy w leczeniu pierwszoliniowym szpiczaka plazmocytowego z uwzglÄ™dnieniem efektÃ³w terapii z zastosowaniem bortezomibu. Acta Haematologica Polonica, 2014, 45, 26-34.	0.1	0
1628	Inhibitory effects of bortezomib on platelet aggregation in patients with multiple myeloma. Thrombosis Research, 2014, 134, 404-411.	0.8	9
1629	Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3614-3617.	1.0	17
1630	Applied techniques for mining natural proteasome inhibitors. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 26-38.	1.9	19
1631	Emerging therapies targeting the ubiquitin proteasome system in cancer. Journal of Clinical Investigation, 2014, 124, 6-12.	3.9	110
1632	Advances in Supportive Care for Multiple Myeloma. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 502-511.	2.3	17

#	Article	IF	Citations
1633	Health-based pharmaceutical pay-for-performance risk-sharing agreements. Journal of the Operational Research Society, 2014, 65, 588-604.	2.1	9
1634	IKKÎ² inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells. International Journal of Oncology, 2014, 44, 1171-1176.	1.4	14
1635	Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood, 2014, 123, 632-639.	0.6	98
1636	CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma. Blood, 2014, 123, 3770-3779.	0.6	79
1637	Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood, 2014, 123, 1826-1832.	0.6	327
1638	Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood, 2014, 124, 1047-1055.	0.6	185
1639	A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood, 2014, 124, 899-906.	0.6	73
1640	Curing myeloma at last: defining criteria and providing the evidence. Blood, 2014, 124, 3043-3051.	0.6	194
1641	Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. Haematologica, 2014, 99, 1114-1122.	1.7	42
1642	The evolving field of post-transplant therapy in multiple myeloma. Clinical Investigation, 2014, 4, 825-838.	0.0	0
1643	Antitumor effects of tyropeptinâ€boronic acid derivatives: New proteasome inhibitors. Cancer Science, 2014, 105, 1609-1615.	1.7	13
1644	shRNA-mediated Bmi-1 silencing sensitizes multiple myeloma cells to bortezomib. International Journal of Molecular Medicine, 2014, 34, 616-623.	1.8	11
1646	Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica, 2014, 99, 360-364.	1.7	133
1648	Proteasome inhibitors and knockdown of SMG1 cause accumulation of Upf1 and Upf2 in human cells. International Journal of Oncology, 2014, 44, 222-228.	1.4	5
1649	Targeting the integrated networks of aggresome formation, proteasome, and autophagy potentiates ER stress-mediated cell death in multiple myeloma cells. International Journal of Oncology, 2015, 46, 474-486.	1.4	39
1650	Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma. Medicine (United States), 2015, 94, e2305.	0.4	43
1651	Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. European Journal of Haematology, 2015, 95, 316-324.	1.1	33
1652	Effects of Hydroxy Groups in the A-Ring on the Anti-proteasome Activity of Flavone. Biological and Pharmaceutical Bulletin, 2015, 38, 935-940.	0.6	6

#	Article	IF	Citations
1653	Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. Haematologica, 2015, 100, 100-106.	1.7	33
1654	How I treat relapsed myeloma. Blood, 2015, 125, 1532-1540.	0.6	31
1655	Treatment options for relapsed and refractory multiple myeloma. Blood, 2015, 125, 3085-3099.	0.6	136
1656	Guidelines for determination of the number of prior lines of therapy in multiple myeloma. Blood, 2015, 126, 921-922.	0.6	71
1657	Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition. Scientific Reports, 2015, 5, 9694.	1.6	21
1658	Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century. British Journal of Haematology, 2015, 171, 189-196.	1.2	80
1659	Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD^{Â®}immunomodulatory drug pomalidomide. British Journal of Haematology, 2015, 171, 798-812.	1.2	41
1660	Reduced expression of <scp>TRIM</scp>21/Ro52 predicts poor prognosis in diffuse large Bâ€cell lymphoma patients with and without rheumatic disease. Journal of Internal Medicine, 2015, 278, 323-332.	2.7	43
1661	NFÎºB signaling drives pro-granulocytic astroglial responses to neuromyelitis optica patient IgG. Journal of Neuroinflammation, 2015, 12, 185.	3.1	27
1662	Salvage therapy with bortezomib and dexamethasone in elderly patients with relapsed/refractory multiple myeloma. Anti-Cancer Drugs, 2015, 26, 1078-1082.	0.7	8
1663	Development of Acute Pulmonary Hypertension After Bortezomib Treatment in a Patient With Multiple Myeloma. American Journal of Therapeutics, 2015, 22, e88-e92.	0.5	12
1664	The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies. OncoTargets and Therapy, 2015, 8, 761.	1.0	16
1665	Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes. Therapeutics and Clinical Risk Management, 2015, 11, 1663.	0.9	1
1666	Induction Therapy with Bortezomib, Thalidomide and Dexamethasone (VTD) in Caucasian Patients with Multiple Myeloma: A Single Center Experience. Journal of Blood Disorders & Transfusion, 2015, 06, .	0.1	0
1667	Chalazia Development in Multiple Myeloma: A New Complication Associated with Bortezomib Therapy. Hematology Reports, 2015, 7, 5729.	0.3	11
1668	An Overview of Bortezomib-Induced Neurotoxicity. Toxics, 2015, 3, 294-303.	1.6	40
1669	Proteasom inhibitors in multiple myeloma: an update. Hematologie, 2015, 21, 326-332.	0.0	0
1670	Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling. BioMed Research International, 2015, 2015, 1-13.	0.9	87

#	Article	IF	Citations
1671	Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients. BioMed Research International, 2015, 2015, 1-6.	0.9	13
1672	The role and mechanism of CRL4 E3 ubiquitin ligase in cancer and its potential therapy implications. Oncotarget, 2015, 6, 42590-42602.	0.8	37
1673	Bortezomib inhibits the survival and proliferation of bone marrow stromal cells. Blood Research, 2015, 50, 87.	0.5	5
1674	When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response. Molecular Cancer Research, 2015, 13, 1163-1173.	1.5	43
1675	Curcumin as a protector for normal cells during bortezomib therapy. Human and Experimental Toxicology, 2015, 34, 780-783.	1.1	2
1676	The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma. Journal of Hematology and Oncology, 2015, 8, 37.	6.9	10
1677	Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens. Journal of Clinical Oncology, 2015, 33, 3921-3929.	0.8	131
1678	Therapeutic Landscape of Carfilzomib and Other Modulators of the Ubiquitin-Proteasome Pathway. Journal of Clinical Oncology, 2015, 33, 782-785.	0.8	15
1679	Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma. Pharmaceuticals, 2015, 8, 1-20.	1.7	76
1680	Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment. BMC Cancer, 2015, 15, 444.	1.1	26
1681	Thrombotic microangiopathy associated with proteasome inhibitors. CKJ: Clinical Kidney Journal, 2015, 8, 632-636.	1.4	52
1682	Targeting ubiquitination for cancer therapies. Future Medicinal Chemistry, 2015, 7, 2333-2350.	1.1	85
1683	Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. JAMA Oncology, 2015, 1, 746.	3.4	266
1684	Treatment of relapsed multiple myeloma. , 2015, , 65-77.		0
1685	Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment. Leukemia Research, 2015, 39, 786-792.	0.4	17
1686	USP14 activation promotes tumor progression in hepatocellular carcinoma. Oncology Reports, 2015, 34, 2917-2924.	1.2	43
1687	Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug Resistance Updates, 2015, 18, 18-35.	6.5	153
1688	The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit. American Journal of Hematology, 2015, 90, E86-91.	2.0	7

#	Article	IF	Citations
1689	Novel agents have a significant impact on survival of patients with multiple myeloma. Wiener Klinische Wochenschrift, 2015, 127, 92-97.	1.0	3
1690	The ubiquitinâ€“proteasome system: opportunities for therapeutic intervention in solid tumors. Endocrine-Related Cancer, 2015, 22, T1-T17.	1.6	81
1691	Proteasome Inhibitors with Pyrazole Scaffolds from Structure-Based Virtual Screening. Journal of Medicinal Chemistry, 2015, 58, 2036-2041.	2.9	45
1692	Clinical Grade â€œSNaPshotâ€•Genetic Mutation Profiling in Multiple Myeloma. EBioMedicine, 2015, 2, 71-73.	2.7	12
1693	Targeting the hallmarks of cancer with therapy-induced endoplasmic reticulum (ER) stress. Molecular and Cellular Oncology, 2015, 2, e975089.	0.3	58
1694	Delivery of bortezomib with nanoparticles for basal-like triple-negative breast cancer therapy. Journal of Controlled Release, 2015, 208, 14-24.	4.8	67
1695	Trial Watch: Proteasomal inhibitors for anticancer therapy. Molecular and Cellular Oncology, 2015, 2, e974463.	0.3	18
1696	NF-Î²B in cancer therapy. Archives of Toxicology, 2015, 89, 711-731.	1.9	169
1697	Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters. Cancer Chemotherapy and Pharmacology, 2015, 75, 281-291.	1.1	22
1698	Promising therapies in multiple myeloma. Blood, 2015, 126, 300-310.	0.6	86
1699	An in vitro and in vivo investigation of the cytotoxic effects of caffeic acid (3,4-dihydroxycinnamic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2015, 45, 38-46.	0.4	7
1700	Immune tolerance strategies in siblings with infantile Pompe disease â€" Advantages for a preemptive approach to high-sustained antibody titers. Molecular Genetics and Metabolism Reports, 2015, 4, 30-34.	0.4	24
1701	Switching from body surface areaâ€based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis. British Journal of Clinical Pharmacology, 2015, 79, 789-800.	1.1	50
1702	Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management. Circulation, 2015, 131, 1608-1639.	1.6	268
1703	Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma. Clinical Cancer Research, 2015, 21, 4663-4675.	3.2	80
1704	Inhibition of the Immunoproteasome Subunit LMP7 with ONXÂ0914 Ameliorates Graft-versus-Host Disease in an MHC-MatchedÂMinor Histocompatibility Antigenâ€“Disparate Murine Model. Biology of Blood and Marrow Transplantation, 2015, 21, 1555-1564.	2.0	15
1706	Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study. Haematologica, 2015, 100, 541-547.	1.7	34
1707	NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma. Clinical Cancer Research, 2015, 21, 5532-5542.	3.2	31

#	Article	IF	Citations
1708	Ixazomib for the treatment of multiple myeloma. Expert Opinion on Investigational Drugs, 2015, 24, 1287-1298.	1.9	42
1709	An inhibitor of ubiquitin conjugation and aggresome formation. Chemical Science, 2015, 6, 5235-5245.	3.7	37
1710	Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs. Expert Opinion on Biological Therapy, 2015, 15, 857-872.	1.4	18
1711	Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib. Supportive Care in Cancer, 2015, 23, 2813-2824.	1.0	21
1712	Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of Susceptibility to Bortezomib-Induced Severe Neurological Adverse Events in Patients with Multiple Myeloma. Acta Haematologica, 2015, 134, 25-31.	0.7	1
1713	Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance. Advances in Cancer Research, 2015, 127, 191-226.	1.9	13
1714	<scp>TM</scp>â€233, a novel analog of 1â€²â€acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both <scp>JAK</scp>/<scp>STAT</scp> and proteasome activities. Cancer Science, 2015, 106, 438-446.	1.7	12
1715	Proteasome inhibitors. Biochemical Pharmacology, 2015, 96, 1-9.	2.0	144
1716	Potent antiâ€tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma. Molecular Oncology, 2015, 9, 1348-1358.	2.1	27
1717	The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. Future Oncology, 2015, 11, 1153-1168.	1.1	25
1718	The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma. Journal of Biological Chemistry, 2015, 290, 29854-29868.	1.6	64
1719	BCL-2 is dispensable for thrombopoiesis and platelet survival. Cell Death and Disease, 2015, 6, e1721-e1721.	2.7	68
1720	CCR 20th Anniversary Commentary: In the Beginning, There Was PS-341. Clinical Cancer Research, 2015, 21, 939-941.	3.2	23
1721	Logic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells. Journal of Pharmacology and Experimental Therapeutics, 2015, 354, 448-458.	1.3	25
1722	Functional Roles of the E3 Ubiquitin Ligase UBR5 in Cancer. Molecular Cancer Research, 2015, 13, 1523-1532.	1.5	102
1723	A Single Î± Helix Drives Extensive Remodeling of the Proteasome Lid and Completion of Regulatory Particle Assembly. Cell, 2015, 163, 432-444.	13.5	73
1724	Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Leukemia and Lymphoma, 2015, 56, 3320-3328.	0.6	67
1725	Integrative network modeling approaches to personalized cancer medicine. Personalized Medicine, 2015, 12, 245-257.	0.8	12

#	Article	IF	Citations
1726	A new staging system to predict prognosis of patients with multiple myeloma in an era of novel therapeutic agents. European Journal of Haematology, 2015, 94, 145-151.	1.1	13
1727	Role of the ubiquitin proteasome system in hematologic malignancies. Immunological Reviews, 2015, 263, 224-239.	2.8	30
1728	Therapyâ€related peripheral neuropathy in multiple myeloma patients. Hematological Oncology, 2015, 33, 113-119.	0.8	63
1729	Current treatment landscape for relapsed and/or refractory multiple myeloma. Nature Reviews Clinical Oncology, 2015, 12, 42-54.	12.5	175
1730	Respiratory Muscle Plasticity. , 2015, 2, 1441-1462.		26
1731	Mechanisms of resistance to apoptosis in the human acute promyelocytic leukemia cell line NB4. Annals of Hematology, 2015, 94, 379-392.	0.8	7
1732	A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line. Journal of Proteomics, 2015, 113, 315-325.	1.2	21
1733	A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases. Scientific Reports, 2014, 4, 5240.	1.6	60
1734	Efficacy and Safety of Bortezomib in Multiple Myeloma Patients with Hepatitis B. Chinese Medical Journal, 2016, 129, 274-278.	0.9	2
1735	Heme oxygenase-1 nuclear translocation regulates bortezomib-induced cytotoxicity and mediates genomic instability in myeloma cells. Oncotarget, 2016, 7, 28868-28880.	0.8	53
1736	Skin lesions caused by bortezomib targeted therapy of multiple myeloma. Przeglad Dermatologiczny, 2016, 6, 498-499.	0.0	1
1737	Maintenance Therapy in Multiple Myeloma: Novel Concepts in Clinical Practice from Recent Clinical Trials. Reviews on Recent Clinical Trials, 2016, 11, 124-127.	0.4	0
1738	Bryostatin I inhibits growth and proliferation of pancreatic cancer cells via suppression of NF-ÎºB activation. Tropical Journal of Pharmaceutical Research, 2016, 15, 2071.	0.2	1
1739	Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma. Oncotarget, 2016, 7, 30876-30891.	0.8	89
1740	Assessment and monitoring of patients receiving chemotherapy for multiple myeloma: strategies to improve outcomes. Blood and Lymphatic Cancer: Targets and Therapy, 2016, 6, 21.	1.2	2
1741	Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date. OncoTargets and Therapy, 2016, Volume 9, 6037-6048.	1.0	15
1742	Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?. OncoTargets and Therapy, 2016, Volume 9, 4843-4858.	1.0	4
1743	Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma. Case Reports in Hematology, 2016, 2016, 1-5.	0.3	11

#	Article	IF	Citations
1744	Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity. Case Reports in Cardiology, 2016, 2016, 1-5.	0.1	22
1745	Redox Homeostasis and Cellular Antioxidant Systems: Crucial Players in Cancer Growth and Therapy. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-16.	1.9	225
1746	Managing treatment-related peripheral neuropathy in patients with multiple myeloma. Blood and Lymphatic Cancer: Targets and Therapy, 2016, Volume 6, 37-47.	1.2	30
1747	Cost-effectiveness of bortezomib for multiple myeloma: a systematic review. ClinicoEconomics and Outcomes Research, 2016, 8, 137.	0.7	11
1748	Management of Multiple Myeloma and Usage of Bortezomib: Perspective from India and Ukraine. Frontiers in Oncology, 2016, 6, 243.	1.3	3
1749	Identification of Long Nonâ€Coding RNAs Deregulated in Multiple Myeloma Cells Resistant to Proteasome Inhibitors. Genes, 2016, 7, 84.	1.0	15
1750	Elotuzumab for the treatment of multiple myeloma. Journal of Hematology and Oncology, 2016, 9, 55.	6.9	36
1751	The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD). Oncotarget, 2016, 7, 9666-9679.	0.8	33
1752	Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy. Biochemical Pharmacology, 2016, 116, 22-38.	2.0	33
1753	Proteasome inhibitor associated thrombotic microangiopathy. American Journal of Hematology, 2016, 91, E348-52.	2.0	95
1754	Plasma cell maturity as a predictor of prognosis in multiple myeloma. Medical Oncology, 2016, 33, 87.	1.2	13
1755	Combination treatment with proteasome inhibitors and antiestrogens has a synergistic effect mediated by p21WAF1 in estrogen receptor-positive breast cancer. Oncology Reports, 2016, 36, 1127-1134.	1.2	9
1756	RSK1 protects P-glycoprotein/ABCB1 against ubiquitinâ€“proteasomal degradation by downregulating the ubiquitin-conjugating enzyme E2 R1. Scientific Reports, 2016, 6, 36134.	1.6	26
1757	A role for plasma cell targeting agents in immune tolerance induction in autoimmune disease and antibody responses to therapeutic proteins. Clinical Immunology, 2016, 165, 55-59.	1.4	18
1758	Targeting the 19S proteasomal subunit, Rpt4, for the treatment of colon cancer. European Journal of Pharmacology, 2016, 780, 53-64.	1.7	12
1759	Touch and go: nuclear proteolysis in the regulation of metabolic genes and cancer. FEBS Letters, 2016, 590, 908-923.	1.3	18
1760	Inhibition of chymotryptic-like standard proteasome activity exacerbates doxorubicin-induced cytotoxicity in primary cardiomyocytes. Toxicology, 2016, 353-354, 34-47.	2.0	24
1761	Treatment of relapsed and refractory multiple myeloma. Haematologica, 2016, 101, 396-406.	1.7	132

#	Article	IF	Citations
1762	A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors. Investigational New Drugs, 2016, 34, 216-224.	1.2	42
1763	Syrbactin Structural Analog TIR-199 Blocks Proteasome Activity and Induces Tumor Cell Death. Journal of Biological Chemistry, 2016, 291, 8350-8362.	1.6	14
1764	Bortezomib attenuates palmitic acid-induced ER stress, inflammation and insulin resistance in myotubes via AMPK dependent mechanism. Cellular Signalling, 2016, 28, 788-797.	1.7	30
1765	Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura. British Journal of Haematology, 2016, 173, 779-785.	1.2	69
1766	Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma. Haematologica, 2016, 101, e149-e152.	1.7	6
1767	3D-QSAR-aided design, synthesis, in vitro and in vivo evaluation of dipeptidyl boronic acid proteasome inhibitors and mechanism studies. Bioorganic and Medicinal Chemistry, 2016, 24, 2576-2588.	1.4	13
1768	Bortezomib-based chemotherapy to treat refractory angioimmunoblastic T-cell lymphoma: A case report and review of the literature. Oncology Letters, 2016, 11, 2310-2314.	0.8	5
1769	Pragmatic randomized clinical trials: a proposal to enhance evaluation of new cancer therapies with early signs of exceptional activity. Annals of Oncology, 2016, 27, 1342-1348.	0.6	12
1770	Strategies to optimize respiratory muscle function in ICU patients. Critical Care, 2016, 20, 103.	2.5	33
1771	Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma. Leukemia, 2016, 30, 1877-1886.	3.3	68
1772	Tight Junction Protein 1: New Insights into Proteasome Inhibitor Resistance and Myeloma Pathophysiology. Cancer Cell, 2016, 29, 611-612.	7.7	1
1773	QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30. Quality of Life Research, 2016, 25, 625-636.	1.5	83
1774	Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. Blood, 2016, 127, 2693-2700.	0.6	66
1775	Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood, 2016, 128, 37-44.	0.6	347
1776	Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood, 2016, 127, 713-721.	0.6	121
1777	Bone Disease in Multiple Myeloma. Cancer Treatment and Research, 2016, 169, 251-270.	0.2	23
1778	Plasma Cell Dyscrasias. Cancer Treatment and Research, 2016, , .	0.2	3
1779	Treatment of Relapsed/Refractory Multiple Myeloma. Cancer Treatment and Research, 2016, 169, 169-194.	0.2	6

#	Article	IF	Citations
1780	Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. Cancer Treatment and Research, 2016, 169, 145-167.	0.2	7
1781	New investigational drugs with single-agent activity in multiple myeloma. Blood Cancer Journal, 2016, 6, e451-e451.	2.8	62
1782	The influence of baseline characteristics and disease stage on healthâ€related quality of life in multiple myeloma: findings from six randomized controlled trials. British Journal of Haematology, 2016, 174, 368-381.	1.2	32
1783	Synergistic inhibition of PARPâ€1 and NFâ€ÎºB signaling downregulates immune response against recombinant AAV2 vectors during hepatic gene therapy. European Journal of Immunology, 2016, 46, 154-166.	1.6	7
1784	The Effect of a Highâ€Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma. Journal of Clinical Pharmacology, 2016, 56, 1288-1295.	1.0	34
1785	Phase I/II study of weekly PM00104 (Zalypsis^{Â®}) in patients with relapsed/refractory multiple myeloma. British Journal of Haematology, 2016, 172, 625-628.	1.2	8
1786	Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients. British Journal of Haematology, 2016, 174, 711-720.	1.2	44
1787	Multiple myeloma in the marrow: pathogenesis and treatments. Annals of the New York Academy of Sciences, 2016, 1364, 32-51.	1.8	132
1788	Effect of the specific proteasome inhibitor bortezomib on cancerâ€related muscle wasting. Journal of Cachexia, Sarcopenia and Muscle, 2016, 7, 345-354.	2.9	58
1789	Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality?. Journal of Clinical Pharmacy and Therapeutics, 2016, 41, 189-197.	0.7	22
1790	The proteasome â€" victim or culprit in autoimmunity. Clinical Immunology, 2016, 172, 83-89.	1.4	12
1791	NF-ÎºB dysregulation in multiple myeloma. Seminars in Cancer Biology, 2016, 39, 68-76.	4.3	43
1792	Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity. Journal of Cancer Research and Clinical Oncology, 2016, 142, 2141-2158.	1.2	17
1793	Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 2016, 375, 754-766.	13.9	1,246
1794	Integrative Genomic Analysis Identifies the Core Transcriptional Hallmarks of Human Hepatocellular Carcinoma. Cancer Research, 2016, 76, 6374-6381.	0.4	48
1795	The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders. Expert Review of Hematology, 2016, 9, 873-889.	1.0	21
1796	Safety of proteasome inhibitors for treatment of multiple myeloma. Expert Opinion on Drug Safety, 2017, 16, 1-17.	1.0	40
1797	Cancer Drug Discovery. , 2016, , .		6

#	Article	IF	Citations
1798	Progress and Paradigms in Multiple Myeloma. Clinical Cancer Research, 2016, 22, 5419-5427.	3.2	142
1799	Schizophrenia-Associated hERG channel Kv11.1-3.1 Exhibits a Unique Trafficking Deficit that is Rescued Through Proteasome Inhibition for High Throughput Screening. Scientific Reports, 2016, 6, 19976.	1.6	16
1800	Stabilizing mutations of KLHL24 ubiquitin ligase cause loss of keratin 14 and human skin fragility. Nature Genetics, 2016, 48, 1508-1516.	9.4	101
1801	Carfilzomib for treating myeloma. Expert Opinion on Orphan Drugs, 2016, 4, 989-999.	0.5	2
1802	Advances toward the Synthesis of Functionalized Î³-Lactams. Organic Preparations and Procedures International, 2016, 48, 254-295.	0.6	50
1803	Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 387-394.	0.2	11
1804	Mechanisms of action and resistance for multiple myeloma novel drug treatments. International Journal of Hematology, 2016, 104, 271-272.	0.7	10
1805	Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma. Cancer Research, 2016, 76, 3340-3350.	0.4	90
1806	Impact of access to <scp>NCI</scp>â€•and <scp>NCCN</scp>â€designated cancer centers on outcomes for multiple myeloma patients: A <scp>SEER</scp> registry analysis. Cancer, 2016, 122, 618-625.	2.0	21
1807	Bortezomib for the treatment of multiple myeloma. The Cochrane Library, 2016, 2016, CD010816.	1.5	80
1808	A phase 1, openâ€label, doseâ€escalation study of pralatrexate inÂcombination with bortezomib in patients with relapsed/refractory multiple myeloma. British Journal of Haematology, 2016, 173, 253-259.	1.2	3
1809	Neurological Complications of Systemic Cancer and Antineoplastic Therapy. , 0, , .		3
1810	Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 431-441.	2.2	54
1811	Transdermal drug targeting and functional imaging of tumor blood vessels in the mouse auricle. FASEB Journal, 2016, 30, 923-932.	0.2	3
1812	Oral ixazomib maintenance therapy in multiple myeloma. Expert Review of Anticancer Therapy, 2016, 16, 21-32.	1.1	6
1813	A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma. International Journal of Hematology, 2016, 103, 25-33.	0.7	14
1814	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncology, The, 2016, 17, 27-38.	5.1	723
1815	Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution. Clinical Cancer Research, 2016, 22, 4206-4214.	3.2	28

#	Article	IF	Citations
1816	Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?. Immunotherapy, 2016, 8, 367-384.	1.0	6
1817	Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy. Supportive Care in Cancer, 2016, 24, 3105-10.	1.0	21
1818	Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from Î±Î±- and Î±Î²-amino acids. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1958-1962.	1.0	9
1819	Systemic amyloidosis. Lancet, The, 2016, 387, 2641-2654.	6.3	703
1820	Multiple Myeloma: Diagnosis and Treatment. Mayo Clinic Proceedings, 2016, 91, 101-119.	1.4	473
1821	Daratumumab in multiple myeloma. Lancet, The, 2016, 387, 1490-1492.	6.3	12
1822	Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia, 2016, 30, 1005-1017.	3.3	204
1823	Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF. Leukemia and Lymphoma, 2016, 57, 1389-1397.	0.6	6
1824	Changes in survival rate of multiple myeloma after the introduction of bortezomib: a single institutional experience over 20Âyears. Annals of Hematology, 2016, 95, 63-72.	0.8	11
1825	The therapeutic potential of microbial proteasome inhibitors. International Immunopharmacology, 2016, 37, 23-30.	1.7	10
1826	Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma. Expert Review of Hematology, 2016, 9, 91-105.	1.0	7
1827	ESRD due to Multiple Myeloma in the United States, 2001â€“2010. Journal of the American Society of Nephrology: JASN, 2016, 27, 1487-1494.	3.0	31
1828	Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in Older Adults. Clinics in Geriatric Medicine, 2016, 32, 191-205.	1.0	4
1829	Small molecule therapeutics targeting F-box proteins in cancer. Seminars in Cancer Biology, 2016, 36, 105-119.	4.3	22
1830	A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research, 2016, 22, 1067-1075.	3.2	35
1831	Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicity. Leukemia and Lymphoma, 2016, 57, 1122-1129.	0.6	8
1832	Clinical significance of cancerous inhibitor of protein phosphatase 2A in human cancers. International Journal of Cancer, 2016, 138, 525-532.	2.3	53
1833	Proteasome inhibitors in cancer therapy. Nature Reviews Clinical Oncology, 2017, 14, 417-433.	12.5	675

#	Article	IF	Citations
1834	Antiproliferative effects of Bortezomib in endothelial cells transformed by viral G protein-coupled receptor associated to Kaposi's sarcoma. Cellular Signalling, 2017, 32, 124-132.	1.7	10
1835	Bortezomib interferes with adhesion of B cell precursor acute lymphoblastic leukemia cells through SPARC up-regulation in human bone marrow mesenchymal stromal/stem cells. International Journal of Hematology, 2017, 105, 587-597.	0.7	10
1836	USP7 inhibitor P5091 inhibits Wnt signaling and colorectal tumor growth. Biochemical Pharmacology, 2017, 131, 29-39.	2.0	92
1837	The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis. Lupus, 2017, 26, 952-958.	0.8	31
1838	In situ generated Dâ€peptidic nanofibrils as multifaceted apoptotic inducers to target cancer cells. Cell Death and Disease, 2017, 8, e2614-e2614.	2.7	40
1839	Tyropeptins, proteasome inhibitors produced by Kitasatospora sp. MK993-dF2. Journal of Antibiotics, 2017, 70, 542-550.	1.0	8
1840	Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells. Clinical Cancer Research, 2017, 23, 4280-4289.	3.2	71
1841	How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?. Critical Reviews in Oncology/Hematology, 2017, 112, 153-170.	2.0	37
1842	New monoclonal antibodies on the horizon in multiple myeloma. Therapeutic Advances in Hematology, 2017, 8, 41-53.	1.1	15
1843	Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma. Journal of Bone and Mineral Research, 2017, 32, 1261-1266.	3.1	9
1844	Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis. Acta Haematologica, 2017, 137, 163-172.	0.7	10
1845	The safety of daratumumab for the treatment of multiple myeloma. Expert Opinion on Drug Safety, 2017, 16, 753-760.	1.0	6
1846	New Agents in Multiple Myeloma: AnÂExamination of Safety Profiles. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 391-407.e5.	0.2	41
1847	Chemotherapy-induced peripheral neuropathy. Biomedical Reports, 2017, 6, 267-271.	0.9	16
1848	A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. British Journal of Haematology, 2017, 178, 547-560.	1.2	48
1849	Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy. Anti-Cancer Drugs, 2017, 28, 660-668.	0.7	11
1850	Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment. Supportive Care in Cancer, 2017, 25, 3217-3224.	1.0	2
1851	Raman spectroscopy differentiates between sensitive and resistant multiple myeloma cell lines. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2017, 187, 15-22.	2.0	24

#	Article	IF	Citations
1852	Proteasome inhibitor-induced gastrointestinal toxicity. Current Opinion in Supportive and Palliative Care, 2017, 11, 133-137.	0.5	16
1853	Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 424-432.	0.2	14
1854	Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib. Oncology Letters, 2017, 13, 3803-3808.	0.8	8
1855	Myeloma; living better and living longer - a look at the advances. Expert Review of Quality of Life in Cancer Care, 2017, 2, 153-166.	0.6	0
1856	CUL4A overexpression as an independent adverse prognosticator in intrahepatic cholangiocarcinoma. BMC Cancer, 2017, 17, 395.	1.1	9
1858	Generation and Validation of Intracellular Ubiquitin Variant Inhibitors for USP7 and USP10. Journal of Molecular Biology, 2017, 429, 3546-3560.	2.0	44
1859	Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions. British Journal of Haematology, 2017, 179, 198-218.	1.2	47
1860	Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma. Expert Opinion on Pharmacotherapy, 2017, 18, 1061-1079.	0.9	5
1861	A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2017, 145, 236-242.	0.6	17
1862	Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and/or dexamethasone (Dex). Leukemia Research, 2017, 57, 45-54.	0.4	9
1863	Prospects of combining adoptive cell immunotherapy with bortezomib. Immunotherapy, 2017, 9, 305-308.	1.0	3
1864	The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma. Expert Opinion on Drug Discovery, 2017, 12, 225-235.	2.5	26
1865	Bortezomib Relieves Immune Tolerance in Nasopharyngeal Carcinoma via STAT1 Suppression and Indoleamine 2,3-Dioxygenase Downregulation. Cancer Immunology Research, 2017, 5, 42-51.	1.6	24
1866	Gliomaâ€derived cancer stem cells are hypersensitive to proteasomal inhibition. EMBO Reports, 2017, 18, 150-168.	2.0	29
1867	Proteasome inhibitors in cancer therapy: Treatment regimen and peripheral neuropathy as a side effect. Free Radical Biology and Medicine, 2017, 103, 1-13.	1.3	62
1868	The Proteasome Inhibitor Bortezomib Inhibits Inflammatory Response of Periodontal Ligament Cells and Ameliorates Experimental Periodontitis in Rats. Journal of Periodontology, 2017, 88, 473-483.	1.7	13
1869	Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors. Cancer and Metastasis Reviews, 2017, 36, 585-598.	2.7	11
1870	Lead discovery and chemical biology approaches targeting the ubiquitin proteasome system. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4589-4596.	1.0	8

#	Article	IF	Citations
1871	Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study. Annals of Hematology, 2017, 96, 1857-1866.	0.8	17
1872	The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma. Molecular Cancer Therapeutics, 2017, 16, 2375-2386.	1.9	90
1873	Proteasome inhibitor-induced cleavage of HSP90 is mediated by ROS generation and caspase 10-activation in human leukemic cells. Redox Biology, 2017, 13, 470-476.	3.9	29
1874	The essential role of TAp73 in bortezomib-induced apoptosis in p53-deficient colorectal cancer cells. Scientific Reports, 2017, 7, 5423.	1.6	28
1875	Disulfiram and disulfiram-loaded poly-[lactide-co-glycolic acid] nanoparticles modulate metastatic markers and proteasomal activity in hepatocarcinoma Hep3b cell line. European Journal of Nanomedicine, 2017, 9, .	0.6	1
1876	Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry. Clinics in Laboratory Medicine, 2017, 37, 821-853.	0.7	20
1877	The proteasome and proteasome inhibitors in multiple myeloma. Cancer and Metastasis Reviews, 2017, 36, 561-584.	2.7	229
1878	An overview of the role of carfilzomib in the treatment of multiple myeloma. Expert Opinion on Pharmacotherapy, 2017, 18, 1883-1897.	0.9	23
1879	Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation. Cell Death and Disease, 2017, 8, e2913-e2913.	2.7	20
1880	The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma. Therapeutic Advances in Hematology, 2017, 8, 209-220.	1.1	24
1881	Nuclear ubiquitin C-terminal hydrolase L5 expression associates with increased patient survival in pancreatic ductal adenocarcinoma. Tumor Biology, 2017, 39, 101042831771041.	0.8	12
1882	Strategies for Selecting the Optimal Treatment in Newly Diagnosed Multiple Myeloma Patients. Seminars in Oncology Nursing, 2017, 33, 254-264.	0.7	3
1883	Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma. Seminars in Oncology Nursing, 2017, 33, 279-291.	0.7	9
1884	Safety of ixazomib for the treatment of multiple myeloma. Expert Opinion on Drug Safety, 2017, 16, 973-980.	1.0	16
1886	Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma. Leukemia, 2017, 31, 645-653.	3.3	47
1887	Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance. Leukemia and Lymphoma, 2017, 58, 428-437.	0.6	18
1888	The therapeutic effect of modified Huangqi Guizhi Wuwu Tang for multiple myeloma. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10	0.4	6
1889	Proteasome inhibitors: structure and function. Seminars in Oncology, 2017, 44, 377-380.	0.8	93

#	Article	IF	Citations
1890	6 Quantitative VerÃnderungen der Zellen des peripheren Blutes. , 2017, , 331-401.		0
1891	Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. Blood Advances, 2017, 1, 1911-1918.	2.5	37
1892	Second Generation Proteasome Inhibitors in Multiple Myeloma. Anti-Cancer Agents in Medicinal Chemistry, 2017, 17, 920-926.	0.9	11
1893	The Small Molecules Targeting Ubiquitin-Proteasome System for Cancer Therapy. Combinatorial Chemistry and High Throughput Screening, 2017, 20, 403-413.	0.6	29
1894	Management of multiple myeloma in the relapsed/refractory patient. Hematology American Society of Hematology Education Program, 2017, 2017, 508-517.	0.9	65
1895	Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review. Frontiers in Pharmacology, 2017, 8, 86.	1.6	219
1896	Pharmaceutical Chaperones and Proteostasis Regulators in the Therapy of Lysosomal Storage Disorders: Current Perspective and Future Promises. Frontiers in Pharmacology, 2017, 8, 448.	1.6	51
1897	Velcade, a Biotech Success Story. , 2017, , 27-32.		0
1898	Bortezomib, carfilzomib and ixazomib do not mediate relevant transporter-based drug-drug interactions. Oncology Letters, 2017, 14, 3185-3192.	0.8	6
1899	Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics. Pharmaceuticals, 2017, 10, 40.	1.7	33
1900	Update on the optimal use of bortezomib in the treatment of multiple myeloma. Cancer Management and Research, 2017, Volume 9, 51-63.	0.9	48
1901	Induction regimens for transplant-eligible patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials. Cancer Management and Research, 2017, Volume 9, 287-298.	0.9	16
1902	The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma. Cancers, 2017, 9, 29.	1.7	31
1903	Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis. PLoS ONE, 2017, 12, e0172996.	1.1	20
1904	Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells. BMC Research Notes, 2017, 10, 544.	0.6	16
1905	Protein deubiquitinase USP7 is required for osteogenic differentiation of human adipose-derived stem cells. Stem Cell Research and Therapy, 2017, 8, 186.	2.4	31
1906	Multiple Myeloma Presenting with Autoimmune Autonomic Ganglionopathy. Internal Medicine, 2017, 56, 3347-3351.	0.3	6
1907	Clarifying the molecular mechanism associated with carfilzomib resistance in human multiple myeloma using microarray gene expression profile and genetic interaction network. OncoTargets and Therapy, 2017, Volume 10, 1327-1334.	1.0	13

#	Article	IF	Citations
1908	Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma. Blood and Lymphatic Cancer: Targets and Therapy, 2017, Volume 7, 53-60.	1.2	1
1909	Should minimal residual disease negativity be the end point of myeloma therapy?. Blood Advances, 2017, 1, 517-521.	2.5	10
1910	Identification and Structure-Guided Development of Pyrimidinone Based USP7 Inhibitors. ACS Medicinal Chemistry Letters, 2018, 9, 238-243.	1.3	47
1911	Proteomic profiling of VCP substrates links VCP to K6â€linked ubiquitylation and câ€Myc function. EMBO Reports, 2018, 19, .	2.0	82
1912	Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management, and Prevention. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 19.	0.4	22
1913	Proteasome inhibitors for the treatment of multiple myeloma. Expert Opinion on Pharmacotherapy, 2018, 19, 375-386.	0.9	30
1914	The combination of ionizing radiation and proteasomal inhibition by bortezomib enhances the expression of NKG2D ligands in multiple myeloma cells. Journal of Radiation Research, 2018, 59, 245-252.	0.8	15
1915	Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease. Seminars in Hematology, 2018, 55, 33-37.	1.8	22
1917	Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma. Cancer Science, 2018, 109, 1552-1561.	1.7	10
1918	Pain Syndromes and Management in Adult Hematopoietic Stem Cell Transplantation. Hematology/Oncology Clinics of North America, 2018, 32, 551-567.	0.9	15
1919	Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 422-430.	0.2	8
1920	Mechanisms of the CDK4/6 inhibitor palbociclib (PD 0332991) and its future application in cancer treatment (Review). Oncology Reports, 2018, 39, 901-911.	1.2	60
1921	How the evolution of multicellularity set the stage for cancer. British Journal of Cancer, 2018, 118, 145-152.	2.9	89
1922	Therapeutic plasma exchange for thrombotic thrombocytopenic purpura with refractory thrombocytopenia. Journal of Clinical Apheresis, 2018, 33, 436-438.	0.7	3
1923	CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens. Annals of Hematology, 2018, 97, 485-495.	0.8	14
1924	Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma. Quality of Life Research, 2018, 27, 979-985.	1.5	5
1925	A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment. Nature Medicine, 2018, 24, 186-193.	15.2	258
1926	Proteases and Cancer. Methods in Molecular Biology, 2018, , .	0.4	1

#	Article	IF	Citations
1927	Targeting Deubiquitinases in Cancer. Methods in Molecular Biology, 2018, 1731, 295-305.	0.4	9
1928	The immunoproteasomeâ€specific inhibitor ONX 0914 reverses susceptibility to acute viral myocarditis. EMBO Molecular Medicine, 2018, 10, 200-218.	3.3	48
1930	Next-generation proteasome inhibitors for cancer therapy. Translational Research, 2018, 198, 1-16.	2.2	99
1931	Bortezomib for Reduction of Proteinuria inÂIgA Nephropathy. Kidney International Reports, 2018, 3, 861-866.	0.4	32
1932	Injectable Coacervate Hydrogel for Delivery of Anticancer Drug-Loaded Nanoparticles in vivo. ACS Applied Materials & Interfaces, 2018, 10, 13274-13282.	4.0	63
1933	Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review. Supportive Care in Cancer, 2018, 26, 2075-2090.	1.0	21
1934	Bortezomib is safe in and stabilizes pulmonary function in patients with allo-HSCT-associated pulmonary CGVHD. Bone Marrow Transplantation, 2018, 53, 1124-1130.	1.3	5
1935	Pharmacokinetic study of bortezomib administered intravenously in Taiwanese patients with multiple myeloma. Hematological Oncology, 2018, 36, 238-244.	0.8	2
1937	Proteasome 26S subunit PSMD1 regulates breast cancer cell growth through p53 protein degradation. Journal of Biochemistry, 2018, 163, 19-29.	0.9	34
1938	Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma. , 2018, 182, 176-192.		76
1939	A Benefitâ€“Risk Analysis Approach to Capture Regulatory Decisionâ€Making: Multiple Myeloma. Clinical Pharmacology and Therapeutics, 2018, 103, 67-76.	2.3	14
1940	Chk1 inhibitor SCH 900776 enhances the antitumor activity of MLN4924 on pancreatic cancer. Cell Cycle, 2018, 17, 191-199.	1.3	10
1941	Modified HyperCVAD Versus Bortezomib-HyperCAD in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e77-e84.	0.2	9
1942	A historical perspective on milestones in multiple myeloma research. European Journal of Haematology, 2018, 100, 221-228.	1.1	12
1943	Treatment of Patients in First or Second Relapse. , 2018, , 77-102.		0
1944	Drug response prediction in high-risk multiple myeloma. Gene, 2018, 644, 80-86.	1.0	14
1945	Cardiovascular adverse events in multiple myeloma patients. Journal of Thoracic Disease, 2018, 10, S4296-S4305.	0.6	20
1946	Molecular mechanisms underlying cardiotoxicity of novel cancer therapeutics. Journal of Thoracic Disease, 2018, 10, S4335-S4343.	0.6	5

#	Article	IF	Citations
1948	Proteasomal Protein Degradation: Adaptation of Cellular Proteolysis With Impact on Virusâ€"and Cytokine-Mediated Damage of Heart Tissue During Myocarditis. Frontiers in Immunology, 2018, 9, 2620.	2.2	9
1949	A Low-Cost Flash Photographic System for Visualization of Droplets in Drop-on-Demand Inkjet. Journal of Imaging Science and Technology, 2018, 62, 060502-1-060502-9.	0.3	3
1950	Generating Intracellular Modulators of E3 Ligases and Deubiquitinases from Phage-Displayed Ubiquitin Variant Libraries. Methods in Molecular Biology, 2018, 1844, 101-119.	0.4	6
1951	Chalazia associated with bortezomib therapy. Journal Francais D'Ophtalmologie, 2018, 41, e381-e382.	0.2	5
1952	Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and Î±-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data. Integrative Cancer Therapies, 2018, 17, 1115-1124.	0.8	23
1954	The challenges of checkpoint inhibition in the treatment of multiple myeloma. Cellular Immunology, 2018, 334, 87-98.	1.4	15
1955	Triplet therapies â€" the new standard of care for multiple myeloma: how to manage common toxicities. Expert Review of Hematology, 2018, 11, 957-973.	1.0	7
1956	Sorafenib and Carfilzomib Synergistically Inhibit the Proliferation, Survival, and Metastasis of Hepatocellular Carcinoma. Molecular Cancer Therapeutics, 2018, 17, 2610-2621.	1.9	18
1957	NFAT5 Isoform C Controls Biomechanical Stress Responses of Vascular Smooth Muscle Cells. Frontiers in Physiology, 2018, 9, 1190.	1.3	9
1958	Discovery of Natural Proteasome Inhibitors as Novel Anticancer Therapeutics: Current Status and Perspectives. Current Protein and Peptide Science, 2018, 19, 358-367.	0.7	12
1959	A look at treatment strategies for relapsed multiple myeloma. Expert Review of Anticancer Therapy, 2018, 18, 735-750.	1.1	2
1960	A novel NAE/UAE dual inhibitor LP0040 blocks neddylation and ubiquitination leading to growth inhibition and apoptosis of cancer cells. European Journal of Medicinal Chemistry, 2018, 154, 294-304.	2.6	20
1961	Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016). Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 480-485.e3.	0.2	27
1962	Drug-Induced Thrombotic Microangiopathy due to Cumulative Toxicity of Ixazomib. Case Reports in Hematology, 2018, 2018, 1-5.	0.3	15
1963	Preclinical Evaluation of Combined Topoisomerase and Proteasome Inhibition Against Pediatric Malignancies. Anticancer Research, 2018, 38, 3977-3984.	0.5	3
1964	The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis. Annals of Hematology, 2018, 97, 2137-2144.	0.8	11
1965	Bortezomibâ€based therapy for relapsed/refractory multiple myeloma in realâ€world medical practice. European Journal of Haematology, 2018, 101, 556-565.	1.1	15
1966	USP7: Target Validation and Drug Discovery for Cancer Therapy. Medicinal Chemistry, 2018, 14, 3-18.	0.7	79

#	Article	IF	Citations
1967	Disease-Associated Particulates and Joint Inflammation; Mechanistic Insights and Potential Therapeutic Targets. Frontiers in Immunology, 2018, 9, 1145.	2.2	20
1968	Constitutive Activation of STAT3 in Myeloma Cells Cultured in a Three-Dimensional, Reconstructed Bone Marrow Model. Cancers, 2018, 10, 206.	1.7	16
1969	Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 8155-8160.	3.3	121
1970	Oncogenic addiction to high 26S proteasome level. Cell Death and Disease, 2018, 9, 773.	2.7	49
1971	Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies. International Journal of Molecular Sciences, 2018, 19, 2087.	1.8	14
1972	Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-Î²B signaling pathway in multiple myeloma. Journal of Leukocyte Biology, 2018, 104, 1105-1115.	1.5	21
1973	Cancer research in the United States: A critical review of current status and proposal for alternative models. Cancer, 2018, 124, 2881-2889.	2.0	14
1974	The safety of bortezomib for the treatment of multiple myeloma. Expert Opinion on Drug Safety, 2018, 17, 953-962.	1.0	64
1975	Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001â€“2010: a retrospective, population based analysis. BMC Cancer, 2018, 18, 801.	1.1	3
1976	An engineered, quantifiable in vitro model for analysing the effect of proteostasis-targeting drugs on tissue physical properties. Biomaterials, 2018, 183, 102-113.	5.7	6
1977	Clinical, electrophysiological, and cutaneous innervation changes in patients with bortezomib-induced peripheral neuropathy reveal insight into mechanisms of neuropathic pain. Molecular Pain, 2018, 14, 174480691879704.	1.0	26
1978	Proteasome inhibitors for multiple myeloma. Japanese Journal of Clinical Oncology, 2018, 48, 785-793.	0.6	37
1979	Small-Molecule Inhibitors for the Treatment of Diffuse Large B Cell Lymphoma. Current Hematologic Malignancy Reports, 2018, 13, 356-368.	1.2	14
1980	Design, synthesis, in vitro and in vivo evaluation, and structure-activity relationship (SAR) discussion of novel dipeptidyl boronic acid proteasome inhibitors as orally available anti-cancer agents for the treatment of multiple myeloma and mechanism studies. Bioorganic and Medicinal Chemistry, 2018, 26, 3975-3981.	1.4	9
1981	Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib. Clinical Pharmacokinetics, 2019, 58, 157-168.	1.6	92
1982	A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematology,the, 2019, 6, e521-e529.	2.2	211
1983	Bis-benzoxaboroles: Design, Synthesis, and Biological Evaluation as Carbonic Anhydrase Inhibitors. ACS Medicinal Chemistry Letters, 2019, 10, 1205-1210.	1.3	19
1984	A randomized phase II, open-label and multicenter study of combination regimens of bortezomib at two doses by subcutaneous injection for newly diagnosed multiple myeloma patients. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2343-2355.	1.2	4

#	Article	IF	Citations
1985	IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma. Cancer Research, 2019, 79, 4679-4688.	0.4	53
1986	Asymmetric Synthesis of Fluoroâ€MLN4924 as a Selective NEDD8â€Activating Enzyme (NAE) Inhibitor. Asian Journal of Organic Chemistry, 2019, 8, 1641-1647.	1.3	2
1987	Analysis of the efficacy and safety of bortezomib for treating newly diagnosed multiple myeloma through different administration methods . Cancer Management and Research, 2019, Volume 11, 8295-8302.	0.9	2
1988	XPO1 is a critical player for bortezomib resistance in multiple myeloma: A quantitative proteomic approach. Journal of Proteomics, 2019, 209, 103504.	1.2	44
1989	The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma. Cellular Immunology, 2019, 345, 103964.	1.4	18
1990	Peripheral neuropathy following bortezomib therapy in multiple myeloma patients: association with cumulative dose, heparanase, and TNF-Î±. Annals of Hematology, 2019, 98, 2793-2803.	0.8	11
1991	Postâ€allogeneic transplant Evans syndrome successfully treated with daratumumab. British Journal of Haematology, 2019, 187, e48-e51.	1.2	27
1992	Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: A nationwide population-based study and a single-institute analysis. PLoS ONE, 2019, 14, e0222522.	1.1	1
1993	New Drugs in Multiple Myeloma. Annual Review of Medicine, 2019, 70, 521-547.	5.0	34
1994	Bortezomib retreatment for relapsed and refractory multiple myeloma in realâ€world clinical practice. Health Science Reports, 2019, 2, e104.	0.6	16
1995	Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. Leukemia, 2019, 33, 1736-1746.	3.3	45
1996	Methodological aspects of healthâ€related quality of life measurement and analysis in patients with multiple myeloma. British Journal of Haematology, 2019, 185, 11-24.	1.2	13
1997	Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 459-473.	1.5	10
1998	Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Leukemia Research, 2019, 83, 106172.	0.4	15
1999	A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and WaldenstrÃ¶m Macroglobulinemia. Clinical Cancer Research, 2019, 25, 4907-4916.	3.2	36
2000	An optical and nonâ€invasive method to detect the accumulation of ubiquitin chains. Cell Biology International, 2019, 43, 1393-1406.	1.4	1
2001	Preparation and characterization of nanoliposomal bortezomib formulations and evaluation of their anti-cancer efficacy in mice bearing C26 colon carcinoma and B16F0 melanoma. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 20, 102013.	1.7	21
2002	Anticancer Activity and Underlying Mechanism of Phytochemicals against Multiple Myeloma. International Journal of Molecular Sciences, 2019, 20, 2302.	1.8	11

#	Article	IF	Citations
2003	Management and outcomes of proteasome inhibitor associated chalazia and blepharitis: a case series. BMC Ophthalmology, 2019, 19, 110.	0.6	24
2004	Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells. Leukemia Research, 2019, 81, 62-66.	0.4	36
2005	Cell-type-specific sensitivity of bortezomib in the methotrexate-resistant primary central nervous system lymphoma cells. International Journal of Clinical Oncology, 2019, 24, 1020-1029.	1.0	7
2006	The proteasome inhibitor, bortezomib, induces prostate cancer cell death by suppressing the expression of prostate-specific membrane antigen, as well as androgen receptor. International Journal of Oncology, 2019, 54, 1357-1366.	1.4	4
2007	The Selection of NFÎºB Inhibitors to Block Inflammation and Induce Sensitisation to FasL-Induced Apoptosis in HNSCC Cell Lines Is Critical for Their Use as a Prospective Cancer Therapy. International Journal of Molecular Sciences, 2019, 20, 1306.	1.8	12
2008	Emerging drug development technologies targeting ubiquitination for cancer therapeutics. , 2019, 199, 139-154.		52
2009	Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 397-405.	0.2	13
2010	E3 ubiquitin ligases in B-cell malignancies. Cellular Immunology, 2019, 340, 103905.	1.4	3
2011	Challenges in the treatment and prevention of delayed hemolytic transfusion reactions with hyperhemolysis in sickle cell disease patients. Transfusion, 2019, 59, 1698-1705.	0.8	19
2012	H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth. Scientific Reports, 2019, 9, 4089.	1.6	11
2013	Thrombotic Thrombocytopenic Purpura and Hemolytic-Uremic Syndromes. , 2019, , 769-794.		0
2014	Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma. Leukemia, 2019, 33, 2685-2694.	3.3	34
2015	Ultrastructural traits of apoptosis. Cell Biology International, 2019, 43, 728-738.	1.4	13
2016	TRAILblazing Strategies for Cancer Treatment. Cancers, 2019, 11, 456.	1.7	62
2017	Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma. Oncology Reviews, 2019, 13, 377.	0.8	4
2018	Clinical Trial Outcomes. JACC: Heart Failure, 2019, 7, 272-273.	1.9	6
2019	p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell, 2019, 35, 204-220.e9.	7.7	62
2020	Lactacystin: first-in-class proteasome inhibitor still excelling and an exemplar for future antibiotic research. Journal of Antibiotics, 2019, 72, 189-201.	1.0	34

#	Article	IF	Citations
2021	Sensitization in Heart Transplantation: Emerging Knowledge: A Scientific Statement From the American Heart Association. Circulation, 2019, 139, e553-e578.	1.6	89
2022	New strategies and perspectives on managing IgA nephropathy. Clinical and Experimental Nephrology, 2019, 23, 577-588.	0.7	55
2023	Proteasome inhibitor b-AP15 induces enhanced proteotoxicity by inhibiting cytoprotective aggresome formation. Cancer Letters, 2019, 448, 70-83.	3.2	21
2024	Target Therapy in Hematological Malignancies. , 2019, , .		0
2025	Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study. Blood Advances, 2019, 3, 751-760.	2.5	8
2026	Survival analysis of multiple myeloma patients after autologous stem cell transplantation. Stem Cell Investigation, 2019, 6, 42-42.	1.3	2
2027	Molecular/Targeted Therapy of Cancer. , 2019, , 251-285.		0
2028	The Effect of Docosahexaenoic Acid and Î±-Lipoic Acid as Prevention of Bortezomib-Related Neurotoxicity in Patients With Multiple Myeloma. Integrative Cancer Therapies, 2019, 18, 153473541988858.	0.8	7
2029	Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR. Blood, 2019, 133, 147-155.	0.6	33
2030	Diverse roles of the E2/E3 hybrid enzyme <scp>UBE</scp>2O in the regulation of protein ubiquitination, cellular functions, and disease onset. FEBS Journal, 2019, 286, 2018-2034.	2.2	28
2031	Zwitterionic Systems Obtained by Condensation of Heteroarylâ€Boronic Acids and Rhodizonic Acid. European Journal of Organic Chemistry, 2019, 2019, 1574-1582.	1.2	4
2032	Dysfunction of immune system in the development of large granular lymphocyte leukemia. Hematology, 2019, 24, 139-147.	0.7	21
2033	Synthesis of new chalcone-based homoserine lactones and their antiproliferative activity evaluation. European Journal of Medicinal Chemistry, 2019, 163, 500-511.	2.6	17
2034	AMP Kinase Activation Attenuates Cardiac Remodeling in Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction; Lung Epithelial Progenitor Cells in Alveolar Regeneration; and Drug Discovery and Novel Therapies for Lung Cancer. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 244-247.	1.4	0
2035	Protein Degradation and the Pathologic Basis of Disease. American Journal of Pathology, 2019, 189, 94-103.	1.9	66
2036	HBV reactivation after hematopoietic stem cell transplantation and rituximab-containing chemotherapy: a 12-year experience at a single center. Bone Marrow Transplantation, 2019, 54, 629-631.	1.3	4
2037	Targeting IÎºappaB kinases for cancer therapy. Seminars in Cancer Biology, 2019, 56, 12-24.	4.3	39
2038	Effect of lowâ€dose bortezomib on bone formation in smouldering multiple myeloma. British Journal of Haematology, 2019, 184, 308-310.	1.2	2

#	Article	IF	Citations
2039	Carfilzomib Induced Tumor Lysis Syndrome and Other Adverse Events. Journal of Pharmacy Practice, 2020, 33, 213-216.	0.5	2
2040	Anticancer drug discovery by targeting cullin neddylation. Acta Pharmaceutica Sinica B, 2020, 10, 746-765.	5.7	46
2041	Strategies to improve patient-reported outcome completion rates in longitudinal studies. Quality of Life Research, 2020, 29, 335-346.	1.5	27
2042	Withaferin A: From ayurvedic folk medicine to preclinical anti-cancer drug. Biochemical Pharmacology, 2020, 173, 113602.	2.0	73
2043	Incidence of chemotherapy-induced peripheral neuropathy within 12Âweeks of starting neurotoxic chemotherapy for multiple myeloma or lymphoma: a prospective, single-center, observational study. Supportive Care in Cancer, 2020, 28, 1901-1912.	1.0	7
2044	A prospective, iterative, adaptive trial of carfilzomib-based desensitization. American Journal of Transplantation, 2020, 20, 411-421.	2.6	47
2045	Impact of age, sex, ethnicity, socioâ€economic deprivation and novel pharmaceuticals on the overall survival of patients with multiple myeloma in New Zealand. British Journal of Haematology, 2020, 188, 692-700.	1.2	13
2046	Multiple Myeloma and Related Disorders. , 2020, , 1884-1910.e7.		4
2047	Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials. Hematological Oncology, 2020, 38, 229-243.	0.8	28
2048	How are patient-reported outcomes and symptoms being measured in adults with relapsed/refractory multiple myeloma? A systematic review. Quality of Life Research, 2020, 29, 1419-1431.	1.5	28
2049	Bortezomib induces HSV-1 lethality in mice with neutrophil deficiency. Journal of Leukocyte Biology, 2020, 107, 105-112.	1.5	1
2050	Tuning isoform selectivity and bortezomib sensitivity with a new class of alkenyl indene PDI inhibitor. European Journal of Medicinal Chemistry, 2020, 186, 111906.	2.6	16
2051	Colon perforation in multiple myeloma patients â€“ A complication of highâ€dose steroid treatment. Cancer Medicine, 2020, 9, 8895-8901.	1.3	3
2052	Post-translational Modifications of IÎºBÎ±: The State of the Art. Frontiers in Cell and Developmental Biology, 2020, 8, 574706.	1.8	21
2053	Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. Lancet Haematology,the, 2020, 7, e861-e873.	2.2	34
2054	Bioactive natural products from the genus Salinospora: a review. Archives of Pharmacal Research, 2020, 43, 1230-1258.	2.7	10
2055	When the chains do not break: the role of USP10 in physiology and pathology. Cell Death and Disease, 2020, 11, 1033.	2.7	35
2056	Emerging Modes of Treatment of IgA Nephropathy. International Journal of Molecular Sciences, 2020, 21, 9064.	1.8	21

#	Article	IF	Citations
2057	Proteasome inhibition for the treatment of glioblastoma. Expert Opinion on Investigational Drugs, 2020, 29, 1133-1141.	1.9	28
2058	Multiple myeloma: the (r)evolution of current therapy and a glance into future. Haematologica, 2020, 105, 2358-2367.	1.7	73
2059	Biological and Translational Considerations regarding the Recent Therapeutic Successes and Upcoming Challenges for Multiple Myeloma. Cold Spring Harbor Perspectives in Medicine, 2020, 11, a034900.	2.9	0
2060	Targeting poor proteasomal function with radioiodine eliminates CT26 colon cancer stem cells resistant to bortezomib therapy. Scientific Reports, 2020, 10, 14308.	1.6	1
2061	Evidence-based supportive care in multiple myeloma. Journal of Community Hospital Internal Medicine Perspectives, 2020, 10, 313-317.	0.4	1
2062	Non-Hematologic Toxicity of Bortezomib in Multiple Myeloma: The Neuromuscular and Cardiovascular Adverse Effects. Cancers, 2020, 12, 2540.	1.7	36
2063	Genomics-guided pre-clinical development of cancer therapies. Nature Cancer, 2020, 1, 482-492.	5.7	23
2064	The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges. , 2020, 213, 107579.		62
2065	Hakin-1, a New Specific Small-Molecule Inhibitor for the E3 Ubiquitin-Ligase Hakai, Inhibits Carcinoma Growth and Progression. Cancers, 2020, 12, 1340.	1.7	15
2066	Changing trend in mortality rate of multiple myeloma after introduction of novel agents: A populationâ€based study. International Journal of Cancer, 2020, 147, 3102-3109.	2.3	9
2067	The Role of Imaging and Systemic Treatments in Myeloma: A Primer for Radiologists. American Journal of Roentgenology, 2020, 214, 1321-1334.	1.0	1
2068	Potent USP10/13 antagonist spautinâ€1 suppresses melanoma growth via ROSâ€mediated DNA damage and exhibits synergy with cisplatin. Journal of Cellular and Molecular Medicine, 2020, 24, 4324-4340.	1.6	30
2069	Mechanistic insights of adipocyte metabolism in regulating breast cancer progression. Pharmacological Research, 2020, 155, 104741.	3.1	19
2070	Proteasome inhibitors and Smac mimetics cooperate to induce cell death in diffuse large Bâ€cell lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis. International Journal of Cancer, 2020, 147, 1485-1498.	2.3	6
2071	Bortezomib Treatment Modulates Autophagy in Multiple Myeloma. Journal of Clinical Medicine, 2020, 9, 552.	1.0	40
2072	The safety of current and emerging therapies for multiple myeloma. Expert Opinion on Drug Safety, 2020, 19, 269-279.	1.0	6
2073	The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduction and Targeted Therapy, 2020, 5, 11.	7.1	338
2074	Treatment and diseaseâ€related complications in multiple myeloma: Implications for survivorship. American Journal of Hematology, 2020, 95, 672-690.	2.0	22

#	Article	IF	Citations
2075	Multiple Myeloma: Available Therapies and Causes of Drug Resistance. Cancers, 2020, 12, 407.	1.7	136
2076	Proteaseâ€activated prodrugs: strategies, challenges, and future directions. FEBS Journal, 2020, 287, 1936-1969.	2.2	71
2077	Addition of lowâ€dose decitabine to bortezomib and dexamethasone as secondâ€line therapy in multiple myeloma. British Journal of Haematology, 2020, 189, e258-e262.	1.2	5
2079	Role of Deubiquitinases in Human Cancers: Potential Targeted Therapy. International Journal of Molecular Sciences, 2020, 21, 2548.	1.8	33
2080	Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13. Leukemia, 2021, 35, 550-561.	3.3	11
2081	Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE. Leukemia, 2021, 35, 1134-1144.	3.3	36
2082	IgA Nephropathy: An Interesting Autoimmune Kidney Disease. American Journal of the Medical Sciences, 2021, 361, 176-194.	0.4	91
2083	Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance. British Journal of Cancer, 2021, 124, 770-776.	2.9	16
2084	A bird's eye view of the advanced approaches and strategies for overshadowing triple negative breast cancer. Journal of Controlled Release, 2021, 330, 72-100.	4.8	18
2085	Targeted modulation of E3 ligases using engineered ubiquitin variants. FEBS Journal, 2021, 288, 2143-2165.	2.2	12
2086	Bisphosphonates for delivering drugs to bone. British Journal of Pharmacology, 2021, 178, 2008-2025.	2.7	21
2087	PTEN deficiency leads to proteasome addiction: a novel vulnerability in glioblastoma. Neuro-Oncology, 2021, 23, 1072-1086.	0.6	23
2088	Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13. Blood Cancer Journal, 2021, 11, 13.	2.8	8
2089	Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy. International Journal of Molecular Sciences, 2021, 22, 888.	1.8	58
2090	Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany. Journal of Medical Economics, 2021, 24, 114-122.	1.0	7
2091	Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?. , 2021, 4, 634-645.		2
2092	Old and new generation proteasome inhibitors in multiple myeloma. Panminerva Medica, 2021, 62, 193-206.	0.2	6
2093	The emerging roles of E3 ubiquitin ligases in ovarian cancer chemoresistance. , 2021, 4, 365-381.		4

#	Article	IF	Citations
2094	Ubiquitination of Nonhistone Proteins in Cancer Development and Treatment. Frontiers in Oncology, 2020, 10, 621294.	1.3	8
2095	Theoretical Studies of the Acidâ€“Base Equilibria in a Model Active Site of the Human 20S Proteasome. Journal of Chemical Information and Modeling, 2021, 61, 1942-1953.	2.5	4
2096	Proteases and Their Modulators in Cancer Therapy: Challenges and Opportunities. Journal of Medicinal Chemistry, 2021, 64, 2851-2877.	2.9	22
2097	The paradoxical pharmacological mechanisms of lenalidomide and bortezomib in the treatment of multiple myeloma. Anti-Cancer Drugs, 2021, 32, 227-232.	0.7	6
2098	Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma. Journal of Experimental and Clinical Cancer Research, 2021, 40, 110.	3.5	16
2100	Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 154-161.e3.	0.2	11
2101	Role of Proteasomes in Inflammation. Journal of Clinical Medicine, 2021, 10, 1783.	1.0	43
2102	Treating MCF7 breast cancer cell with proteasome inhibitor Bortezomib restores apoptotic factors and sensitizes cell to Docetaxel. Medical Oncology, 2021, 38, 64.	1.2	14
2103	Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice. Pharmacological Research, 2021, 167, 105537.	3.1	12
2104	Resolution of bortezomib-associated chalazia/blepharitis after switch to ixazomib: A case report. Current Research in Translational Medicine, 2021, 69, 103283.	1.2	3
2105	CUL3 (cullin 3)-mediated ubiquitination and degradation of BECN1 (beclin 1) inhibit autophagy and promote tumor progression. Autophagy, 2021, 17, 4323-4340.	4.3	56
2106	NMS-873 functions as a dual inhibitor of mitochondrial oxidative phosphorylation. Biochimie, 2021, 185, 33-42.	1.3	8
2107	Role of innate immunity in chemotherapy-induced peripheral neuropathy. Neuroscience Letters, 2021, 755, 135941.	1.0	7
2108	Immunoproteasome Function in Normal and Malignant Hematopoiesis. Cells, 2021, 10, 1577.	1.8	18
2109	Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma. Frontiers in Pharmacology, 2021, 12, 699629.	1.6	17
2110	Selinexor for the treatment of patients with previously treated multiple myeloma. Expert Review of Hematology, 2021, 14, 697-706.	1.0	6
2111	Epidemiology, genetics and treatment of multiple myeloma and precursor diseases. International Journal of Cancer, 2021, 149, 1980-1996.	2.3	25
2112	Deep learning detects cardiotoxicity in a high-content screen with induced pluripotent stem cell-derived cardiomyocytes. ELife, 2021, 10, .	2.8	25

#	Article	IF	Citations
2113	Real-Life Experience With First-Line Therapy Bortezomib Plus Melphalan and Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma Ineligible for High Dose Chemotherapy With Autologous Stem-Cell Transplantation. Frontiers in Medicine, 2021, 8, 712070.	1.2	4
2114	Transplantation and immunosuppression: a review of novel transplant-related immunosuppressant drugs. Immunopharmacology and Immunotoxicology, 2021, 43, 651-665.	1.1	44
2115	Î²2-microglobulin triggers NLRP3 inflammasome activation in tumor-associated macrophages to promote multiple myeloma progression. Immunity, 2021, 54, 1772-1787.e9.	6.6	49
2116	The evolving role and utility of off-label drug use in multiple myeloma. Exploration of Targeted Anti-tumor Therapy, 0, , .	0.5	0
2117	Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma. Cancers, 2021, 13, 4706.	1.7	11
2118	Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN). Cancer Treatment Reviews, 2021, 99, 102241.	3.4	29
2119	TGSA: proteinâ€“protein association-based twin graph neural networks for drug response prediction with similarity augmentation. Bioinformatics, 2022, 38, 461-468.	1.8	16
2120	Albendazole inhibits NF-Î°B signaling pathway to overcome tumor stemness and bortezomib resistance in multiple myeloma. Cancer Letters, 2021, 520, 307-320.	3.2	18
2121	Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments. Communications Biology, 2021, 4, 44.	2.0	7
2122	Myeloma. , 0, , 681-702.		2
2123	Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. , 0, , 1262-1282.		1
2124	Quantitative Changes in Blood Cells. , 0, , 217-262.		2
2125	Periphere Neuropathie. , 2006, , 303-328.		1
2126	Novel Small Molecules in the Treatment of Lymphomas. , 2006, , 413-460.		1
2127	Homogeneous, Bioluminescent Proteasome Assays. Methods in Molecular Biology, 2015, 1219, 95-114.	0.4	4
2128	Lessons Learned from Proteasome Inhibitors, the Paradigm for Targeting Protein Homeostasis in Cancer. Advances in Experimental Medicine and Biology, 2020, 1243, 147-162.	0.8	8
2130	Targeting Mantle Cell Lymphoma with a Strategy of Combined Proteasome and Histone Deacetylase Inhibition. Resistance To Targeted Anti-cancer Therapeutics, 2014, , 149-179.	0.1	2
2131	New Molecular Therapy Targets in Acute Myeloid Leukemia. Recent Results in Cancer Research, 2007, 176, 243-262.	1.8	6

#	Article	IF	Citations
2132	History of Multiple Myeloma. Recent Results in Cancer Research, 2011, 183, 3-23.	1.8	13
2133	Therapy of Relapsed and Refractory Multiple Myeloma. Recent Results in Cancer Research, 2011, 183, 239-271.	1.8	18
2134	Bortezomib. Recent Results in Cancer Research, 2010, 184, 173-187.	1.8	31
2135	Bortezomib. Recent Results in Cancer Research, 2014, 201, 325-345.	1.8	17
2137	Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma: Principles of Identification and Management. , 2011, , 95-105.		1
2138	Targeting SCF E3 Ligases for Cancer Therapies. Advances in Experimental Medicine and Biology, 2020, 1217, 123-146.	0.8	34
2139	Lymphoplasmacytic Lymphoma/WaldenstrÃ¶m's Macroglobulinemia. , 2006, , 374-380.		2
2140	Biologics and Their Interactions with Radiation. , 2012, , 83-94.		1
2141	Plasma cell dyscrasias and leukemias. Cancer Chemotherapy and Biological Response Modifiers, 2005, , 343-389.	0.5	1
2142	Proteasome inhibitors as therapeutics. Essays in Biochemistry, 2005, 41, 205-218.	2.1	7
2143	Proteasome inhibitors as therapeutics. Essays in Biochemistry, 2005, 41, 205.	2.1	31
2144	DeepCDR: a hybrid graph convolutional network for predicting cancer drug response. Bioinformatics, 2020, 36, i911-i918.	1.8	98
2145	Hepatic Plasmacytosis as a Manifestation of Relapse in Multiple Myeloma Treated With Thalidomide. Southern Medical Journal, 2005, 98, 238-240.	0.3	9
2146	Bortezomib Plus Docetaxel in Advanced Non-small Cell Lung Cancer and Other Solid Tumors: A Phase I California Cancer Consortium Trial. Journal of Thoracic Oncology, 2006, 1, 126-134.	0.5	27
2148	Reversible posterior leucoencephalopathy syndrome associated with bortezomib in a patient with relapsed multiple myeloma. BMJ Case Reports, 2009, 2009, bcr0620091926-bcr0620091926.	0.2	9
2149	Proteasome function is required for platelet production. Journal of Clinical Investigation, 2014, 124, 3757-3766.	3.9	55
2150	Dominant-negative NFKBIA mutation promotes IL-1Î² production causing hepatic disease with severe immunodeficiency. Journal of Clinical Investigation, 2020, 130, 5817-5832.	3.9	17
2151	A Novel Luminescence-Based High-Throughput Approach for Cellular Resolution of Protein Ubiquitination Using Tandem Ubiquitin Binding Entities (TUBEs). SLAS Discovery, 2020, 25, 350-360.	1.4	6

#	Article	IF	Citations
2152	Evidence-Based Mini-Review: Treatment Options for Patients with Relapsed/Refractory Myeloma Previously Treated with Novel Agents and High-Dose Chemotherapy and Autologous Stem-Cell Transplantation. Hematology American Society of Hematology Education Program, 2010, 2010, 310-313.	0.9	2
2153	A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.. Blood, 2008, 112, 3332-3332.	0.6	2
2154	Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma. Blood Advances, 2017, 1, 2247-2256.	2.5	15
2155	A dose-escalating and pharmacologic study of bortezomib in adult cancer patients with impaired renal function. Journal of Clinical Oncology, 2006, 24, 2032-2032.	0.8	12
2156	B and H-NMR Evaluation of Chemical Interactions between Two Polyphenols; Epigallocatechingallate and Quercetin with Bortezomib. Biosciences, Biotechnology Research Asia, 2014, 11, 577-586.	0.2	2
2157	Apotosis-based therapies for hematological malignancies. Drugs of the Future, 2005, 30, 707.	0.0	1
2158	Dysferlin-Peptides Reallocate Mutated Dysferlin Thereby Restoring Function. PLoS ONE, 2012, 7, e49603.	1.1	9
2159	Variation in Drug Sensitivity of Malignant Mesothelioma Cell Lines with Substantial Effects of Selenite and Bortezomib, Highlights Need for Individualized Therapy. PLoS ONE, 2013, 8, e65903.	1.1	17
2160	Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple Myeloma. PLoS ONE, 2015, 10, e0128662.	1.1	2
2161	Positive cytoplasmic UCHL5 tumor expression in gastric cancer is linked to improved prognosis. PLoS ONE, 2018, 13, e0193125.	1.1	17
2162	Targeting NF-Î²B to Increase the Activity of Cisplatin in Solid Tumors. , 2005, , 197-207.		1
2163	Proteasome Inhibitor-Induced IÎ²B/NF-Î²B Activation is Mediated by Nrf2-Dependent Light Chain 3B Induction in Lung Cancer Cells. Molecules and Cells, 2018, 41, 1008-1015.	1.0	4
2164	Bortezomib-Induced Cardiac Tamponade in a 49-Year-Old Man. Texas Heart Institute Journal, 2018, 45, 260-263.	0.1	6
2166	Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials. Oncotarget, 2017, 8, 39805-39817.	0.8	13
2167	A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma. Oncotarget, 2016, 7, 70168-70174.	0.8	3
2168	Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells. Oncotarget, 2017, 8, 3396-3411.	0.8	59
2169	Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases. Oncotarget, 2017, 8, 13942-13956.	0.8	25
2170	A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma. Oncotarget, 2017, 8, 37605-37618.	0.8	6

#	Article	IF	Citations
2171	Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. Oncotarget, 2014, 5, 5453-5471.	0.8	139
2172	The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells. Oncotarget, 2014, 5, 6252-6266.	0.8	43
2173	A dominant-negative F-box deleted mutant of E3 ubiquitin ligase, Î²-TrCP1/FWD1, markedly reduces myeloma cell growth and survival in mice. Oncotarget, 2015, 6, 21589-21602.	0.8	11
2174	Visualizing the antivascular effect of bortezomib on the hypoxic tumor microenvironment. Oncotarget, 2015, 6, 34732-34744.	0.8	7
2175	Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-ÎºB crosstalk. Oncotarget, 2015, 6, 32439-32455.	0.8	28
2176	Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?. Oncotarget, 2012, 3, 1335-1347.	0.8	13
2177	Novel strategies to target the ubiquitin proteasome system in multiple myeloma. Oncotarget, 2016, 7, 6521-6537.	0.8	66
2178	Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evidence, 2010, 4, 215.	4.7	18
2179	Bortezomib (Velcade?) in the treatment of multiple myeloma. Therapeutics and Clinical Risk Management, 2006, 2, 271-279.	0.9	197
2180	Targeting the Ubiquitin Proteasome System: Beyond Proteasome Inhibition. Current Pharmaceutical Design, 2013, 19, 4053-4093.	0.9	27
2181	Proteasome Inhibitors in Cancer Therapy and their Relation to Redox Regulation. Current Pharmaceutical Design, 2019, 24, 5252-5267.	0.9	2
2182	Small Molecule Antagonists of the MDM2 Oncoprotein as Anticancer Agents. Current Cancer Drug Targets, 2005, 5, 57-68.	0.8	69
2183	Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System. Current Cancer Drug Targets, 2014, 14, 517-536.	0.8	224
2184	Achievements in Cancer Research and its Therapeutics in Hundred Years. Current Topics in Medicinal Chemistry, 2019, 19, 1545-1562.	1.0	2
2185	Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents. Recent Patents on Anti-Cancer Drug Discovery, 2007, 2, 119-134.	0.8	51
2186	Multiple Myeloma: A Paradigm for Translation of the Cancer Stem Cell Hypothesis. Anti-Cancer Agents in Medicinal Chemistry, 2010, 10, 116-120.	0.9	39
2187	Turning to Computer-aided Drug Design in the Treatment of Diffuse Large B-cell Lymphoma: Has it been Helpful?. Anti-Cancer Agents in Medicinal Chemistry, 2019, 19, 1325-1339.	0.9	2
2188	Transient Receptor Potential Channels in Chemotherapy-Induced Neuropathy. Open Pain Journal, 2013, 6, 127-136.	0.4	5

#	Article	IF	Citations
2190	Possible mechanisms of action of clarithromycin and its clinical application as a repurposing drug for treating multiple myeloma. Ecancermedicalscience, 2020, 14, 1088.	0.6	7
2191	The Ubiquitin Proteasome System in Periodontal Disease: A Comprehensive Review. Frontiers in Dental Medicine, 2020, 1, .	0.5	1
2192	Proteasome inhibition-induces endoplasmic reticulum dysfunction and cell death of human cholangiocarcinoma cells. World Journal of Gastroenterology, 2007, 13, 851.	1.4	31
2193	Proteasome inhibitor treatment in alcoholic liver disease. World Journal of Gastroenterology, 2011, 17, 2558.	1.4	11
2194	Recent advances in multiple myeloma: a Korean perspective. Korean Journal of Internal Medicine, 2016, 31, 820-834.	0.7	22
2195	Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment. Korean Journal of Internal Medicine, 2019, 34, 1333-1346.	0.7	3
2196	Bortezomib-induced Severe Congestive Heart Failure. Cardiology Research, 2010, 1, 20-23.	0.5	17
2197	Bortezomib in newly diagnosed patients with multiple myeloma: A retrospective analysis from a tertiary care center in India. Indian Journal of Cancer, 2015, 52, 537.	0.2	4
2198	Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma. South Asian Journal of Cancer, 2018, 07, 058-060.	0.2	5
2199	Bortezomib-Induced Multiple Chalazia: A Case Report. Case Reports in Clinical Medicine, 2015, 04, 32-35.	0.1	4
2200	Novel agents and new therapeutic approaches for treatment of multiple myeloma. World Journal of Methodology, 2014, 4, 73.	1.1	32
2201	Ubiquitin at the crossroad of cell death and survival. Chinese Journal of Cancer, 2013, 32, 640-647.	4.9	15
2202	Multiple Myeloma, Version 2.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1398-1435.	2.3	55
2203	PCI-24781 (abexinostat), a novel histone deacetylase inhibitor, induces reactive oxygen species-dependent apoptosis and is synergistic with bortezomib in neuroblastoma. Journal of Cancer Therapeutics & Research, 2013, 2, 21.	1.2	25
2204	Immunoproteasome functions explained by divergence in cleavage specificity and regulation. ELife, 2017, 6, .	2.8	66
2205	Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. ELife, 2019, 8, .	2.8	32
2206	Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma. Blood Cancer Journal, 2021, 11, 169.	2.8	2
2207	Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment. Oncology and Therapy, 2021, 9, 385-450.	1.0	92

#	Article	IF	Citations
2208	Clinical significance of SIRT3 and inflammatory factors in multiple myeloma patients with bortezomib-induced peripheral neuropathy: a cohort study. Scandinavian Journal of Clinical and Laboratory Investigation, 2021, 81, 615-621.	0.6	1
2209	Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e241-e249.	0.2	2
2210	Novel therapies for immune thrombocytopenia. British Journal of Haematology, 2022, 196, 1311-1328.	1.2	19
2211	Treatment of Multiple Myeloma. , 2004, , 137-157.		0
2212	Remission Maintenance in Multiple Myeloma. , 2004, , 223-249.		0
2213	New Therapeutic Approaches to Myeloma. , 2004, , 319-353.		0
2214	Phase II Trials of Bortezomib for the Treatment of Multiple Myeloma. , 2004, , 301-305.		0
2215	Rationale for Combining the Proteasome Inhibitor Bortezomib with Cisplatin. , 2004, , 193-205.		1
2216	Biological basis of therapy. , 2004, , 292-304.		0
2217	Recent insights into myeloma bone disease. BoneKEy Osteovision, 2005, 2, 17-25.	0.6	0
2218	Multiples Myelom. Pharma-Kritik (discontinued), 2005, 26, .	0.0	0
2220	Nonmyeloablative Unrelated Donor (URD) Hematopoietic Cell Transplantation (HCT) for the Treatment of Patients (pts) with Poor-Risk, Relapsed or Refractory Multiple Myeloma.. Blood, 2005, 106, 2893-2893.	0.6	1
2221	The Ubiquitin-Proteasome Pathway. , 2005, , 511-542.		0
2223	Peripheral Neuropathy Due to Chemotherapy and Radiation Therapy. , 2006, , 107-121.		0
2224	Multiples Myelom. , 2006, , 3165-3205.		0
2226	Horizons for Cancer Chemotherapy (and Nonchemotherapy). , 2006, , 445-457.		0
2227	Regulating the Master Regulator NF-_B. , 2006, , 195-221.		0
2228	Bortezomib in Multiple Myeloma and Lymphoma: A Systematic Review and Clinical Practice Guideline. Current Oncology, 2006, 13, 160-172.	0.9	8

#	Article	IF	Citations
2229	Inhibiting the Proteasome in Advanced Prostate Cancer. Translational Medicine Series, 2006, , 237-243.	0.0	0
2230	Multiples Myelom und verwandte Plasmazellerkrankungen. , 2007, , 1-12.		0
2231	Plasmazellerkrankungen. , 2007, , 493-510.		0
2232	Mieloma MÃºltiplo neste fascÃculo. Revista Brasileira De Hematologia E Hemoterapia, 2007, 29, .	0.7	0
2233	Novel Agents for Previously Untreated Multiple Myeloma. Translational Medicine Series, 2007, , 141-168.	0.0	0
2234	The Role of the Bone Marrow Microenvironment in the Pathogenesis of Multiple Myeloma. Translational Medicine Series, 2007, , 23-44.	0.0	0
2235	Agents that Regulate DR5 and Sensitivity to TRAIL. , 2008, , 41-49.		1
2236	The Role of Heat Shock Protein 90 as a Therapeutic Target for Multiple Myeloma. , 2008, , 291-308.		0
2237	The Role of Bortezomib in the Treatment of Relapsed and Refractory Multiple Myeloma. , 2008, , 239-252.		0
2238	Multiple Myeloma and Related Disorders. , 2008, , 2323-2351.		1
2239	Anemia and Erythropoeitic Growth Factors in Multiple Myeloma. , 2008, , 455-468.		0
2240	Co-Development of Drugs and Pharmacogenomics-Based Diagnostics in Oncology. Methods in Pharmacology and Toxicology, 2008, , 267-298.	0.1	1
2241	Proteasome Inhibition: Potential for Sensitization of Immune Effector Mechanisms in Cancer. , 2008, , 51-60.		1
2242	Phase 1 Trials Today. , 2008, , 553-570.		0
2243	ï¼“ï¼Žéª¨é«„è…«ãƒ»ãƒªãƒ³ãƒ'è…«æ²»ç™,ã,ã®ãƒ—ãƒãƒ†ã,¢ã,½ãƒ¼ãƒé˜»å®³å‰ Bortezomibã®åºŽå…¥ï¼šè–¬ç‰©å‹•æ…‹ã«åŸºã¥ã	0.1	0
2244	New drugs in the therapy of multiple myeloma. Revista Brasileira De Hematologia E Hemoterapia, 0, 30, .	0.7	1
2245	Senescence Regulation in Cancer Therapy. , 2008, , 251-271.		0
2246	Recent Advances in the Understanding and Treatment of Multiple Myeloma. Journal of Managed Care Pharmacy, 2008, 14, 1-30.	2.2	20

#	Article	IF	Citations
2247	Diagnostic-Therapeutic Combinations in the Treatment of Cancer. , 2009, , 990-1007.		0
2248	Molecular Mechanisms of Hepatocellular Carcinoma: Insights to Therapy. , 2009, , 109-130.		0
2249	Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.. Blood, 2009, 114, 2727-2727.	0.6	0
2251	Investigation of Adverse Drug Reactions in Bortezomib Therapy for Relapsed Multiple Myeloma. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2010, 36, 270-276.	0.0	3
2252	Tumor Microenvironment. , 2010, , 27-69.		1
2253	Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations. Swiss Medical Weekly, 2010, 140, w13054.	0.8	4
2254	Bortezomib in Relapsed and Relapsed/Refractory Multiple Myeloma. , 2011, , 79-94.		0
2255	The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification. Srpski Arhiv Za Celokupno Lekarstvo, 2011, 139, 84-89.	0.1	3
2256	HÃmatologische und onkologische Erkrankungen. , 2011, , 607-718.		0
2257	Proper Use of Bortezomib Therapy in Multiple Myeloma. Iryo Yakugaku (Japanese Journal of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T f	0.0	0
2258	Signalling Molecules as Selective Targets for Therapeutic Strategies in Multiple Myeloma. , 2012, , 87-108.		0
2259	Use of rHuG-CSF in New Chemotherapy Strategies. , 2012, , 225-247.		0
2260	Targeted Therapies in Hematological Malignancies. , 0, , .		0
2261	Evaluation of Adverse Events in Patients with Bortezomib Concomitantly used with Azole-based Antifungal Agents. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2012, 38, 664-671.	0.0	0
2262	The Ubiquitin-Proteasomal System and Blood Cancer Therapy. , 0, , .		0
2263	Genomic Strategies Determining Progression from MGUS to Multiple Myeloma. , 2013, , 3-24.		0
2264	Novel Agents in Multiple Myeloma. , 2013, , 215-228.		0
2265	Clinical Studies of Molecular Targeted Therapy for Multiple Myeloma. Translational Medicine (Sunnyvale, Calif), 2013, 01, .	0.4	0

#	Article	IF	Citations
2266	Drug-Induced Toxic Neuropathies. , 2014, , 715-731.		0
2267	Neurologic Complications of Myeloma. , 2014, , 245-255.		1
2268	Approach to Relapsed Refractory Myeloma. , 2014, , 95-100.		0
2271	Novel Agents for the Treatment of Multiple Myeloma: Proteasome Inhibitors and Immunomodulatory Agents. Journal of the Advanced Practitioner in Oncology, 2013, 4, .	0.2	7
2272	Acknowledgments / The Authors. , 2013, , 295-295.		0
2274	Proteasome Inhibitors and Lessons Learned from Their Mechanisms of Action and Resistance in Human Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2014, , 1-46.	0.1	1
2275	Proteasome Defects and Cytokine Signaling in SjÃ¶grenâ€™s Syndrome. , 2014, , 37-51.		0
2276	Multiple Myeloma and Related Disorders. , 2014, , 1991-2017.e7.		1
2277	Proteasome Inhibitors in the Treatment of Multiple Myeloma and AL Amyloidosis. Resistance To Targeted Anti-cancer Therapeutics, 2014, , 99-115.	0.1	0
2278	Development of Drug-Induced Cutaneous Vasculitis in a Patient with Relapsed Angioimmunoblastic T-cell Lymphoma Treated with Novel Bortezomib and Panobinostat Combination: A Possible Surrogate Marker of Response. Cancer Science & Research Open Access, 2014, 1, 1-4.	1.4	0
2280	Comparison of Two Therapeutic Regimes, Lenalidomide with Dexamethasone and Thalidomide with Dexamethasone, in the Treatment of Multiple Myeloma at a Tertiary Care Hospital in India. Journal of Clinical and Diagnostic Research JCDR, 2015, 9, XC01-XC04.	0.8	0
2281	Bortezomib-Based Salvage Chemotherapy in Refractory/Relapsed Multiple Myeloma Patients: A Single Center Experience in Real Clinical Practice. Korean Journal of Medicine, 2015, 88, 537.	0.1	0
2282	Treatment of elderly patients with myeloma. , 2015, , 41-63.		0
2283	Pulmonary Embolism: A Rare Initial Manifestation of Multiple Myeloma. American Journal of Medical Case Reports, 2015, 3, 244-246.	0.1	1
2284	Clinical Features, Management, and Therapy of Plasma Cell Neoplasms: What Pathologists Need to Know. , 2016, , 9-34.		0
2285	Molecular Targeted Anticancer Drugs. , 2016, , 175-238.		0
2286	Role of Immunomodulatory Drugs and Proteasome Inhibitors in the Treatment of Myeloma Bone Disease: Literature of Review. International Journal of Medical Science, 2016, 3, 1-7.	0.1	0
2287	Bortezomib plus dexamethasone induction followed by autologous stem cell transplantation in multiple myeloma: A study from India. Asian Journal of Medical Sciences, 2016, 7, 44-48.	0.0	0

#	Article	IF	Citations
2288	Elotuzumab for Treatment of Multiple Myeloma (Literature Review). Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2016, 9, 438-445.	0.1	0
2289	Stem Cell Transplantation for Multiple Myeloma. Pancreatic Islet Biology, 2017, , 73-86.	0.1	0
2290	Lymphoma and Myeloma of the Sacrum. , 2017, , 227-235.		1
2291	Daratumumab: Dawn of a New Paradigm in Multiple Myeloma?. Journal of the Advanced Practitioner in Oncology, 2017, 8, 82-90.	0.2	1
2293	Risk Stratification in Newly Diagnosed Transplant-Eligible Multiple Myeloma. , 2018, , 15-36.		0
2294	Truncated protein tyrosine phosphatase receptor type O suppresses AKT signaling through IQ motif containing GTPase activating protein 1 and confers sensitivity to bortezomib in multiple myeloma. Oncotarget, 2017, 8, 113858-113873.	0.8	0
2295	Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma in the Era of New Drugs. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2018, 11, 187-191.	0.1	0
2297	Comorbidities in patients with multiple myeloma. AktualÊ¹nÃ¬ PitannÃ¢ FarmacevtiÄnoÃ¯ Ã¬ MediÄnoÃ¯ Nauki Ta Praktiki, 2019, .	0.0	0
2298	Neurological Complications of Targeted Therapies. , 2020, , 341-363.		0
2299	Plasma cell myeloma and related monoclonal gammopathies. , 2020, , 5310-5324.		0
2300	Apoptosis and Cancer. , 2020, , 307-353.		0
2301	Adherence to and effectiveness of lenalidomide after 1 year of treatment in a real world setting. Journal of Oncology Pharmacy Practice, 2022, 28, 24-30.	0.5	3
2302	HÃmatologische und onkologische Erkrankungen. , 2020, , 329-335.		0
2303	Predictors of relapse and preventative strategies in immune thrombotic thrombocytopenic purpura. Expert Review of Hematology, 2021, 14, 1027-1040.	1.0	5
2305	NF-Î°B in Human Cancers. , 2006, , 131-146.		0
2306	Monoklonale Gammopathien. , 2005, , 1148-1162.		0
2307	Erkrankungen des lymphatischen Systems. , 2005, , 337-364.		0
2308	Neue Arzneimittel. , 0, , 37-107.		0

#	Article	IF	Citations
2310	Dawn of a new era in molecular cancer therapeutics. , 2005, 63, 1-17.		1
2311	Cytokines in Multiple Myeloma. , 2007, , 181-197.		0
2313	Multiples Myelom. , 0, , 421-455.		0
2314	Front line treatment of elderly multiple myeloma in the era of novel agents. Biologics: Targets and Therapy, 2009, 3, 99-109.	3.0	6
2315	Endoplasmic reticulum stress response in cancer: molecular mechanism and therapeutic potential. American Journal of Translational Research (discontinued), 2010, 2, 65-74.	0.0	85
2317	Pharmacological ER stress promotes hepatic lipogenesis and lipid droplet formation. American Journal of Translational Research (discontinued), 2012, 4, 102-13.	0.0	102
2318	The ubiquitin-proteasomal system is critical for multiple myeloma: implications in drug discovery. American Journal of Blood Research, 2011, 1, 46-56.	0.6	17
2322	Bortezomib: the evidence of its clinical impact in multiple myeloma. Core Evidence, 2006, 1, 265-77.	4.7	1
2323	Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline. Current Oncology, 2006, 13, 160-72.	0.9	6
2324	Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma. Journal of Research in Medical Sciences, 2012, 17, 8-14.	0.4	36
2329	Novel agents for the treatment of multiple myeloma: proteasome inhibitors and immunomodulatory agents. Journal of the Advanced Practitioner in Oncology, 2013, 4, 307-21.	0.2	9
2330	Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discovery Medicine, 2011, 12, 471-80.	0.5	105
2331	The future of proteasome inhibitors in relapsed/refractory multiple myeloma. Oncology, 2011, 25 Suppl 2, 56-64.	0.4	0
2335	The effects of bortezomib on the ovariectomy applied rat uterus: A histopathological, stereological, and immunohistochemical study. Iranian Journal of Basic Medical Sciences, 2018, 21, 1118-1125.	1.0	0
2336	Functional Significance of the E3 Ubiquitin Ligases in Disease and Therapeutics. Biochemistry, 0, , .	0.8	1
2337	Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis. Cancers, 2021, 13, 5674.	1.7	1
2338	Improved Scalable Synthesis of Clinical Candidate KZRâ€616, a Selective Immunoproteasome Inhibitor. ChemistrySelect, 2021, 6, 12461-12465.	0.7	1
2339	Genome Instability in Multiple Myeloma: Facts and Factors. Cancers, 2021, 13, 5949.	1.7	17

#	Article	IF	Citations
2340	Insights Into the Regulation of Gynecological Inflammation-Mediated Malignancy by Metalloproteinases. Frontiers in Cell and Developmental Biology, 2021, 9, 780510.	1.8	2
2341	Efficacy and safety of ixazomib maintenance therapy for patients with multiple myeloma: a meta-analysis. Hematology, 2021, 26, 1031-1039.	0.7	3
2342	THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors. International Journal of Molecular Sciences, 2022, 23, 1207.	1.8	4
2343	Bone-Targeted Bortezomib Inhibits Bortezomib-Resistant Multiple Myeloma in Mice by Providing Higher Levels of Bortezomib in Bone. Journal of Bone and Mineral Research, 2020, 37, 629-642.	3.1	3
2344	The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences. Critical Reviews in Oncology/Hematology, 2022, 172, 103602.	2.0	5
2345	Targeted Therapy in Leukaemia, Lymphoma and Myeloma. Journal of Personalized Medicine, 2022, 12, 74.	1.1	1
2346	E2-E3 ubiquitin enzyme pairing - partnership in provoking or mitigating cancers. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188679.	3.3	12
2347	Practical guidance for new multiple myeloma treatment regimens: A nursing perspective. Seminars in Oncology, 2022, , .	0.8	1
2349	Cardiovascular-specific mortality among multiple myeloma patients: a population-based study. Therapeutic Advances in Hematology, 2022, 13, 204062072210867.	1.1	5
2350	Neurological complications of multiple myeloma. , 2022, , 415-431.		0
2352	Bortezomib-Induced Epigenetic Alterations in Nerve Cells: Focus on the Mechanisms Contributing to the Peripheral Neuropathy Development. International Journal of Molecular Sciences, 2022, 23, 2431.	1.8	7
2353	Structures and Reactivities of Cocrystals Involving Diboronic Acids and Bipyridines: In Situ Linker Reaction and 1Dâ€toâ€2D Dimensionality Change via Crystalâ€toâ€Crystal Photodimerization. Chemistry - A European Journal, 2022, 28, .	1.7	4
2354	DeepTTA: a transformer-based model for predicting cancer drug response. Briefings in Bioinformatics, 2022, 23, .	3.2	25
2355	Promising therapeutic approaches for relapsed/refractory multiple myeloma. Hematology, 2022, 27, 343-352.	0.7	4
2356	Bortezomib-Induced Ovarian Toxicity in Mice. Toxicologic Pathology, 2022, , 019262332210835.	0.9	0
2357	Targeting MALT1 Suppresses the Malignant Progression of Colorectal Cancer via miR-375/miR-365a-3p/NF-ÎºB Axis. Frontiers in Cell and Developmental Biology, 2022, 10, 845048.	1.8	3
2358	Specific Attenuation of Purinergic Signaling during Bortezomib-Induced Peripheral Neuropathy In Vitro. International Journal of Molecular Sciences, 2022, 23, 3734.	1.8	8
2359	Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study. Cancer Reports, 2022, 5, e1614.	0.6	1

#	Article	IF	Citations
2360	Bortezomib-Induced Reversible Cardiomyopathy: Recovered with Guideline-Directed Medical Therapy. Cureus, 2021, 13, e20295.	0.2	1
2362	Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations. Biomolecules, 2022, 12, 51.	1.8	17
2363	Flow synthesis of an Î±-amino boronic ester as a key precursor of bortezomib drug. Reaction Chemistry and Engineering, 2022, 7, 1285-1288.	1.9	2
2364	The Next Frontier: Translational Development of Ubiquitination, SUMOylation, and NEDDylation in Cancer. International Journal of Molecular Sciences, 2022, 23, 3480.	1.8	16
2365	Translational Strategies to Target Metastatic Bone Disease. Cells, 2022, 11, 1309.	1.8	4
2366	Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and multiple myeloma. , 0, , 155-183.		0
2372	The Molecular Biology of Multiple Myeloma. , 0, , 115-124.		0
2373	Myeloma and other Paraproteinaemias. , 0, , 469-481.		1
2374	Myeloma and other Paraproteinaemias. , 0, , 500-513.		0
2375	Dissecting Intracellular Proteolysis Using Small Molecule Inhibitors and Molecular Probes. , 0, , 51-78.		0
2376	Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium. Acta Clinica Belgica, 2011, 66, 371-5.	0.5	5
2378	AntagomiR-19a Induced Better Responsiveness to Bortezomib in Myeloma Cell Lines. Cell Journal, 2021, 23, 503-509.	0.2	0
2380	Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review. Current Cardiology Reviews, 2023, 19, .	0.6	3
2381	Multinomial network meta-analysis using response rates: relapsed/refractory multiple myeloma treatment rankings differ depending on the choice of outcome. BMC Cancer, 2022, 22, .	1.1	1
2382	Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies. Haematologica, 2022, 107, 1243-1263.	1.7	28
2383	Treatment of drug-induced immune thrombocytopenias. Haematologica, 2022, 107, 1264-1277.	1.7	17
2384	Mechanistic Involvement of Inflammation in Bortezomib-induced Peripheral Neuropathy. Combinatorial Chemistry and High Throughput Screening, 2022, 25, 1595-1600.	0.6	2
2386	Bortezomib rapidly suppresses ubiquitin thiolesterification to ubiquitin-conjugating enzymes and inhibits ubiquitination of histones and type I inositol 1,4,5-trisphosphate receptor. Molecular Cancer Therapeutics, 2004, 3, 1263-1269.	1.9	41

#	Article	IF	Citations
2387	Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-Î¹B dependent. Molecular Cancer Therapeutics, 2004, 3, 727-736.	1.9	46
2388	Myeloma and Leukemia. , 2023, , 503-528.		0
2389	Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Molecular Cancer Therapeutics, 2004, 3, 551-566.	1.9	137
2390	Natural Products of Marine Origin for the Treatment of Colorectal and Pancreatic Cancers: Mechanisms and Potential. International Journal of Molecular Sciences, 2022, 23, 8048.	1.8	4
2391	Discovery of the oncogenic MDM2, a direct binding target of berberine and a potential therapeutic, in multiple myeloma. Functional and Integrative Genomics, 2022, 22, 1031-1041.	1.4	1
2392	Brain-derived neurotrophic factor: focus on the pathogenesis of multiple myeloma and the development of treatment-induced peripheral neuropathy. Leukemia and Lymphoma, 0, , 1-8.	0.6	0
2393	LTÎ²R overexpression promotes plasma cell accumulation. PLoS ONE, 2022, 17, e0270907.	1.1	0
2394	Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Cancer Medicine, 2023, 12, 3999-4009.	1.3	3
2395	An update on the safety of ixazomib for the treatment of multiple myeloma. Expert Opinion on Drug Safety, 0, , 1-18.	1.0	0
2396	Ligand-based discovery of a novel GATA2 inhibitor targeting acute myeloid leukemia cells. Frontiers in Drug Discovery, 0, 2, .	1.1	1
2397	NF-Î¹B Mutations in Germinal Center B-Cell Lymphomas: Relation to NF-Î¹B Function in Normal B Cells. Biomedicines, 2022, 10, 2450.	1.4	8
2399	Investigation of the frequency of bortezomib neuropathy in patients with multiple myeloma diagnosis with normal and abnormal genetic characteristics. Journal of Oncology Pharmacy Practice, 0, , 107815522211325.	0.5	0
2400	A feline case of multiple myeloma treated with bortezomib. BMC Veterinary Research, 2022, 18, .	0.7	1
2401	Preventing osteolytic lesions and osteomyelitis in multiple myeloma. Journal of Bone Oncology, 2022, 37, 100460.	1.0	4
2403	Factors associated with infection events after chimeric antigen receptor T-cell therapy for relapsed or refractory multiple myeloma. Journal of Infection and Chemotherapy, 2023, 29, 179-185.	0.8	4
2406	Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma. Nature Communications, 2022, 13, .	5.8	18
2407	HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs. PLoS ONE, 2022, 17, e0274704.	1.1	2
2408	The Evidence That 25(OH)D3 and VK2 MK-7 Vitamins Influence the Proliferative Potential and Gene Expression Profiles of Multiple Myeloma Cells and the Development of Resistance to Bortezomib. Nutrients, 2022, 14, 5190.	1.7	5

#	Article	IF	Citations
2409	Serum metabolomics reveals the effects of accompanying treatment on fatigue in patients with multiple myeloma. Supportive Care in Cancer, 2023, 31, .	1.0	2
2410	The impact of current therapeutic options on the health-related quality of life of patients with relapse/refractory multiple myeloma: a systematic review of clinical studies. Journal of Cancer Survivorship, 0, , .	1.5	1
2411	Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple Myeloma. International Journal of Molecular Sciences, 2023, 24, 644.	1.8	4
2412	Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma. Blood Advances, 2023, 7, 5703-5712.	2.5	1
2413	Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities. Leukemia, 2023, 37, 843-853.	3.3	4
2414	Periplocin Overcomes Bortezomib Resistance by Suppressing the Growth and Down-Regulation of Cell Adhesion Molecules in Multiple Myeloma. Cancers, 2023, 15, 1526.	1.7	1
2415	Autophagy: A Potential Therapeutic Target to Tackle Drug Resistance in Multiple Myeloma. International Journal of Molecular Sciences, 2023, 24, 6019.	1.8	5
2416	Transcription factors: a potential therapeutic target in head and neck squamous cell carcinoma. Epigenomics, 2023, 15, 57-60.	1.0	4
2417	A Machine Learning Model to Predict Survival and Therapeutic Responses in Multiple Myeloma. International Journal of Molecular Sciences, 2023, 24, 6683.	1.8	2
2418	Management of Relapsedâ€“Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice. Cancers, 2023, 15, 2160.	1.7	3
2419	Targeted therapy. , 2023, , 205-411.		0
2432	Editorial: Proteomic and metabolic reprogramming in myeloma cells within the tumor microenvironment. Frontiers in Oncology, 0, 13, .	1.3	0